APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 6
JUNE 2015



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

Cumulative Supplement 6

June 2015

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

CUMULATIVE SUPPLEMENT 6
June 2015

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic

Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2014	MAR 2015	JUN 2015	SEPT 2015	DEC 2015
DRUG PRODUCTS LISTED	16150	16352	16543		
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)		
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)		
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)		
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)		
EXCEPTIONS[1]	77 (0.5%)	75 (0.5%)	75 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	13	22	12		
NUMBER OF APPLICANTS	927	935	957		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN

SOLUTION;IV (INFUSION)

OFIRMEV

>D>		+	CADENCE PHARMS	1000MG/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Jun CAHN
>A>		+	MALLINCKRODT IP	1000MG/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Jun CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

FIORICET

		@	ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORICET W/ CODEINE

	AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	AA		SUN PHARM INDS LTD	300MG;30MG	A085868	001		Apr CAHN
	AA			300MG;60MG	A087083	001		Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA	+	MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010	Feb CTEC
		@	SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007	Apr CAHN

NORCO

	AA		ACTAVIS LABS FL INC	325MG;2.5MG	A040148	004	Jul 07, 2014	Feb NEWA
	AA			325MG;5MG	A040148	005	Jul 07, 2014	Feb NEWA

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

DIAMOX

>D>	AB	+	DURAMED PHARMS BARR	500MG	N012945	001		Jun CAHN
>A>	AB	+	TEVA BRANDED PHARM	500MG	N012945	001		Jun CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

	AP		AKORN INC	6GM/30ML (200MG/ML)	A203173	001	Mar 24, 2015	Mar NEWA
>A>	AP		MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)	A203624	001	Jun 19, 2015	Jun NEWA

ACITRETIN

CAPSULE;ORAL

ACITRETIN

	AB		SIGMAPHARM LABS LLC	10MG	A204633	001	May 22, 2015	May NEWA
	AB			17.5MG	A204633	002	May 22, 2015	May NEWA
	AB			22.5MG	A204633	003	May 22, 2015	May NEWA
	AB			25MG	A204633	004	May 22, 2015	May NEWA

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

		+	ASTRAZENECA PHARMS	0.375MG/INH	N202450	001	Jul 23, 2012	Apr CAHN

ACYCLOVIR

TABLET;ORAL

ACYCLOVIR

	AB		SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Apr CAHN
	AB			800MG	A074980	002	Sep 30, 1998	Apr CAHN

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

>A>	AP		EUROHLTH INTL SARL	3MG/ML	A076500	001	Jun 16, 2004	Jun CAHN
>D>	AP		HIKMA MAPLE	3MG/ML	A076500	001	Jun 16, 2004	Jun CAHN
	AP		MYLAN PHARMS INC	3MG/ML	A078686	001	May 13, 2009	Apr CAHN
		@	WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009	May DISC

		ALBENDAZOLE							
>A>		TABLET, CHEWABLE;ORAL							
>A>		ALBENZA							
>A>	+	AMEDRA PHARMS LLC	200MG		N207844	001	Jun 11, 2015	Jun	NEWA
		ALBUTEROL SULFATE							
		POWDER, METERED;INHALATION							
		PROAIR RESPICLICK							
	+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH		N205636	001	Mar 31, 2015	Mar	NEWA
		SYRUP;ORAL							
		ALBUTEROL SULFATE							
AA		G AND W LABS INC	EQ 2MG BASE/5ML		A074454	001	Sep 25, 1995	Apr	CAHN
		ALBUTEROL SULFATE; IPRATROPIUM BROMIDE							
		AEROSOL, METERED;INHALATION							
		COMBIVENT							
	@	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH		N020291	001	Oct 24, 1996	May	DISC
		ALFUZOSIN HYDROCHLORIDE							
		TABLET, EXTENDED RELEASE;ORAL							
		ALFUZOSIN HYDROCHLORIDE							
	@	WOCKHARDT LTD	10MG		A090221	001	Aug 10, 2012	Feb	DISC
		UROXATRAL							
>A> AB	+	CONCORDIA PHARMS INC	10MG		N021287	001	Jun 12, 2003	Jun	CAHN
>D> AB	+	COVIS PHARMA SARL	10MG		N021287	001	Jun 12, 2003	Jun	CAHN
		ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE							
		TABLET;ORAL							
		TEKAMLO							
	@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE		N022545	001	Aug 26, 2010	May	DISC
	@		EQ 150MG BASE;EQ 10MG BASE		N022545	002	Aug 26, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE		N022545	003	Aug 26, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE		N022545	004	Aug 26, 2010	May	DISC
		ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE							
		TABLET;ORAL							
		AMTURNIDE							
	@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG		N200045	001	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE;12.5MG		N200045	002	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE;25MG		N200045	003	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE;12.5MG		N200045	004	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE;25MG		N200045	005	Dec 21, 2010	May	DISC
		ALMOTRIPTAN MALATE							
		TABLET;ORAL							
>A>		ALMOTRIPTAN MALATE							
>A> AB		TEVA PHARMS USA	EQ 6.25MG BASE		A078027	001	Jul 07, 2015	Jun	NEWA
>A> AB			EQ 12.5MG BASE		A078027	002	Jul 07, 2015	Jun	NEWA
		AXERT							
>D>		JANSSEN PHARMS	EQ 6.25MG BASE		N021001	001	May 07, 2001	Jun	CFTG
>A> AB			EQ 6.25MG BASE		N021001	001	May 07, 2001	Jun	CFTG
>D>	+		EQ 12.5MG BASE		N021001	002	May 07, 2001	Jun	CFTG
>A> AB	+		EQ 12.5MG BASE		N021001	002	May 07, 2001	Jun	CFTG
		ALOSETRON HYDROCHLORIDE							
		TABLET;ORAL							
		ALOSETRON HYDROCHLORIDE							
AB		ROXANE	EQ 0.5MG BASE		A200652	001	May 04, 2015	Apr	NEWA
AB			EQ 1MG BASE		A200652	002	May 04, 2015	Apr	NEWA
		LOTRONEX							
AB		PROMETHEUS LABS	EQ 0.5MG BASE		N021107	002	Dec 23, 2003	Apr	CFTG
AB	+		EQ 1MG BASE		N021107	001	Feb 09, 2000	Apr	CFTG
		ALPRAZOLAM							
		TABLET;ORAL							
		ALPRAZOLAM							
AB		NATCO PHARMA LTD	0.25MG		A200739	001	Apr 15, 2015	Mar	NEWA
AB			0.5MG		A200739	002	Apr 15, 2015	Mar	NEWA
AB			1MG		A200739	003	Apr 15, 2015	Mar	NEWA
AB			2MG		A200739	004	Apr 15, 2015	Mar	NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB	BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan	CAHN

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

	@ G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990	May	CAHN

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

	@ IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar	CAHN
	@	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar	CAHN

AMINO ACIDS

INJECTABLE;INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER

	@ BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984	Feb	DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

	@ BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995	Feb	DISC

AMINOCAPROIC ACID

SYRUP;ORAL

AMINOCAPROIC ACID

AA	VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998	May	CAHN

TABLET;ORAL

AMINOCAPROIC

AB	VERSAPHARM INC	500MG	A075602	001	May 24, 2001	May	CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011	Mar	CAHN
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Mar	CAHN
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Apr	CAHN
AB		EQ 5MG BASE	A077974	002	Jul 09, 2007	Apr	CAHN
AB		EQ 10MG BASE	A077974	003	Jul 09, 2007	Apr	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015	May	NEWA
AB		5MG;25MG;160MG	A200797	002	Jun 03, 2015	May	NEWA
AB		10MG;12.5MG;160MG	A200797	003	Jun 03, 2015	May	NEWA
AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015	May	NEWA
AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015	May	NEWA
AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015	May	NEWA
AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015	May	NEWA
AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015	May	NEWA
AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015	May	NEWA
AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015	May	NEWA
AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	May	CAIN
AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012	May	CAIN
AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	May	CAIN
AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012	May	CAIN
AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012	May	CAIN
AB	TORRENT PHARMS LTD	5MG;12.5MG;160MG	A201593	001	Jun 04, 2015	May	NEWA
AB		5MG;25MG;160MG	A201593	002	Jun 04, 2015	May	NEWA
AB		10MG;12.5MG;160MG	A201593	003	Jun 04, 2015	May	NEWA
AB		10MG;25MG;160MG	A201593	004	Jun 04, 2015	May	NEWA
AB		10MG;25MG;320MG	A201593	005	Jun 04, 2015	May	NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Jan NEWA
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Jan NEWA
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar NEWA
AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar NEWA
AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr NEWA
>A>	CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun NEWA
AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr CAHN

FOR SUSPENSION;ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	200MG/5ML	A065113	001	Nov 29, 2002	Apr CAHN
@		400MG/5ML	A065113	002	Nov 29, 2002	Apr CAHN

TABLET;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr CAHN
AB		875MG	A065059	002	Nov 24, 2000	Apr CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr CAHN
@		200MG	A065060	001	Nov 29, 2000	Apr CAHN
AB		250MG	A065021	002	Dec 23, 1999	Apr CAHN
@		400MG	A065060	002	Nov 29, 2000	Apr CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr	CAHN

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@	SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr	CAHN
AB		875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Apr	CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr	CAHN
AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May	NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

EVEKEO

	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar	CTNA
+		10MG	A200166	002	Aug 09, 2012	Mar	CTNA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

@	G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		Apr	CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

@	KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011	Mar	CAHN

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Apr	CDFR

INJECTABLE;IV (INFUSION)

ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Mar	NEWA

ARIPIPRAZOLE

TABLET;ORAL

ABILIFY

AB	OTSUKA	2MG	N021436	006	Nov 15, 2002	Apr	CFTG
AB	+	5MG	N021436	005	Nov 15, 2002	Apr	CFTG
AB	+	10MG	N021436	001	Nov 15, 2002	Apr	CFTG
AB		15MG	N021436	002	Nov 15, 2002	Apr	CFTG
AB		20MG	N021436	003	Nov 15, 2002	Apr	CFTG
AB		30MG	N021436	004	Nov 15, 2002	Apr	CFTG

ARIPIPRAZOLE

AB	ALEMBIC PHARMS LTD	2MG	A202101	001	Apr 28, 2015	Apr	NEWA
AB		5MG	A202101	002	Apr 28, 2015	Apr	NEWA
AB		10MG	A202101	003	Apr 28, 2015	Apr	NEWA
AB		15MG	A202101	004	Apr 28, 2015	Apr	NEWA
AB		20MG	A202101	005	Apr 28, 2015	Apr	NEWA
AB		30MG	A202101	006	Apr 28, 2015	Apr	NEWA
AB	HETERO LABS LTD V	2MG	A205064	001	Apr 28, 2015	Apr	NEWA
AB		5MG	A205064	002	Apr 28, 2015	Apr	NEWA
AB		10MG	A205064	003	Apr 28, 2015	Apr	NEWA
AB		15MG	A205064	004	Apr 28, 2015	Apr	NEWA
AB		20MG	A205064	005	Apr 28, 2015	Apr	NEWA
AB		30MG	A205064	006	Apr 28, 2015	Apr	NEWA
AB	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Apr	NEWA
AB		5MG	A078607	002	Apr 28, 2015	Apr	NEWA
AB		10MG	A078608	001	Apr 28, 2015	Apr	NEWA

TABLET;ORAL
ARIPIPRAZOLE

AB			15MG		A078708	001	Apr 28, 2015	Apr NEWA
AB			20MG		A078708	002	Apr 28, 2015	Apr NEWA
AB			30MG		A078708	003	Apr 28, 2015	Apr NEWA
AB		TORRENT PHARMS LTD	2MG		A201519	001	Apr 28, 2015	Apr NEWA
AB			10MG		A201519	003	Apr 28, 2015	Apr NEWA
AB			5MG		A201519	002	Apr 28, 2015	Apr NEWA
AB			15MG		A201519	004	Apr 28, 2015	Apr NEWA
AB			20MG		A201519	005	Apr 28, 2015	Apr NEWA
AB			30MG		A201519	006	Apr 28, 2015	Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
ABILIFY

AB	+	OTSUKA	10MG		N021729	002	Jun 07, 2006	Apr CFTG
AB			15MG		N021729	003	Jun 07, 2006	Apr CFTG

ARIPIPRAZOLE

AB		ALEMBIC PHARMS LTD	10MG		A202102	001	Apr 28, 2015	Apr NEWA
AB			15MG		A202102	002	Apr 28, 2015	Apr NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION
M.V.I.-12 LYOPHILIZED

>D>		@ ASTRAZENECA	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL		N018933	002	Aug 08, 1985	Jun CAHN
>A>		@ IGI LABS INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL		N018933	002	Aug 08, 1985	Jun CAHN

ASENAPINE MALEATE

TABLET;SUBLINGUAL
SAPHRIS

>D>		FOREST LABS INC	EQ 5MG BASE		N022117	001	Aug 13, 2009	Jun CAHN
>D>	+		EQ 10MG BASE		N022117	002	Aug 13, 2009	Jun CAHN
>A>		FOREST LABS LLC	EQ 5MG BASE		N022117	001	Aug 13, 2009	Jun CAHN
>A>	+		EQ 10MG BASE		N022117	002	Aug 13, 2009	Jun CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
FIORINAL

AA	+	ACTAVIS LABS UT INC	325MG;50MG;40MG		N017534	005	Apr 16, 1986	Jan CAHN

TABLET;ORAL
FIORINAL

		@ ACTAVIS LABS UT INC	325MG;50MG;40MG		N017534	003	Apr 16, 1986	Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
FIORINAL W/CODEINE

AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG		N019429	003	Oct 26, 1990	Jan CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL
NORGESIC

		@ MEDICIS	385MG;30MG;25MG		N013416	003	Oct 27, 1982	Mar DISC

NORGESIC FORTE

		@ MEDICIS	770MG;60MG;50MG		N013416	004	Oct 27, 1982	Mar DISC

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

		SANDOZ	385MG;30MG;25MG		A074654	001	Dec 31, 1996	Mar CTEC
	+		770MG;60MG;50MG		A074654	002	Dec 31, 1996	Mar CTEC

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL
OXYCODONE AND ASPIRIN

AA		ACTAVIS LABS FL INC	325MG;4.8355MG		A090084	001	Mar 22, 2011	Mar CAHN

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

	+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015	Jan	NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

>D>	AB	DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992	Jun	DISC
>A>		@	25MG	A074099	001	Apr 28, 1992	Jun	DISC

TENORMIN

	AB	ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb	CAHN
	AB		50MG	N018240	001		Feb	CAHN
	AB	+	100MG	N018240	002		Feb	CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

TENORETIC 100

	AB	+ ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb	CAHN

TENORETIC 50

	AB	ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb	CAHN

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

	AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar	CAHN
	AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar	CAHN
	AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar	CAHN
	AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar	CAHN
	AB	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr	CAHN
	AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr	CAHN
	AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr	CAHN
	AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr	CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

	@	MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May	DISC
	@		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May	DISC
	@		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May	DISC
	@		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May	DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

	AB	GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar	NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

	AP	AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar	NEWA

ATRACURIUM BESYLATE PRESERVATIVE FREE

	AP	AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar	NEWA

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

	+	AKORN	1%	N206289	001	Jul 18, 2014	May	CRLD

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

	+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Feb	CAHN

MOTOFEN HALF-STRENGTH

	@	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Feb	CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

	+	CEREXA INC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Feb	NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB		LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	May	NEWA
AB			EQ 200MG BASE/5ML	A065488	002	May 15, 2015	May	NEWA

INJECTABLE;INJECTION

AZITHROMYCIN

>A> AP		AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A203294	001	Jun 19, 2015	Jun	NEWA

TABLET;ORAL

AZITHROMYCIN

AB		LUPIN LTD	EQ 250MG BASE	A065398	001	May 15, 2015	May	NEWA
AB			EQ 500MG BASE	A065399	001	May 15, 2015	May	NEWA
AB			EQ 600MG BASE	A065400	001	May 15, 2015	May	NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB		AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Jan	CAHN
AB			10MG	A076820	002	Feb 03, 2006	Jan	CAHN
AB			20MG	A076820	003	Feb 03, 2006	Jan	CAHN
AB			40MG	A076820	004	Feb 03, 2006	Jan	CAHN
AB		SUN PHARM INDS LTD	5MG	A076344	001	Feb 11, 2004	Apr	CAHN
AB			10MG	A076344	002	Feb 11, 2004	Apr	CAHN
AB			20MG	A076344	003	Feb 11, 2004	Apr	CAHN
AB			40MG	A076344	004	Feb 11, 2004	Apr	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Apr	CAHN
AB			10MG;12.5MG	A077483	002	Sep 08, 2005	Apr	CAHN
AB			20MG;12.5MG	A077483	003	Sep 08, 2005	Apr	CAHN
AB			20MG;25MG	A077483	004	Sep 08, 2005	Apr	CAHN

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA		APOTEX INC	100MG	A091310	001	Jan 16, 2015	Jan	NEWA
AA			200MG	A091310	002	Jan 16, 2015	Jan	NEWA
AA		BANNER LIFE SCIENCES	100MG	A081297	001	Jan 29, 1993	Jan	CAHN
AA			200MG	A081297	002	Oct 30, 2007	Jan	CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ACANYA

>D>	+	DOW PHARM	2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Jun	CFTG
>A> AB	+		2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Jun	CFTG

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>A> AB		ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jun	NEWA

ONEXTON

	+	DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan	CRLD

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

>D> AA		KVK TECH	50MG	A090968	001	Jul 20, 2010	Jun	CRLD
>A> AA	+		50MG	A090968	001	Jul 20, 2010	Jun	CRLD

>D>

DIDREX

>D> AA	+	PHARMACIA AND UPJOHN	50MG	N012427	002		Jun	DISC
>D> AA	+		50MG	N012427	002		Jun	DISC
>A>	@		50MG	N012427	002		Jun	DISC

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA		NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Mar NEWA
AA			1MG	A204713	002	Apr 14, 2015	Mar NEWA
AA			2MG	A204713	003	Apr 14, 2015	Mar NEWA

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		G AND W LABS INC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr CAHN
	@		EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr CAHN

BETAMETHASONE VALERATE

LOTION;TOPICAL

BETA-VAL

AB		G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA		HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Mar CAHN
AA			10MG	A091256	002	May 04, 2010	Mar CAHN
AA			25MG	A091256	003	May 04, 2010	Mar CAHN
AA			50MG	A091256	004	May 04, 2010	Mar CAHN
AA		LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Feb CMFD
AA			50MG	A040677	001	Mar 27, 2008	Feb CMFD

DUVOID

AA		WELLSPRING PHARM	10MG	A086262	001		Jan CMFD
AA			25MG	A086263	001		May CMFD
AA			50MG	A085882	003		May CMFD

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

>D>		@	BANNER LIFE SCIENCES	75MG	A203174	001	Aug 12, 2014	Jun CMFD
>A>	AB			75MG	A203174	001	Aug 12, 2014	Jun CMFD
		@		75MG	A203174	001	Aug 12, 2014	Jan CAHN

TARGRETIN

>D>		+	VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun CTEC
>A>	AB	+		75MG	N021055	001	Dec 29, 1999	Jun CTEC

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB		APOTEX INC	50MG	A200274	001	May 21, 2015	May NEWA
AB		STASON PHARMS	50MG	A091011	001	Jun 10, 2015	May NEWA

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT			ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Apr NEWA
AT	+		LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Apr CTEC
	+			0.03%	A203991	001	Feb 20, 2015	Mar CTEC
AT	+			0.03%	A203991	001	Feb 20, 2015	Feb NEWA

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

ANGIOMAX

>D>		+	MEDICINES CO	250MG/VIAL	N020873	001	Dec 15, 2000	Jun CFTG
>A>	AP	+		250MG/VIAL	N020873	001	Dec 15, 2000	Jun CFTG

BIVALIRUDIN

>A>	AP		HOSPIRA INC	250MG/VIAL	A090811	001	Jul 14, 2015	Jun NEWA
>A>	AP			250MG/VIAL	A090816	001	Jul 14, 2015	Jun NEWA

BOSUTINIB MONOHYDRATE

TABLET;ORAL

BOSULIF

>D>			WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun CRLD
>A>		+		EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun CRLD
>D>		+		EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun CRLD

		TABLET;ORAL						
		BOSULIF						
>A>			EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun	CRLD
		BROMFENAC SODIUM						
		SOLUTION/DROPS;OPHTHALMIC						
		BROMDAY						
	AT2	+ BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	May	CTEC
		BROMFENAC SODIUM						
	AT2	APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May	CTEC
	AT1	+ COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May	CRLD
	AT2	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May	CTEC
	AT1	PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan	NEWA
		BUDESONIDE						
		AEROSOL, FOAM;RECTAL						
		UCERIS						
		+ VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014	Apr	CAHN
		SPRAY, METERED;NASAL						
		BUDESONIDE						
		APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Mar	CTEC
		BUMETANIDE						
		INJECTABLE;INJECTION						
		BUMETANIDE						
>A>	AP	EUROHLTH INTL SARL	0.25MG/ML	A079196	001	Apr 30, 2008	Jun	CAHN
>D>	AP	HIKMA MAPLE	0.25MG/ML	A079196	001	Apr 30, 2008	Jun	CAHN
		BUPRENORPHINE HYDROCHLORIDE						
		TABLET;SUBLINGUAL						
		BUPRENORPHINE HYDROCHLORIDE						
	AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb	NEWA
	AB		EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb	NEWA
	AB	MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb	NEWA
	AB		EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb	NEWA
	AB	SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May	NEWA
	AB		EQ 8MG BASE	A090279	002	Jun 10, 2015	May	NEWA
		BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE						
		TABLET;SUBLINGUAL						
		ZUBSOLV						
>A>		OREXO AB	EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jun	NEWA
		BUPROPION HYDROBROMIDE						
		TABLET, EXTENDED RELEASE;ORAL						
		APLENZIN						
		VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
			348MG	N022108	002	Apr 23, 2008	Feb	CAHN
		+	522MG	N022108	003	Apr 23, 2008	Feb	CAHN
		BUPROPION HYDROCHLORIDE						
		TABLET, EXTENDED RELEASE;ORAL						
		BUPROPION HYDROCHLORIDE						
	AB1	PRINSTON INC	100MG	A202304	001	May 26, 2015	May	NEWA
	AB1		150MG	A202304	002	May 26, 2015	May	NEWA
	AB1		200MG	A202304	003	May 26, 2015	May	NEWA
	AB2	SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar	CAHN
		@ WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012	May	DISC
		@	150MG	A201331	002	Aug 30, 2012	May	DISC
		@	200MG	A201331	003	Aug 30, 2012	May	DISC
		BUTABARBITAL SODIUM						
		TABLET;ORAL						
		BUTISOL SODIUM						
		@ MEDA PHARMS	50MG	N000793	003		May	DISC

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

		@	ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	May CTNA
>D>		+	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Jun CTNA

GYNAZOLE-1

>A>		+	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Jun CTNA

CALCIPOTRIENE

CREAM;TOPICAL

CALCIPOTRIENE

	AB		GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015	May NEWA

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

		@	IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995	Mar CAHN

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

	AB		BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013	Jan CAHN
	AB			0.5MCG	A091174	002	May 24, 2013	Jan CAHN
	AB		STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014	Jan CAHN
	AB			0.5MCG	A091356	002	Dec 12, 2014	Jan CAHN

INJECTABLE;INJECTION

CALCIJEX

>D>								
>D>	AP	+	ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	Jun DISC
>A>		@		0.001MG/ML	N018874	001	Sep 25, 1986	Jun DISC
>D>	AP	+		0.002MG/ML	N018874	002	Sep 25, 1986	Jun DISC
>A>		@		0.002MG/ML	N018874	002	Sep 25, 1986	Jun DISC

CALCITRIOL

>D>	AP		AKORN	0.002MG/ML	A078066	002	Jan 29, 2008	Jun DISC
>A>		@		0.002MG/ML	A078066	002	Jan 29, 2008	Jun DISC
>D>	AP		FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002	Jun DISC
>A>		@		0.001MG/ML	A075836	001	Dec 31, 2002	Jun DISC
>D>	AP			0.002MG/ML	A075836	002	Dec 31, 2002	Jun DISC
>A>		@		0.002MG/ML	A075836	002	Dec 31, 2002	Jun DISC
>D>	AP		FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003	Jun DISC
>A>		@		0.001MG/ML	A075766	001	Feb 20, 2003	Jun DISC
>D>	AP			0.002MG/ML	A075766	002	Feb 20, 2003	Jun DISC
>A>		@		0.002MG/ML	A075766	002	Feb 20, 2003	Jun DISC
>D>	AP		LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003	Jun DISC
>A>		@		0.001MG/ML	A075746	001	Sep 26, 2003	Jun DISC
>D>	AP			0.002MG/ML	A075746	002	Sep 26, 2003	Jun DISC
>A>		@		0.002MG/ML	A075746	002	Sep 26, 2003	Jun DISC
>D>	AP		SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006	Jun DISC
>A>		@		0.001MG/ML	A077102	001	Feb 08, 2006	Jun DISC

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

>A>	AB		LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015	Jun NEWA
>A>	AB		ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Jun NEWA

TABLET;ORAL

CALCIUM ACETATE

	AB		ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

		+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan CPOT

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

		@	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan CPOT

INJECTABLE;INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan CPOT

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan CPOT

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan CPOT

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan CPOT

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan CPOT

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan CPOT

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan CPOT

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan CPOT

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	N/A/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan NEWA

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	3.68GM/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314	N207026	001	Jan 13, 2015	Jan NEWA

		INJECTABLE;INJECTION						
		PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER						
			GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187					
>D>		CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE						
>D>		SOLUTION;IRRIGATION						
>D>		NAVSTEL						
>D>	+	ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008	Jun DISC	
>A>	@		0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008	Jun DISC	
		CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE						
		INJECTABLE;INJECTION						
		PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@	BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML	N017390	001		Mar DISC	
		CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE						
		INJECTABLE;INJECTION						
		PLASMA-LYTE R IN PLASTIC CONTAINER						
	@	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N017438	001		Mar DISC	
		CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE						
		INJECTABLE;INJECTION						
		PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER						
	+	GAMBRO LUNDIA	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Feb CAIN	
		PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER						
	+	GAMBRO LUNDIA	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187	N207026	001	Jan 13, 2015	Feb CAIN	
		CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE						
		TABLET;ORAL						
		CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE						
AB		MACLEODS PHARMS LTD	16MG;12.5MG	A204100	001	Feb 27, 2015	Feb NEWA	
AB			32MG;12.5MG	A204100	002	Feb 27, 2015	Feb NEWA	
AB			32MG;25MG	A204100	003	Feb 27, 2015	Feb NEWA	
>A>		CANGRELOR						
>A>		POWDER;IV (INFUSION)						
>A>		KENGREAL						
>A>	+	MEDICNES CO	50MG/VIAL	N204958	001	Jun 22, 2015	Jun NEWA	
		CAPECITABINE						
		TABLET;ORAL						
		CAPECITABINE						
AB		ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr NEWA	
AB			500MG	A202593	002	Apr 23, 2015	Apr NEWA	
		CAPTOPRIL						
		TABLET;ORAL						
		CAPOTEN						
	@	PAR PHARM	12.5MG	N018343	005	Jan 17, 1985	May DISC	
	@		25MG	N018343	002		May DISC	
	@		50MG	N018343	001		May DISC	
	@		100MG	N018343	003		May DISC	
		CAPTOPRIL						
	@	G AND W LABS INC	12.5MG	A074462	001	Feb 13, 1996	Apr CAHN	
	@		12.5MG	A074590	004	Aug 30, 1996	Apr CAHN	
	@		25MG	A074462	002	Feb 13, 1996	Apr CAHN	
	@		25MG	A074590	002	Aug 30, 1996	Apr CAHN	
	@		50MG	A074462	003	Feb 13, 1996	Apr CAHN	

		TABLET;ORAL						
		CAPTOPRIL						
		@	50MG	A074590	001	Aug 30, 1996	Apr	CAHN
		@	100MG	A074462	004	Feb 13, 1996	Apr	CAHN
		@	100MG	A074590	003	Aug 30, 1996	Apr	CAHN
	AB +	MYLAN	100MG	A074434	004	Feb 13, 1996	May	CRLD
		CAPTOPRIL; HYDROCHLOROTHIAZIDE						
		TABLET;ORAL						
		CAPTOPRIL AND HYDROCHLOROTHIAZIDE						
	AB	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Apr	CAHN
	AB		25MG;25MG	A074827	002	Dec 29, 1997	Apr	CAHN
	AB		50MG;15MG	A074827	004	Dec 29, 1997	Apr	CAHN
	AB		50MG;25MG	A074827	003	Dec 29, 1997	Apr	CAHN
		CARBAMAZEPINE						
		CAPSULE, EXTENDED RELEASE;ORAL						
		CARBAMAZEPINE						
	AB	MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May	CAHN
	AB		200MG	A076697	002	May 20, 2011	May	CAHN
	AB		300MG	A076697	003	May 20, 2011	May	CAHN
		CARBIDOPA; LEVODOPA						
		CAPSULE, EXTENDED RELEASE;ORAL						
		RYTARY						
		IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015	Jan	NEWA
			36.25MG;145MG	N203312	002	Jan 07, 2015	Jan	NEWA
			48.75MG;195MG	N203312	003	Jan 07, 2015	Jan	NEWA
	+		61.25MG;245MG	N203312	004	Jan 07, 2015	Jan	NEWA
		SUSPENSION;ENTERAL						
		DUOPA						
	+	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan	NEWA
		CARBOPLATIN						
		INJECTABLE;IV (INFUSION)						
		CARBOPLATIN						
	AP	MYLAN PHARMS INC	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	May	CAHN
	AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	May	CAHN
	AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	May	CAHN
	AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	May	CAHN
	+		1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	May	CAHN
		CARISOPRODOL						
		TABLET;ORAL						
		CARISOPRODOL						
>A>	AB	INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun	NEWA
>A>	AA		350MG	A205126	002	Jul 08, 2015	Jun	NEWA
		SOMA						
>D>	+	MEDA PHARMS	250MG	N011792	004	Sep 13, 2007	Jun	CTEC
>A>	AB +		250MG	N011792	004	Sep 13, 2007	Jun	CTEC
		CARVEDILOL						
		TABLET;ORAL						
		CARVEDILOL						
>D>	AB	HIKMA	3.125MG	A077887	001	Sep 07, 2007	Jun	DISC
>A>		@	3.125MG	A077887	001	Sep 07, 2007	Jun	DISC
>D>	AB		6.25MG	A077887	002	Sep 07, 2007	Jun	DISC
>A>		@	6.25MG	A077887	002	Sep 07, 2007	Jun	DISC
>D>	AB		12.5MG	A077887	003	Sep 07, 2007	Jun	DISC
>A>		@	12.5MG	A077887	003	Sep 07, 2007	Jun	DISC
>D>	AB		25MG	A077887	004	Sep 07, 2007	Jun	DISC
>A>		@	25MG	A077887	004	Sep 07, 2007	Jun	DISC
	AB	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr	CAHN
	AB		6.25MG	A076989	002	Sep 05, 2007	Apr	CAHN
	AB		12.5MG	A076989	003	Sep 05, 2007	Apr	CAHN
	AB		25MG	A076989	004	Sep 05, 2007	Apr	CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL

CEFADROXIL

		SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr	CAHN
AB			EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr	CAHN
AB			EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr	CAHN

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

AP		FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan	CAHN
AP	+		EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan	CAHN

CEFIXIME

FOR SUSPENSION;ORAL

CEFIXIME

AB		AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr	NEWA
AB			200MG/5ML	A204835	002	Apr 14, 2015	Apr	NEWA

SUPRAX

AB		LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr	CFTG
AB			200MG/5ML	A065355	001	Apr 10, 2007	Apr	CFTG

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN

	@	IGI LABS INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May	CAHN
	@		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar	CAHN
	@		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May	CAHN
	@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar	CAHN
	@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar	CAHN

CEFOTAN IN PLASTIC CONTAINER

	@	IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar	CAHN
	@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar	CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

CEFPODOXIME PROXETIL

AB		SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr	CAHN
AB			EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr	CAHN

TABLET;ORAL

CEFPODOXIME PROXETIL

AB		SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr	CAHN
AB			EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr	CAHN

CEFTAZIDIME

INJECTABLE;INJECTION

FORTAZ

>A>	AP	+	CONCORDIA PHARMS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Jun	CAHN
>A>	AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun	CAHN
>A>	AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun	CAHN
>A>	AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun	CAHN
>D>	AP	+	COVIS INJECTABLES	500MG/VIAL	N050578	001	Jul 19, 1985	Jun	CAHN
>D>	AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun	CAHN
>D>	AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun	CAHN
>D>	AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun	CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION

FORTAZ IN PLASTIC CONTAINER

>A>		@	CONCORDIA PHARMS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun	CAHN
>A>		+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun	CAHN
>A>		+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun	CAHN
>D>		@	COVIS INJECTABLES	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun	CAHN
>D>		+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun	CAHN
>D>		+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun	CAHN

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AP	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan	CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

@	FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan	CAHN
@		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan	CAHN

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFUROXIME AXETIL

AB	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr	CAHN
AB		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr	CAHN

TABLET;ORAL

CEFUROXIME AXETIL

AB	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr	CAHN
AB		EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr	CAHN
AB		EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr	CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME SODIUM

AP	FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan	CAHN

ZINACEF

>A> AP	+	CONCORDIA PHARMS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun	CAHN
>A> AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun	CAHN
>D> AP	+	COVIS INJECTABLES	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun	CAHN
>D> AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun	CAHN

ZINACEF IN PLASTIC CONTAINER

>A>	@	CONCORDIA PHARMS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun	CAHN
>A>	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun	CAHN
>D>	@	COVIS INJECTABLES	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun	CAHN
>D>	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun	CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

AB	FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan	CAHN

ZINACEF

>A> AB	+	CONCORDIA PHARMS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun	CAHN
>D> AB	+	COVIS INJECTABLES	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun	CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	APOTEX INC	50MG	A204197	001	Jun 02, 2015	May	NEWA
AB		100MG	A204197	002	Jun 02, 2015	May	NEWA
AB		200MG	A204197	003	Jun 02, 2015	May	NEWA
AB	LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May	NEWA
AB		200MG	A202240	003	Jun 09, 2015	May	NEWA
AB		400MG	A202240	004	Jun 09, 2015	May	NEWA
AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan	NEWA
AB		200MG	A078857	003	Feb 11, 2015	Jan	NEWA
AB		400MG	A078857	004	Feb 11, 2015	Jan	NEWA
AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan	NEWA
AB		100MG	A200562	002	Feb 11, 2015	Jan	NEWA
AB		200MG	A200562	003	Feb 11, 2015	Jan	NEWA
AB		400MG	A200562	004	Feb 11, 2015	Jan	NEWA

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr	CAHN
AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr	CAHN

FOR SUSPENSION;ORAL

CEPHALEXIN

@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr	CAHN
@		EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr	CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

AP		SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May	NEWA

>A> CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

>A> TABLET, EXTENDED RELEASE;ORAL

>A> CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

>A>		SPRIASO LLC	8MG;54.3MG	N206323	001	Jun 22, 2015	Jun	NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA		TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015	Jan	NEWA

VITUZ

AA	+	CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Jan	CFTG

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

>D>	+	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun	CAHN
	+		EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr	NEWA
>A>	+	VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun	CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

>A>	@	CYCLE PHARMS LTD	30MG/ML	A088157	001	Apr 27, 1983	Jun	CAHN
>A>	@		100MG/ML	A088158	001	Apr 27, 1983	Jun	CAHN
>D>	@	ROXANE	30MG/ML	A088157	001	Apr 27, 1983	Jun	CAHN
>D>	@		100MG/ML	A088158	001	Apr 27, 1983	Jun	CAHN

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

	+	EUROHLTH INTL SARL	25MG/ML	A083329	001		Feb	CAHN

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

>A>	@	CYCLE PHARMS LTD	10MG	A085331	001		Jun	CAHN
>A>	@		25MG	A085331	002		Jun	CAHN
>A>	@		50MG	A085331	003		Jun	CAHN
>A>	@		100MG	A085331	004		Jun	CAHN
>A>	@		200MG	A085331	005		Jun	CAHN
>D>	@	ROXANE	10MG	A085331	001		Jun	CAHN
>D>	@		25MG	A085331	002		Jun	CAHN
>D>	@		50MG	A085331	003		Jun	CAHN
>D>	@		100MG	A085331	004		Jun	CAHN
>D>	@		200MG	A085331	005		Jun	CAHN
	@	SANDOZ	10MG	A080439	001		May	DISC
	@		25MG	A080439	002		May	DISC
	@		50MG	A080439	003		May	DISC
	@		100MG	A080439	004		May	DISC
	@		200MG	A080439	005		May	DISC

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

	@	G AND W LABS INC	50MG	A088651	001	May 30, 1985	Apr	CAHN
AB		MUTUAL PHARM	50MG	A089286	001	Jul 21, 1986	Mar	CMFD
>D>	+	MYLAN	50MG	A086831	001		Jun	CTEC
>A> AB	+		50MG	A086831	001		Jun	CTEC

>D> THALITONE

>D>	+	CITRON PHARMA LLC	15MG	N019574	001	Dec 20, 1988	Jun	DISC
>A>	@		15MG	N019574	001	Dec 20, 1988	Jun	DISC

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

	ASKLEPION PHARMS LLC	50MG	N205750	001	Mar 17, 2015	Mar	NEWA
+		250MG	N205750	002	Mar 17, 2015	Mar	NEWA
	RTRX	50MG	N205750	001	Mar 17, 2015	Apr	CAHN
+		250MG	N205750	002	Mar 17, 2015	Apr	CAHN

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

AP +	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May	CRLD

VISTIDE

@	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May	DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

@	G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994	Apr	CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN

AP	CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr	CAHN
AP		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr	CAHN

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	200MG/100ML	A078024	001	Mar 18, 2008	Apr	CAHN
AP		400MG/200ML	A078024	002	Mar 18, 2008	Apr	CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr	CAHN
AB		EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr	CAHN
AB		EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr	CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb	NEWA

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb	NEWA
AP		EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb	NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB	G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	CAHN
AB		EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	CAHN
AB		EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	CAHN

CLADRIBINE

INJECTABLE;INJECTION

CLADRIBINE

AP	MYLAN PHARMS INC	1MG/ML	A200510	001	Oct 06, 2011	May	CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

AB	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr	CAHN
AB		250MG/5ML	A065382	002	Aug 30, 2007	Apr	CAHN

TABLET;ORAL

CLARITHROMYCIN

AB	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr	CAHN
AB		500MG	A065174	002	Sep 24, 2004	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL

BIAXIN XL

@	ABBVIE	500MG	N050775	001	Mar 03, 2000	Jan	DISC

CLARITHROMYCIN

AB +	TEVA	500MG	A065154	001	May 18, 2005	Jan	CRLD

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION

TIMENTIN

		@ GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986	May DISC
		@	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985	May DISC
		@	EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985	May DISC
		@	EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May DISC

TIMENTIN IN PLASTIC CONTAINER

		@ GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989	May DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

	AB	G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr CAHN
	AB		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr CAHN
	AB	SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr CAHN
	AB		EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

		@ IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989	Mar CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

		@ BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989	Jan CAHN
	AT	VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	May NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

>A>	AB		ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Jun NEWA

ZIANA

>D>	BX	+	MEDICIS	1.2%;0.025%	N050802	001	Nov 07, 2006	Jun CTEC
>A>	AB	+		1.2%;0.025%	N050802	001	Nov 07, 2006	Jun CTEC

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

	AB2	+	FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	May CRLD

CORMAX

>D>	AB1		HI TECH PHARMA	0.05%	A074220	001	May 16, 1997	Jun CRLD
>A>	AB1	+		0.05%	A074220	001	May 16, 1997	Jun CRLD

>D>

TEMOVATE

>D>	AB1	+	FOUGERA PHARMS	0.05%	N019322	001	Dec 27, 1985	Jun DISC
>A>			@	0.05%	N019322	001	Dec 27, 1985	Jun DISC

TEMOVATE E

			@ FOUGERA PHARMS	0.05%	N020340	001	Jun 17, 1994	May DISC

GEL;TOPICAL

CLOBETASOL PROPIONATE

	AB	+	FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	May CRLD

TEMOVATE

			@ FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	May DISC

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

	AB		G AND W LABS INC	0.05%	A074089	001	Feb 16, 1994	Feb CAHN

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

	AT		G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Mar CMFD

CLOMIPHENE CITRATE

TABLET;ORAL

>D>

SEROPHENE

>D>	AB		EMD SERONO	50MG	N018361	001	Mar 22, 1982	Jun DISC
>A>			@	50MG	N018361	001	Mar 22, 1982	Jun DISC

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

AB	ACTAVIS LABS UT INC	0.1MG/24HR	A090873	001	May 06, 2014	Mar	CAHN
AB		0.2MG/24HR	A090873	002	May 06, 2014	Mar	CAHN
AB		0.3MG/24HR	A090873	003	May 06, 2014	Mar	CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

@	DAVA PHARMS INC	0.1MG	A071783	001	Apr 05, 1988	May	DISC
@		0.2MG	A071784	001	Apr 05, 1988	May	DISC
@		0.3MG	A071785	001	Apr 05, 1988	May	DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	May	NEWA
AB1		0.1MG	A203320	001	May 15, 2015	May	NEWA
AB2		0.2MG	A202792	002	May 15, 2015	May	NEWA
AB1		0.2MG	A203320	002	May 15, 2015	May	NEWA
AB2	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	May	CTEC
AB2		0.2MG	A202983	002	Apr 02, 2014	May	CTEC

CLONIDINE HYDROCHLORIDE

AB1	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	May	CTEC
AB1		0.2MG	A202984	002	Sep 30, 2013	May	CTEC

KAPVAY

>D> AB1	+	CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Jun	CRLD
>A> AB1			0.1MG	N022331	003	Sep 28, 2010	Jun	CRLD
AB1	+		0.1MG	N022331	003	Sep 28, 2010	May	CTEC
>D> AB1			0.2MG	N022331	004	Sep 28, 2010	Jun	CRLD
>A> AB1	+		0.2MG	N022331	004	Sep 28, 2010	Jun	CRLD
AB1			0.2MG	N022331	004	Sep 28, 2010	May	CTEC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB	SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Apr	CAHN
AB		7.5MG	A076911	002	Sep 29, 2004	Apr	CAHN
AB		15MG	A076911	003	Sep 29, 2004	Apr	CAHN

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

+	JANSSEN PRODS	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Jan	NEWA

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

@	ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jan	DISC

COLCHICINE

CAPSULE;ORAL

MITIGARE

	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Jan	CAHN

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

AP	XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356	001	May 29, 2015	May	NEWA

CYANOCOBALAMIN

INJECTABLE;INJECTION

CYANOCOBALAMIN

@	EUROHLTH INTL SARL	1MG/ML	A080515	002		Feb	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

>A> AB		ORIT LABS LLC	5MG	A078218	002	Jun 19, 2015	Jun	NEWA
AB		SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Apr	CAHN
AB			7.5MG	A078722	002	May 12, 2008	Apr	CAHN
AB			10MG	A078722	003	May 12, 2008	Apr	CAHN

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

AP		MYLAN PHARMS INC	20MG/ML	A200915	001	Dec 13, 2011	May CAHN
AP			20MG/ML	A200916	001	Dec 13, 2011	May CAHN

DABRAFENIB MESYLATE

CAPSULE;ORAL

TAFINLAR

		NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013	Mar CAHN
	+		EQ 75MG BASE	N202806	002	May 29, 2013	Mar CAHN

DALTEPARIN SODIUM

INJECTABLE;INJECTION

FRAGMIN

>A>		@ PFIZER INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Jun CAHN
>D>		@ PHARMACIA AND UPJOHN	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Jun CAHN
		@	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Apr CAHN

INJECTABLE;SUBCUTANEOUS

FRAGMIN

>A>		PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Jun CAHN
>A>			5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Jun CAHN
>A>			7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Jun CAHN
>A>		@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun CAHN
>A>			10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Jun CAHN
>A>			12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Jun CAHN
>A>			15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Jun CAHN
>A>			18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Jun CAHN
>A>	+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Jun CAHN
>A>		@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun CAHN
>D>		PHARMACIA AND UPJOHN	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Jun CAHN
			2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Apr CAHN
>D>			5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Jun CAHN
			5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Apr CAHN
>D>			7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Jun CAHN
			7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Apr CAHN
>D>		@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun CAHN
		@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Apr CAHN
>D>			10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Jun CAHN
			10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Apr CAHN
>D>			12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Jun CAHN
			12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Apr CAHN
>D>			15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Jun CAHN
			15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Apr CAHN
>D>			18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Jun CAHN
			18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Apr CAHN
>D>	+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Jun CAHN
	+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Apr CAHN
>D>		@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun CAHN
		@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Apr CAHN

DANTROLENE SODIUM

CAPSULE;ORAL

DANTROLENE SODIUM

AB		ELITE LABS INC	25MG	A076686	001	Oct 24, 2005	May CAHN
AB			50MG	A076686	002	Oct 24, 2005	May CAHN
AB			100MG	A076686	003	Oct 24, 2005	May CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

AB		ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar NEWA
AB			EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar NEWA

ENABLEX

AB		WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar CFTG
AB	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar CFTG

DECITABINE
INJECTABLE;INTRAVENOUS
DACOGEN

AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan	CAHN

DEFERASIROX
TABLET;ORAL
JADENU

		NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Mar	NEWA
			180MG	N206910	002	Mar 30, 2015	Mar	NEWA
	+		360MG	N206910	003	Mar 30, 2015	Mar	NEWA

DEOXYCHOLIC ACID
SOLUTION;SUBCUTANEOUS
KYBELLA

	+	KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr	NEWA

DESIRUDIN RECOMBINANT
INJECTABLE;SUBCUTANEOUS
IPRIVASK

	+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003	May	CAHN

DESLORATADINE
SOLUTION;ORAL
CLARINEX

>D>	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	Jun	CFTG
>A> AA	+		0.5MG/ML	N021300	001	Sep 01, 2004	Jun	CFTG
>A>		DESLORATADINE						
>A> AA		TARO PHARM INDS	0.5MG/ML	A202592	001	Jun 30, 2015	Jun	NEWA

DESMOPRESSIN ACETATE
TABLET;ORAL
DDAVP

AB		FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan	CAHN
AB	+		0.2MG	N019955	002	Sep 06, 1995	Jan	CAHN
		DESMOPRESSIN ACETATE						
AB		GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May	NEWA
AB			0.2MG	A201831	002	May 28, 2015	May	NEWA

DESOGESTREL; ETHINYL ESTRADIOL
TABLET;ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL

AB		FAMY CARE LTD	0.15MG;0.03MG	A202085	001	May 20, 2015	May	NEWA
		KARIVA						
AB	+	BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Apr	CTEC
		KIMIDESS						
AB		VINTAGE PHARMS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Apr	NEWA

DESONIDE
CREAM;TOPICAL
DESONIDE

AB		TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May	CMFD

DESOXIMETASONE
CREAM;TOPICAL
DESOXIMETASONE

>A> AB		VERSAPHARM INC	0.25%	A203234	001	Jun 12, 2015	Jun	NEWA

OINTMENT;TOPICAL
DESOXIMETASONE

AB		PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr	NEWA

DESVENLAFAXINE SUCCINATE
TABLET, EXTENDED RELEASE;ORAL

>A>		DESVENLAFAXINE SUCCINATE						
>A> AB		ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015	Jun	NEWA
>A> AB			EQ 100MG BASE	A204003	002	Jun 29, 2015	Jun	NEWA
>A> AB		LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015	Jun	NEWA
>A> AB			EQ 100MG BASE	A204172	002	Jun 29, 2015	Jun	NEWA
>A> AB		MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun	NEWA
>A> AB			EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun	NEWA

		TABLET, EXTENDED RELEASE;ORAL							
>A>		DESVENLAFAXINE SUCCINATE							
>A>	AB	SANDOZ INC	EQ 50MG BASE		A204028	001	Jun 29, 2015	Jun	NEWA
>A>	AB		EQ 100MG BASE		A204028	002	Jun 29, 2015	Jun	NEWA
		PRISTIQ							
>D>	+	WYETH PHARMS INC	EQ 50MG BASE		N021992	001	Feb 29, 2008	Jun	CFTG
>A>	AB +		EQ 50MG BASE		N021992	001	Feb 29, 2008	Jun	CFTG
>D>	+		EQ 100MG BASE		N021992	002	Feb 29, 2008	Jun	CFTG
>A>	AB +		EQ 100MG BASE		N021992	002	Feb 29, 2008	Jun	CFTG
		DEXAMETHASONE SODIUM PHOSPHATE							
		INJECTABLE;INJECTION							
		DEXAMETHASONE SODIUM PHOSPHATE							
		@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML		A084282	001		Mar	CAHN
	AP +		EQ 10MG PHOSPHATE/ML		A087702	001	Sep 07, 1982	Feb	CAHN
	AP	MYLAN PHARMS INC	EQ 4MG PHOSPHATE/ML		A040803	001	Aug 29, 2008	Apr	CAHN
	AP		EQ 10MG PHOSPHATE/ML		A040802	001	Aug 29, 2008	Apr	CAHN
		DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE							
		OINTMENT;OPHTHALMIC							
		MAXITROL							
	AT +	ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM		N050065	002		Mar	CAHN
		SUSPENSION/DROPS;OPHTHALMIC							
		MAXITROL							
	AT +	ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		N050023	002		Mar	CAHN
		DEXMEDETOMIDINE HYDROCHLORIDE							
		INJECTABLE;INJECTION							
		PRECEDEX							
		HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)		N021038	004	Nov 14, 2014	Jan	NEWA
		DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE							
		SYRUP;ORAL							
		PROMETH W/ DEXTROMETHORPHAN							
		@ G AND W LABS INC	15MG/5ML;6.25MG/5ML		A088762	001	Oct 31, 1984	May	CAHN
		DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE							
		INJECTABLE;INJECTION							
		PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER							
		@ BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML		N017451	001		Mar	DISC
		DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM							
		INJECTABLE;INJECTION							
		MD-76R							
	AP +	LIEBEL-FLARSHEIM	66%;10%		N019292	001	Sep 29, 1989	Feb	CAHN
		SOLUTION;ORAL, RECTAL							
		MD-GASTROVIEW							
	AA	LIEBEL-FLARSHEIM	66%;10%		A087388	001		Jan	CAHN
		DICLOFENAC SODIUM							
		SOLUTION;TOPICAL							
		DICLOFENAC SODIUM							
>A>	AT	IGI LABS INC	1.5%		A202769	001	Jul 08, 2015	Jun	NEWA
		DIETHYLPROPION HYDROCHLORIDE							
		TABLET;ORAL							
		TENUATE							
	AA +	ACTAVIS LABS UT INC	25MG		N011722	002		Mar	CAHN
		TABLET, EXTENDED RELEASE;ORAL							
		TENUATE DOSPAN							
	AB +	ACTAVIS LABS UT INC	75MG		N012546	001		Mar	CAHN

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

AB			HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012	Mar CAHN

DIGOXIN

INJECTABLE;INJECTION

DIGOXIN

AP			EUROHLTH INTL SARL	0.25MG/ML	A083391	001		Feb CAHN

TABLET;ORAL

DIGOXIN

AB			MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jan CTEC
AB				0.25MG	A040282	002	Dec 23, 1999	Jan CTEC
AB			SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Feb CMFD
AB				0.25MG	A076363	002	Jan 31, 2003	Feb CMFD

LANOXIN

			CONCORDIA PHARMS INC	0.0625MG	N020405	001	Sep 30, 1997	Apr CAHN
AB				0.125MG	N020405	002	Sep 30, 1997	Apr CAHN
				0.1875MG	N020405	003	Sep 30, 1997	Apr CAHN
AB	+			0.25MG	N020405	004	Sep 30, 1997	Apr CAHN
		@		0.375MG	N020405	005	Sep 30, 1997	Apr CAHN
		@		0.5MG	N020405	006	Sep 30, 1997	Apr CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILACOR XR

		@	ACTAVIS LABS UT INC	120MG	N020092	001	May 29, 1992	Mar CAHN
		@		180MG	N020092	002	May 29, 1992	Mar CAHN
		@		240MG	N020092	003	May 29, 1992	Mar CAHN
		@	WATSON LABS	120MG	N020092	001	May 29, 1992	Feb DISC
		@		180MG	N020092	002	May 29, 1992	Feb DISC
		@		240MG	N020092	003	May 29, 1992	Feb DISC

DILTIAZEM HYDROCHLORIDE

AB2	+		MYLAN	240MG	A075124	001	Mar 18, 1998	Feb CRLD

TIAZAC

AB4			VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995	Feb CAHN
AB4				180MG	N020401	002	Sep 11, 1995	Feb CAHN
AB4				240MG	N020401	003	Sep 11, 1995	Feb CAHN
AB4				300MG	N020401	004	Sep 11, 1995	Feb CAHN
AB4				360MG	N020401	005	Sep 11, 1995	Feb CAHN
AB4	+			420MG	N020401	006	Oct 16, 1998	Feb CAHN

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

>A> AP			EUROHLTH INTL SARL	5MG/ML	A078538	001	Dec 17, 2008	Jun CAHN
>D> AP			HIKMA MAPLE	5MG/ML	A078538	001	Dec 17, 2008	Jun CAHN
		@	MYLAN PHARMS INC	5MG/ML	A075375	001	Sep 30, 1999	Apr CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

>A> AP	+		EUROHLTH INTL SARL	50MG/ML	A080817	002		Jun CAHN
>D> AP	+		HIKMA MAPLE	50MG/ML	A080817	002		Jun CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

>A> AP			EUROHLTH INTL SARL	5MG/ML	A074521	001	Oct 18, 1996	Jun CAHN
>D> AP			HIKMA MAPLE	5MG/ML	A074521	001	Oct 18, 1996	Jun CAHN
		@	MYLAN PHARMS INC	5MG/ML	A075769	001	Nov 27, 2002	Apr CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB			MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb NEWA
AB				500MG	A203916	002	Mar 04, 2015	Feb NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

AB	AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015	May	NEWA
AB		EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	May	NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

@	IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar	CAHN

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB	HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan	NEWA
AB		10MG	A203034	002	Jan 30, 2015	Jan	NEWA
AB	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr	CAHN
AB		10MG	A076786	002	Nov 26, 2010	Apr	CAHN
AB		23MG	A204293	001	Jun 05, 2015	May	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMZARIC

	FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Mar	CAHN
+		10MG;28MG	N206439	002	Dec 23, 2014	Mar	CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

@	IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985	Mar	CAHN
@		40MG/ML	N018656	001	Jun 28, 1983	Mar	CAHN
@		80MG/ML	A070089	001	Oct 23, 1985	Mar	CAHN
@		80MG/ML	A070090	001	Oct 23, 1985	Mar	CAHN
@		80MG/ML	A070091	001	Oct 23, 1985	Mar	CAHN
@		160MG/ML	A070092	001	Oct 23, 1985	Mar	CAHN
@		160MG/ML	A070093	001	Oct 23, 1985	Mar	CAHN
@		160MG/ML	A070094	001	Oct 23, 1985	Mar	CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

>A> AP	+ EUROHLTH INTL SARL	20MG/ML	N014879	001		Jun	CAHN
>D> AP	+ HIKMA MAPLE	20MG/ML	N014879	001		Jun	CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	+ MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan	CRLD
	+ PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan	CRLD

CREAM;TOPICAL

ZONALON

+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar	CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr	NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	MYLAN PHARMS INC	2MG/ML	A200901	001	Feb 14, 2012	May	CAHN
AP		10MG/VIAL	A200170	001	Oct 28, 2011	May	CAHN
AP		50MG/VIAL	A200170	002	Oct 28, 2011	May	CAHN

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May	NEWA
AB		EQ 75MG BASE	A204446	002	May 28, 2015	May	NEWA
AB		EQ 100MG BASE	A204446	003	May 28, 2015	May	NEWA

		CAPSULE;ORAL						
		DOXYCYCLINE						
	AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr	CAHN
	AB		EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr	CAHN
	AB		EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr	CAHN
		TABLET;ORAL						
		DOXYCYCLINE						
	AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr	CAHN
	AB		EQ 75MG BASE	A065356	002	May 31, 2006	Apr	CAHN
	AB		EQ 100MG BASE	A065356	003	May 31, 2006	Apr	CAHN
		DOXYCYCLINE HYCLATE						
		INJECTABLE;INJECTION						
		DOXYCYCLINE						
>A>		@ EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun	CAHN
>A>		@	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun	CAHN
>D>		@ HIKMA MAPLE	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun	CAHN
>D>		@	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun	CAHN
		DROPERIDOL						
		INJECTABLE;INJECTION						
		DROPERIDOL						
		@ IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar	CAHN
		@	2.5MG/ML	A072020	001	Oct 19, 1988	Mar	CAHN
		@	2.5MG/ML	A072021	001	Oct 19, 1988	Mar	CAHN
		DROSPIRENONE; ETHINYL ESTRADIOL						
		TABLET;ORAL-28						
		DROSPIRENONE AND ETHINYL ESTRADIOL						
	AB	FAMY CARE LTD	3MG;0.03MG	A202131	001	May 04, 2015	Apr	NEWA
		ECONAZOLE NITRATE						
		CREAM;TOPICAL						
		ECONAZOLE NITRATE						
	AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar	CRLD
	AB	+ PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar	CRLD
		EDOXABAN TOSYLATE						
		TABLET;ORAL						
		SAVAYSA						
		DAIICHI SANKYO	EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan	NEWA
			EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan	NEWA
		+	EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan	NEWA
		EDROPHONIUM CHLORIDE						
		INJECTABLE;INJECTION						
		ENLON						
		+ MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar	CRLD
		TENSILON						
		@ IGI LABS INC	10MG/ML	N007959	001		Apr	CAHN
		@ VALEANT PHARMS	10MG/ML	N007959	001		Mar	DISC
		TENSILON PRESERVATIVE FREE						
		@ IGI LABS INC	10MG/ML	N007959	002		Apr	CAHN
		@ VALEANT PHARMS	10MG/ML	N007959	002		Mar	DISC
		ELTROMBOPAG OLAMINE						
		TABLET;ORAL						
		PROMACTA						
		NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar	CAHN
			EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar	CAHN
			EQ 50MG ACID	N022291	002	Nov 20, 2008	May	CRLD
		+	EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar	CAHN
		+	EQ 75MG ACID	N022291	003	Sep 08, 2009	May	CRLD
			EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar	CAHN
		+	EQ 100MG ACID	N022291	005	Nov 16, 2012	May	CRLD
			EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar	CAHN

ELUXADOLINE
TABLET;ORAL
VIBERZI

		FURIEX PHARMS	75MG	N206940	001	May 27, 2015	May NEWA
	+		100MG	N206940	002	May 27, 2015	May NEWA

EMPAGLIFLOZIN; LINAGLIPTIN
TABLET;ORAL
GLYXAMBI

		BOEHRINGER INGELHEIM	10MG;5MG	N206073	001	Jan 30, 2015	Jan NEWA
	+		25MG;5MG	N206073	002	Jan 30, 2015	Jan NEWA

ENALAPRIL MALEATE
TABLET;ORAL
ENALAPRIL MALEATE

AB		SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar CMFD
AB			5MG	A075496	002	Aug 22, 2000	Mar CMFD
AB			10MG	A075459	001	Aug 22, 2000	Mar CMFD
AB			20MG	A075459	002	Aug 22, 2000	Mar CMFD
	@	SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr CAHN
	@		5MG	A075556	002	Aug 22, 2000	Apr CAHN
	@		10MG	A075556	003	Aug 22, 2000	Apr CAHN
	@		20MG	A075556	004	Aug 22, 2000	Apr CAHN

VASOTEC

AB		VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988	Apr CAHN
AB			5MG	N018998	001	Dec 24, 1985	Apr CAHN
AB			10MG	N018998	002	Dec 24, 1985	Apr CAHN
AB	+		20MG	N018998	003	Dec 24, 1985	Apr CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB		G AND W LABS INC	5MG;12.5MG	A075727	001	Sep 18, 2001	Apr CAHN
AB			10MG;25MG	A075727	002	Sep 18, 2001	Apr CAHN

ENTACAPONE
TABLET;ORAL
ENTACAPONE

>A>	AB		AUROBINDO PHARMA LTD	200MG	A203437	001	Jun 19, 2015	Jun NEWA

EPIRUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION
EPIRUBICIN HYDROCHLORIDE

AP		MYLAN PHARMS INC	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	May CAHN
AP			200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	May CAHN

>D> EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE
>D> TABLET;ORAL
>D> TEVETEN HCT

>D>		ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001	Jun DISC
>A>		@	600MG;12.5MG	N021268	001	Nov 01, 2001	Jun DISC
>D>	+		600MG;25MG	N021268	002	Nov 01, 2001	Jun DISC
>A>		@	600MG;25MG	N021268	002	Nov 01, 2001	Jun DISC

EPTIFIBATIDE
INJECTABLE;INJECTION
EPTIFIBATIDE

>A>	AP		TEVA PHARMS USA	2MG/ML	A090854	001	Jun 12, 2015	Jun NEWA
	AP			75MG/100ML	A091555	001	Jun 05, 2015	May NEWA

INTEGRILIN

>D>		+	SCHERING	2MG/ML	N020718	001	May 18, 1998	Jun CTEC
>A>	AP	+		2MG/ML	N020718	001	May 18, 1998	Jun CTEC
	AP	+		75MG/100ML	N020718	002	May 18, 1998	May CFTG

ERGOCALCIFEROL
CAPSULE;ORAL
VITAMIN D

AA		BANNER LIFE SCIENCES	50,000 IU	A080704	001		Jan CAHN

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

	@ G AND W LABS INC	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990	Apr	CAHN
	@	EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990	Apr	CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	May	NEWA

TABLET;ORAL

ESCITALOPRAM OXALATE

AB	MYLAN PHARMS INC	EQ 5MG BASE	A077550	001	May 14, 2015	Apr	NEWA
AB		EQ 10MG BASE	A077550	002	May 14, 2015	Apr	NEWA
AB		EQ 20MG BASE	A077550	003	May 14, 2015	Apr	NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP	LUITPOLD	10MG/ML	A201126	001	Feb 20, 2015	Feb	NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Jan	NEWA
AB		EQ 40MG BASE	A078003	002	Jan 26, 2015	Jan	NEWA

NEXIUM

AB	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153	001	Feb 20, 2001	Jan	CFTG
AB +		EQ 40MG BASE	N021153	002	Feb 20, 2001	Jan	CFTG

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

BX	ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar	CAHN
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar	CAHN
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar	CAHN
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar	CAHN

MINIVELLE

	NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014	Jan	NEWA

TABLET;VAGINAL

ESTRADIOL

	@ AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	May	DISC

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB	MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015	Jan	NEWA
AB		2MG	A202929	002	Jan 30, 2015	Jan	NEWA
AB		3MG	A202929	003	Jan 30, 2015	Jan	NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

AB	VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Jan	CMFD
AB		400MG	A075095	002	Nov 30, 1999	Jan	CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

ASHLYNA

AB	GLENMARK GENERICS	0.03MG,0.01MG;0.15MG,N/A	A203163	001	Feb 23, 2015	Feb	NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	FAMY CARE LTD	0.03MG;0.15MG	A200490	001	Apr 21, 2015	Apr	NEWA
AB	GLENMARK GENERICS	0.02MG;0.09MG	A202791	001	Apr 09, 2015	Mar	NEWA
>A> AB	GLENMARK PHARMS LTD	0.03MG;0.15MG	A203164	001	Jun 12, 2015	Jun	NEWA
AB +	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	Mar	CTEC

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

>A> AB	FAMY CARE LTD	0.02MG,0.01MG;0.1MG,N/A	A200493	001	Jun 17, 2015	Jun	NEWA
AB		0.03MG,0.01MG;0.15MG,N/A	A200492	001	May 27, 2015	May	NEWA

		TABLET;ORAL-28							
		VIENVA							
AB1		SANDOZ INC	0.02MG;0.1MG		A201088	001	May 21, 2015	May	NEWA
		ETHINYL ESTRADIOL; NORELGESTROMIN							
		FILM, EXTENDED RELEASE;TRANSDERMAL							
		ORTHO EVRA							
		@ JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR		N021180	001	Nov 20, 2001	Feb	DISC
		XULANE							
AB	+	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR		A200910	001	Apr 16, 2014	Feb	CRLD
		ETHINYL ESTRADIOL; NORETHINDRONE							
		TABLET;ORAL-21							
		BREVICON 21-DAY							
		@ ACTAVIS LABS UT INC	0.035MG;0.5MG		N017566	001		Mar	CAHN
		NORINYL 1+35 21-DAY							
AB		ACTAVIS LABS UT INC	0.035MG;1MG		N017565	001		Feb	CAHN
		TRI-NORINYL 21-DAY							
		@ ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG		N018977	001	Apr 13, 1984	Feb	CAHN
		TABLET;ORAL-28							
		BREVICON 28-DAY							
AB		ACTAVIS LABS UT INC	0.035MG;0.5MG		N017743	001		Mar	CAHN
		NORETHINDRONE AND ETHINYL ESTRADIOL							
AB		FAMY CARE LTD	0.035MG;0.4MG		A200897	001	May 11, 2015	Apr	NEWA
		NORINYL 1+35 28-DAY							
AB		ACTAVIS LABS UT INC	0.035MG;1MG		N017565	002		Feb	CAHN
		TRI-NORINYL 28-DAY							
AB	+	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG		N018977	002	Apr 13, 1984	Feb	CAHN
		TABLET, CHEWABLE;ORAL							
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB		FAMY CARE LTD	0.035MG;0.4MG		A202086	001	Apr 01, 2015	Mar	NEWA
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE							
		TABLET;ORAL							
		FEMHRT							
AB		WARNER CHILCOTT LLC	0.0025MG;0.5MG		N021065	001	Jan 14, 2005	Mar	CTEC
		LARIN 24 FE							
AB		NOVAST LABS LTD	0.02MG;1MG		A202994	001	Feb 18, 2015	Feb	NEWA
		LOESTRIN 24 FE							
		@ WARNER CHILCOTT	0.02MG;1MG		N021871	001	Feb 17, 2006	Jan	DISC
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	+	BARR LABS INC	0.005MG;1MG		A076221	001	Nov 06, 2009	Mar	CTEC
AB		GLENMARK GENERICS	0.0025MG;0.5MG		A203038	001	Apr 02, 2015	Mar	NEWA
AB			0.005MG;1MG		A203038	002	Apr 02, 2015	Mar	NEWA
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	+	AMNEAL PHARMS	0.02MG;1MG		A078267	001	Sep 01, 2009	Jan	CRLD
		TABLET;ORAL-21							
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB		FAMY CARE LTD	0.03MG;1.5MG		A202770	001	Feb 19, 2015	Feb	NEWA
		TABLET;ORAL-28							
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB		FAMY CARE LTD	0.03MG;1.5MG		A202741	001	Feb 20, 2015	Feb	NEWA
		ETHINYL ESTRADIOL; NORGESTIMATE							
		TABLET;ORAL-28							
		NORGESTIMATE AND ETHINYL ESTRADIOL							
AB		OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG		A200383	001	Apr 07, 2015	Mar	NEWA
AB			0.035MG;0.25MG		A200384	001	Apr 07, 2015	Mar	NEWA
		TRI-LO-ESTARYLLA							
>A> AB		SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG		A091232	001	Jun 29, 2015	Jun	NEWA
		ETHINYL ESTRADIOL; NORGESTREL							
		TABLET;ORAL-28							
		LOW-OGESTREL-28							
AB		WATSON LABS	0.03MG;0.3MG		A075288	002	Jul 28, 1999	Feb	CMFD

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB		BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan	CAHN

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

AP		MYLAN PHARMS INC	2MG/ML	A078289	001	Jan 02, 2009	Apr	CAHN

ETONOGESTREL

IMPLANT;IMPLANTATION

IMPLANON

>D>								
>D>	+	ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jun	DISC
>A>		@	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jun	DISC

EZETIMIBE

TABLET;ORAL

EZETIMIBE

>A>		@ GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Jun	DISC
>A>	AB		10MG	A078560	001	Jun 26, 2015	Jun	NEWA

ZETIA

>D>	+	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Jun	CFTG
>A>	+		10MG	N021445	001	Oct 25, 2002	Jun	CTEC
>A>	AB +		10MG	N021445	001	Oct 25, 2002	Jun	CFTG

FAMOTIDINE

INJECTABLE;INJECTION

FAMOTIDINE

>A>	AP +	EUROHLTH INTL SARL	10MG/ML	A075488	001	Apr 16, 2001	Jun	CAHN
>D>	AP +	HIKMA MAPLE	10MG/ML	A075488	001	Apr 16, 2001	Jun	CAHN

FAMOTIDINE PRESERVATIVE FREE

>A>	AP +	EUROHLTH INTL SARL	10MG/ML	A075486	001	Apr 16, 2001	Jun	CAHN
>D>	AP +	HIKMA MAPLE	10MG/ML	A075486	001	Apr 16, 2001	Jun	CAHN

TABLET;ORAL

PEPCID

AB		VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb	CAHN
AB	+		40MG	N019462	002	Oct 15, 1986	Feb	CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB		ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May	NEWA
AB			5MG	A203032	002	May 21, 2015	May	NEWA
AB			10MG	A203032	003	May 21, 2015	May	NEWA
AB		SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr	CAHN
AB			5MG	A091200	002	Dec 13, 2013	Apr	CAHN
AB			10MG	A091200	003	Dec 13, 2013	Apr	CAHN

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE

AB		SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr	CAHN
AB			130MG	A201748	002	Oct 31, 2014	Apr	CAHN

TABLET;ORAL

FENOFIBRATE

AB		SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr	CAHN
			107MG	A076635	002	Oct 31, 2005	Apr	CAHN
AB			160MG	A076635	003	Oct 31, 2005	Apr	CAHN

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

>D>		MUTUAL PHARM CO INC	35MG	N022418	001	Aug 14, 2009	Jun	CAHN
>D>	+		105MG	N022418	002	Aug 14, 2009	Jun	CAHN
>A>		TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Jun	CAHN
>A>	+		105MG	N022418	002	Aug 14, 2009	Jun	CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

	AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN

FENTANYL-12

>A>	AB	MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Jun	NEWA

FENTANYL-25

	AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN

FENTANYL-50

	AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN

FENTANYL-75

	AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

	@	BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar	CAHN
	@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar	CAHN
	@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar	CAHN
	@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar	CAHN
	@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar	CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

	AP	+ EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb	CAHN

FENTANYL HYDROCHLORIDE

SYSTEM;IONTOPHORESIS, TRANSDERMAL

IONSYS

>D>		@ THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Jun	CMFD
		@	10.8MCG	N021338	001	May 22, 2006	Apr	CAHN
>A>		+	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun	CMFD

FERRIC CITRATE

TABLET;ORAL

AURYXIA

		+ KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan	CTNA

FERRIC PYROPHOSPHATE CITRATE

SOLUTION;IV (INFUSION)

TRIFERIC

		+ ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jan	NEWA

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

	AB	ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr	CAHN
	AB		100MG	A075882	002	Oct 28, 2002	Apr	CAHN
	AB		150MG	A075882	003	Oct 28, 2002	Apr	CAHN
>A>	AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Jul 08, 2015	Jun	NEWA
>A>	AB		100MG	A202821	002	Jul 08, 2015	Jun	NEWA
>A>	AB		150MG	A202821	003	Jul 08, 2015	Jun	NEWA
	AB	SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr	CAHN
	AB		100MG	A076421	002	Mar 28, 2003	Apr	CAHN
	AB		150MG	A076421	003	Mar 28, 2003	Apr	CAHN

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

	AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Apr	CAHN
	AB		200MG/5ML	A076332	002	Jul 29, 2004	Apr	CAHN

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

	AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr	CAHN
	AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr	CAHN
		@ MYLAN PHARMS INC	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Apr	CAHN
		@	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Apr	CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

	AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr	CAHN
	AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr	CAHN

		INJECTABLE;INJECTION					
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
		CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr NEWA
			100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr CAHN
	AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr CAHN
	AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr CAHN
		@ MYLAN PHARMS INC	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Apr CAHN
		@	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Apr CAHN
		TABLET;ORAL					
		FLUCONAZOLE					
	AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	May CMFD
	AB		100MG	A078423	002	Mar 07, 2011	May CMFD
	AB		150MG	A078423	003	Mar 07, 2011	May CMFD
	AB		200MG	A078423	004	Mar 07, 2011	May CMFD
		FLUDARABINE PHOSPHATE					
		INJECTABLE;INJECTION					
		FLUDARABINE PHOSPHATE					
	AP	MYLAN PHARMS INC	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011	May CAHN
		FLUDEOXYGLUCOSE F-18					
		INJECTABLE;INTRAVENOUS					
		FLUDEOXYGLUCOSE F 18					
	AP	BIOMEDCL RES FDN	20-300mCi/ML	A203710	001	May 01, 2015	Apr NEWA
	AP		20-300mCi/ML	A203837	001	May 01, 2015	Apr NEWA
>A>	AP	TRIAD ISOTOPES INC	20-300mCi/ML	A203920	001	Jun 23, 2015	Jun NEWA
		UNIV NORTH DAKOTA	4-500mCi/ML	A203994	001	Feb 04, 2015	Jan NEWA
>A>	AP	UNIV UTAH CYCLOTRON	20-300mCi/ML	A204498	001	Jun 23, 2015	Jun NEWA
		FLUDEOXYGLUCOSE F18					
	AP	METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr NEWA
		PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar NEWA
		SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr NEWA
		FLUMAZENIL					
		INJECTABLE;INJECTION					
		FLUMAZENIL					
		@ CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr CAHN
		@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr CAHN
>A>	AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun CAHN
>A>	AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun CAHN
>D>	AP	HIKMA MAPLE	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun CAHN
>D>	AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun CAHN
	AP	MYLAN PHARMS INC	0.5MG/5ML (0.1MG/ML)	A078595	001	May 13, 2008	Apr CAHN
	AP +		1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Apr CAHN
		FLUOCINOLONE ACETONIDE					
		OIL;TOPICAL					
		FLUOCINOLONE ACETONIDE					
>A>	AT	VERSAPHARM INC	0.01%	A091514	001	Jun 25, 2015	Jun NEWA
		FLUOCINONIDE					
		GEL;TOPICAL					
		FLUOCINONIDE					
	AB	G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr CAHN
		FLUOROURACIL					
		CREAM;TOPICAL					
		CARAC					
	AB +	VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr CFTG
	+		0.5%	N020985	001	Oct 27, 2000	Feb CAHN
		FLUOROURACIL					
	AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr NEWA
		INJECTABLE;INJECTION					
		FLUOROURACIL					
	AP	MYLAN PHARMS INC	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr CAHN
	AP		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

	@	ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar	DISC
	@		EQ 20MG BASE	A076287	002	May 20, 2008	Mar	DISC
	+	MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CRLD
			EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CTEC
	@	SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar	DISC
	@		EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar	DISC
AB1		SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar	NEWA
AB1			EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar	NEWA
AB			EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar	NEWA
AB		SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr	CAHN

SARAFEM

	@	ELI LILLY AND CO	EQ 10MG BASE	N018936	007	Jul 06, 2000	Mar	DISC
	@		EQ 20MG BASE	N018936	008	Jul 06, 2000	Mar	DISC

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

	@	MYLAN PHARMS INC	25MG/ML	A075918	001	Aug 17, 2001	Apr	CAHN

FLURANDRENOLIDE

OINTMENT;TOPICAL

CORDRAN

>D>		AQUA PHARMS	0.05%	N012806	001		Jun	CRLD
>A>	+		0.05%	N012806	001		Jun	CRLD
			0.05%	N012806	001		May	CMFD

TAPE;TOPICAL

CORDRAN

	+	ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Mar	CAHN

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION

BREO ELLIPTA

		GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Apr	CAHN
AB			20MG;12.5MG	A076739	002	Dec 17, 2004	Apr	CAHN

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

	@	IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar	CAHN
	@		10MG/ML	A070096	001	Sep 09, 1985	Mar	CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB		SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr	CAHN
AB			300MG	A076606	002	Oct 07, 2005	Apr	CAHN
AB			400MG	A076606	003	Oct 07, 2005	Apr	CAHN

TABLET;ORAL

GABAPENTIN

>D>	AB	HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jun	DISC
>A>	@		600MG	A078782	001	Jul 21, 2011	Jun	DISC
>D>	AB		800MG	A078782	002	Jul 21, 2011	Jun	DISC
>A>	@		800MG	A078782	002	Jul 21, 2011	Jun	DISC

GADOVERSETAMIDE

INJECTABLE;INJECTION

OPTIMARK

	+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb	CAHN
	+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb	CAHN
	+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb	CAHN
	+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb	CAHN
	+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb	CAHN

		INJECTABLE;INJECTION						
		OPTIMARK IN PLASTIC CONTAINER						
	+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb	CAHN
	+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb	CAHN
	+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb	CAHN
	+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb	CAHN
		GEMCITABINE HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		GEMCITABINE HYDROCHLORIDE						
AP		MYLAN PHARMS INC	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011	May	CAHN
AP			EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011	May	CAHN
AP			EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	May	CAHN
		GEMIFLOXACIN MESYLATE						
		TABLET;ORAL						
		FACTIVE						
>D>	+	LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun	CFTG
>A> AB	+		EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun	CFTG
>A>		GEMIFLOXACIN MESYLATE						
>A> AB		ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jun	NEWA
		GLATIRAMER ACETATE						
		INJECTABLE;SUBCUTANEOUS						
		COPAXONE						
AP	+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar	CFTG
		GLATOPA						
AP		SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar	NEWA
		GLIMEPIRIDE						
		TABLET;ORAL						
		GLIMEPIRIDE						
	@	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr	DISC
	@		2MG	A078952	002	Aug 01, 2013	Apr	DISC
	@		4MG	A078952	003	Aug 01, 2013	Apr	DISC
>D>		GLIMEPIRIDE; ROSIGLITAZONE MALEATE						
>D>		TABLET;ORAL						
>D>		AVANDARYL						
>D>	+	SB PHARMCO	1MG;4MG	N021700	001	Nov 23, 2005	Jun	DISC
>A>	@		1MG;4MG	N021700	001	Nov 23, 2005	Jun	DISC
>D>			2MG;4MG	N021700	002	Nov 23, 2005	Jun	DISC
>A>	@		2MG;4MG	N021700	002	Nov 23, 2005	Jun	DISC
>D>			2MG;8MG	N021700	004	Mar 30, 2007	Jun	DISC
>A>	@		2MG;8MG	N021700	004	Mar 30, 2007	Jun	DISC
>D>			4MG;4MG	N021700	003	Nov 23, 2005	Jun	DISC
>A>	@		4MG;4MG	N021700	003	Nov 23, 2005	Jun	DISC
>D>			4MG;8MG	N021700	005	Mar 30, 2007	Jun	DISC
>A>	@		4MG;8MG	N021700	005	Mar 30, 2007	Jun	DISC
		GLIPIZIDE						
		TABLET, EXTENDED RELEASE;ORAL						
		GLIPIZIDE						
AB		MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	May	NEWA
AB			5MG	A202298	002	May 19, 2015	May	NEWA
AB			10MG	A202298	003	May 19, 2015	May	NEWA
		GLUCAGON HYDROCHLORIDE						
		POWDER;INTRAMUSCULAR, INTRAVENOUS						
		GLUCAGON						
	+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015	May	NEWA
		GLYCEROL PHENYLBUTYRATE						
		LIQUID;ORAL						
		RAVICTI						
	+	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May	CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION

ROBINUL

>A>	AP	+	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Jun CAHN
>D>	AP	+	HIKMA MAPLE	0.2MG/ML	N017558	001		Jun CAHN

TABLET;ORAL

GLYCOPYRROLATE

	AA		SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr CAHN
	AA			2MG	A040844	002	Aug 18, 2009	Apr CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

	AP		BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
	AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
		@	CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr CAHN
		@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr CAHN
>A>	AP		EUROHLTH INTL SARL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jun CAHN
>D>	AP		HIKMA MAPLE	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jun CAHN

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

	AP		BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

FLOWTUSS

			MIKART INC	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	May NEWA

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

		+	MIKART INC	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	May NEWA

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

	AB		MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May NEWA
	AB			EQ 2MG BASE	A202578	002	Jun 02, 2015	May NEWA
	AB			EQ 3MG BASE	A202578	003	Jun 02, 2015	May NEWA
	AB			EQ 4MG BASE	A202578	004	Jun 02, 2015	May NEWA
	AB		SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May NEWA
	AB			EQ 2MG BASE	A202568	002	Jun 03, 2015	May NEWA
	AB			EQ 3MG BASE	A202568	003	Jun 03, 2015	May NEWA
	AB			EQ 4MG BASE	A202568	004	Jun 03, 2015	May NEWA
	AB		TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May NEWA
	AB			EQ 2MG BASE	A201382	002	Jun 02, 2015	May NEWA
	AB			EQ 3MG BASE	A201382	003	Jun 02, 2015	May NEWA
	AB			EQ 4MG BASE	A201382	004	Jun 02, 2015	May NEWA
	AB		TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May NEWA
	AB			EQ 2MG BASE	A201408	002	Jun 02, 2015	May NEWA
	AB			EQ 3MG BASE	A201408	003	Jun 02, 2015	May NEWA
	AB			EQ 4MG BASE	A201408	004	Jun 02, 2015	May NEWA

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

		@	CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May CAHN
>A>		@		1MG	A071129	001	Feb 17, 1987	Jun CAHN
>A>		@		5MG	A071131	001	Feb 17, 1987	Jun CAHN
>A>		@		10MG	A071132	001	May 12, 1987	Jun CAHN
		@		20MG	A071133	001	May 12, 1987	May CAHN
>D>		@	ROXANE	1MG	A071129	001	Feb 17, 1987	Jun CAHN
>D>		@		2MG	A071130	001	Feb 17, 1987	Jun CAHN
>A>		@		2MG	A071130	001	Feb 17, 1987	Jun CAHN
>D>		@		5MG	A071131	001	Feb 17, 1987	Jun CAHN
>D>		@		10MG	A071132	001	May 12, 1987	Jun CAHN

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALOPERIDOL INTENSOL

		@	CYCLE PHARMS LTD	EQ 2MG BASE/ML	A	072045	001	Apr 12, 1988	May CAHN

INJECTABLE;INJECTION

HALOPERIDOL

		@	CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A	076791	001	Aug 25, 2004	Apr CAHN
		@		EQ 5MG BASE/ML	A	076828	001	Aug 25, 2004	May CAHN
	AP		MYLAN PHARMS INC	EQ 5MG BASE/ML	A	078347	001	Sep 14, 2009	Apr CAHN

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

>A>	AP	+	EUROHLTH INTL SARL	1,000 UNITS/ML	N	017037	001		Jun CAHN
>A>	AP	+		5,000 UNITS/ML	N	017037	002		Jun CAHN
>A>		@		5,000 UNITS/0.5ML	N	017037	013	Apr 07, 1986	Jun CAHN
>A>	AP	+		10,000 UNITS/ML	N	017037	003		Jun CAHN
>D>	AP	+	HIKMA MAPLE	1,000 UNITS/ML	N	017037	001		Jun CAHN
>D>	AP	+		5,000 UNITS/ML	N	017037	002		Jun CAHN
>D>		@		5,000 UNITS/0.5ML	N	017037	013	Apr 07, 1986	Jun CAHN
>D>	AP	+		10,000 UNITS/ML	N	017037	003		Jun CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

	AP	+	AKORN	20MG/ML	A	040730	001	Apr 21, 2009	Feb CRLD
	AP		LUITPOLD	20MG/ML	A	040136	001	Jun 30, 1997	Feb CRLD
>A>	AP		X-GEN PHARMS INC	20MG/ML	A	203110	001	Jun 29, 2015	Jun NEWA

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

MICROZIDE

	AB	+	ACTAVIS LABS UT INC	12.5MG	N	020504	001	Dec 27, 1996	Feb CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

	AB		SUN PHARM INDS LTD	12.5MG;10MG	A	076007	001	Jul 01, 2002	Apr CAHN
	AB			12.5MG;20MG	A	076007	002	Jul 01, 2002	Apr CAHN
	AB			25MG;20MG	A	076007	003	Jul 01, 2002	Apr CAHN

ZESTORETIC

	AB		ALVOGEN IPCO SARL	12.5MG;10MG	N	019888	003	Nov 18, 1993	Feb CAHN
	AB	+		12.5MG;20MG	N	019888	001	Sep 20, 1990	Feb CAHN
	AB	+		25MG;20MG	N	019888	002	Jul 20, 1989	Feb CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DUTOPROL

>A>			CONCORDIA PHARMS INC	12.5MG;EQ 25MG TARTRATE	N	021956	001	Aug 28, 2006	Jun CAHN
>A>				12.5MG;EQ 50MG TARTRATE	N	021956	002	Aug 28, 2006	Jun CAHN
>A>		+		12.5MG;EQ 100MG TARTRATE	N	021956	003	Aug 28, 2006	Jun CAHN
>D>			COVIS PHARMA SARL	12.5MG;EQ 25MG TARTRATE	N	021956	001	Aug 28, 2006	Jun CAHN
>D>				12.5MG;EQ 50MG TARTRATE	N	021956	002	Aug 28, 2006	Jun CAHN
>D>		+		12.5MG;EQ 100MG TARTRATE	N	021956	003	Aug 28, 2006	Jun CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	AB		SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A	078211	001	Mar 04, 2009	Apr CAHN
	AB			12.5MG;EQ 20MG BASE	A	078211	002	Mar 04, 2009	Apr CAHN
	AB			25MG;EQ 20MG BASE	A	078211	003	Mar 04, 2009	Apr CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

>D>		+	FERRIMILL LTD	10MG	N	202880	001	Oct 25, 2013	Jun CAHN
		+		10MG	N	202880	001	Oct 25, 2013	Apr CAHN
>D>				15MG	N	202880	002	Oct 25, 2013	Jun CAHN
				15MG	N	202880	002	Oct 25, 2013	Apr CAHN
>D>				20MG	N	202880	003	Oct 25, 2013	Jun CAHN
				20MG	N	202880	003	Oct 25, 2013	Apr CAHN

			CAPSULE, EXTENDED RELEASE;ORAL						
			ZOHYDRO ER						
>D>				30MG		N202880	004	Oct 25, 2013	Jun CAHN
				30MG		N202880	004	Oct 25, 2013	Apr CAHN
>D>				40MG		N202880	005	Oct 25, 2013	Jun CAHN
				40MG		N202880	005	Oct 25, 2013	Apr CAHN
>D>				50MG		N202880	006	Oct 25, 2013	Jun CAHN
				50MG		N202880	006	Oct 25, 2013	Apr CAHN
>A>		+	PERNIX IRELAND PAIN	10MG		N202880	001	Oct 25, 2013	Jun CAHN
>A>				15MG		N202880	002	Oct 25, 2013	Jun CAHN
>A>				20MG		N202880	003	Oct 25, 2013	Jun CAHN
>A>				30MG		N202880	004	Oct 25, 2013	Jun CAHN
>A>				40MG		N202880	005	Oct 25, 2013	Jun CAHN
>A>				50MG		N202880	006	Oct 25, 2013	Jun CAHN
			TABLET, EXTENDED RELEASE;ORAL						
			HYSINGLA						
		+	PURDUE PHARMA LP	20MG		N206627	001	Nov 20, 2014	Mar CRLD
			HYDROCORTISONE						
			CREAM;TOPICAL						
			HYDROCORTISONE						
	AT		RISING PHARMS INC	2.5%		A040879	001	Aug 20, 2010	Mar CAHN
			POWDER;FOR RX COMPOUNDING						
			HYDRO-RX						
		@	X GEN PHARMS	100%		A085982	001		Apr DISC
			TABLET;ORAL						
			HYDROCORTISONE						
	AB		HIKMA INTL PHARMS	5MG		A083365	002	Feb 23, 2015	Feb NEWA
	AB			10MG		A083365	003	Feb 23, 2015	Feb NEWA
	AB			20MG		A083365	001		Feb CMFD
			HYDROCORTISONE ACETATE						
			POWDER;FOR RX COMPOUNDING						
			HYDROCORTISONE ACETATE						
		@	X GEN PHARMS	100%		A085981	001		Apr DISC
			HYDROCORTISONE VALERATE						
			CREAM;TOPICAL						
			HYDROCORTISONE VALERATE						
		@	G AND W LABS INC	0.2%		A074489	001	Aug 12, 1998	Apr CAHN
			HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE						
			SUSPENSION/DROPS;OTIC						
			CORTISPORIN						
>D>	AT	+	CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		A060613	001		Jun CMS2
>A>	AT	+		1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		N060613	001		Jun CMS2
			HYDROMORPHONE HYDROCHLORIDE						
			TABLET, EXTENDED RELEASE;ORAL						
			HYDROMORPHONE HYDROCHLORIDE						
	AB		PADDOCK LLC	8MG		A204278	001	Apr 06, 2015	Mar NEWA
	AB			12MG		A204278	002	Apr 06, 2015	Mar NEWA
	AB			16MG		A204278	003	Apr 06, 2015	Mar NEWA
			HYDROXOCOBALAMIN						
			INJECTABLE;INJECTION						
			CYANOKIT						
		@	SERB SAS	2.5GM/VIAL (5GM/KIT)		N022041	002	Dec 15, 2006	Apr CAHN
		+		5GM/VIAL (5GM/KIT)		N022041	001	Apr 08, 2011	Apr CAHN
			HYDROXYCHLOROQUINE SULFATE						
			TABLET;ORAL						
			PLAQUENIL						
>A>	AB	+	CONCORDIA PHARMS INC	200MG		N009768	001		Jun CAHN
>D>	AB	+	SANOFI AVENTIS US	200MG		N009768	001		Jun CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION

HYDROXYPROGESTERONE CAPROATE

@	ACTAVIS LABS UT INC	125MG/ML	N017439	001			Mar CAHN
@		250MG/ML	N017439	002			Mar CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

>A> AB	ELITE LABS INC	10MG	A040600	001	Dec 28, 2004		Jun CAHN
>A> AB		25MG	A040602	001	Dec 28, 2004		Jun CAHN
>A> AB		50MG	A040604	001	Dec 28, 2004		Jun CAHN
AB	HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014		Mar CAHN
AB		25MG	A204279	002	Aug 20, 2014		Mar CAHN
AB		50MG	A204279	003	Aug 20, 2014		Mar CAHN
>D> AB	MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004		Jun CAHN
AB		10MG	A040600	001	Dec 28, 2004		Mar CMFD
>D> AB		25MG	A040602	001	Dec 28, 2004		Jun CAHN
AB		25MG	A040602	001	Dec 28, 2004		Mar CMFD
>D> AB		50MG	A040604	001	Dec 28, 2004		Jun CAHN
AB		50MG	A040604	001	Dec 28, 2004		Mar CMFD

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013		Mar CAHN
AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013		Mar CAHN

IFOSFAMIDE

INJECTABLE;INJECTION

IFOSFAMIDE

AP	MYLAN PHARMS INC	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012		May CAHN
AP		3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012		May CAHN

ILOPERIDONE

TABLET;ORAL

FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009		Jan CAHN
		2MG	N022192	002	May 06, 2009		Jan CAHN
		4MG	N022192	003	May 06, 2009		Jan CAHN
		6MG	N022192	004	May 06, 2009		Jan CAHN
		8MG	N022192	005	May 06, 2009		Jan CAHN
		10MG	N022192	006	May 06, 2009		Jan CAHN
		12MG	N022192	007	May 06, 2009		Jan CAHN

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

AB	G AND W LABS INC	5%	A200481	001	Apr 18, 2011		Apr CAHN

INGENOL MEBUTATE

GEL;TOPICAL

PICATO

+	LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012		May CRLD

INSULIN GLARGINE RECOMBINANT

SOLUTION;SUBCUTANEOUS

TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300 UNITS/ML (300 UNITS/ML)	N206538	001	Feb 25, 2015		Feb NEWA

INSULIN LISPRO RECOMBINANT

SOLUTION;SUBCUTANEOUS

HUMALOG KWIKPEN

+	ELI LILLY AND CO	200 UNITS/ML	N205747	001	May 26, 2015		May NEWA

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION

AFREZZA

	SANOFI AVENTIS	12 UNITS/INH	N022472	003	Apr 17, 2015		Apr NEWA

IOHEXOL

FOR SOLUTION;ORAL

ORALTAG

	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015	Mar	NEWA

IOPAMIDOL

INJECTABLE;INJECTION

IOPAMIDOL-250

@	FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997	Jan	DISC

IOPAMIDOL-300

@	FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997	Jan	DISC

IOPAMIDOL-370

@	FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997	Jan	DISC

ISOVUE-200

+	BRACCO	41%	N018735	006	Jul 07, 1987	Feb	CTEC

ISOVUE-250

+	BRACCO	51%	N018735	007	Jul 06, 1992	Feb	CTEC
+		51%	N020327	002	Oct 12, 1994	Feb	CTEC

ISOVUE-300

+	BRACCO	61%	N020327	003	Oct 12, 1994	Feb	CTEC

ISOVUE-370

+	BRACCO	76%	N020327	004	Oct 12, 1994	Feb	CTEC

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION

CONRAY

+	LIEBEL-FLARSHEIM	60%	N013295	001		Feb	CAHN

CONRAY 30

+	LIEBEL-FLARSHEIM	30%	N016983	001		Feb	CAHN

CONRAY 43

+	LIEBEL-FLARSHEIM	43%	N013295	002		Feb	CAHN

SOLUTION;INTRAVESICAL

CYSTO-CONRAY II

	LIEBEL-FLARSHEIM	17.2%	N017057	002		Feb	CAHN

IOVERSOL

INJECTABLE;INJECTION

OPTIRAY 160

@	LIEBEL-FLARSHEIM	34%	N019710	003	Dec 30, 1988	Feb	CAHN

OPTIRAY 240

+	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988	Feb	CAHN
@		51%	N020923	001	May 28, 1998	Feb	CAHN

OPTIRAY 300

+	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992	Feb	CAHN
+		64%	N020923	004	May 13, 1999	Feb	CAHN

OPTIRAY 320

+	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988	Feb	CAHN
@		68%	N020923	002	May 29, 1998	Feb	CAHN

OPTIRAY 350

+	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992	Feb	CAHN
+		74%	N020923	003	May 28, 1998	Feb	CAHN

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE;INJECTION

HEXABRIX

@	GUERBET	39.3%;19.6%	N018905	002	Jul 26, 1985	May	DISC

IRBESARTAN

TABLET;ORAL

IRBESARTAN

AB	JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015	Feb	NEWA
AB		150MG	A203534	002	Feb 23, 2015	Feb	NEWA
AB		300MG	A203534	003	Feb 23, 2015	Feb	NEWA

IRON DEXTRAN

INJECTABLE;INJECTION

INFED

BP	+ ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441	001		Mar	CAHN

ISAVUCONAZONIUM SULFATE

	CAPSULE;ORAL						
	CRESEMBA						
	+ ASTELLAS	186MG	N207500	001	Mar 06, 2015	Mar	NEWA
	POWDER;IV (INFUSION)						
	CRESEMBA						
	+ ASTELLAS	372MG	N207501	001	Mar 06, 2015	Mar	NEWA

ISOSORBIDE DINITRATE

	TABLET;ORAL						
	ISORDIL						
AB	VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb	CAHN
	@	10MG	N012093	002	Jul 29, 1988	Feb	CAHN
	@	20MG	N012093	006	Jul 29, 1988	Feb	CAHN
	@	30MG	N012093	005	Jul 29, 1988	Feb	CAHN
	+	40MG	N012093	001	Jul 29, 1988	Feb	CAHN

ISOTRETINOIN

	CAPSULE;ORAL						
	ABSORICA						
	RANBAXY	25MG	N021951	005	Aug 15, 2014	Feb	NEWA
		35MG	N021951	006	Aug 15, 2014	Feb	NEWA
	SOTRET						
AB	SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Apr	CAHN
AB		20MG	A076041	002	Dec 24, 2002	Apr	CAHN
AB		30MG	A076503	001	Jun 20, 2003	Apr	CAHN
AB		40MG	A076041	003	Dec 24, 2002	Apr	CAHN
	ZENATANE						
AB	DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb	NEWA

ISRADIPINE

	CAPSULE;ORAL						
	ISRADIPINE						
AB	ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar	CAHN
AB		5MG	A077169	002	Apr 24, 2006	Mar	CAHN

IVABRADINE HYDROCHLORIDE

	TABLET;ORAL						
	CORLANOR						
	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Apr	NEWA
	+	EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Apr	NEWA

IVACAFTOR

	GRANULE;ORAL						
	KALYDECO						
	VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015	Mar	NEWA
	+	75MG/PACKET	N207925	002	Mar 17, 2015	Mar	NEWA

IXABEPILONE

	INJECTABLE;IV (INFUSION)						
	IXEMPRA KIT						
>D>	+ BRISTOL MYERS SQUIBB	15MG/VIAL	N022065	001	Oct 16, 2007	Jun	CAHN
>D>	+	45MG/VIAL	N022065	002	Oct 16, 2007	Jun	CAHN
>A>	+ R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007	Jun	CAHN
>A>	+	45MG/VIAL	N022065	002	Oct 16, 2007	Jun	CAHN

KANAMYCIN SULFATE

	INJECTABLE;INJECTION						
	KANAMYCIN						
>A>	@ EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324	001		Jun	CAHN
>A>	@	EQ 500MG BASE/2ML	A062324	002		Jun	CAHN
>A>	@	EQ 1GM BASE/3ML	A062324	003		Jun	CAHN
>D>	@ HIKMA MAPLE	EQ 75MG BASE/2ML	A062324	001		Jun	CAHN
>D>	@	EQ 500MG BASE/2ML	A062324	002		Jun	CAHN
>D>	@	EQ 1GM BASE/3ML	A062324	003		Jun	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

		@ CLARIS PHARMASERVICE	15MG/ML	A	075631	002	Jun 29, 2001	Apr CAHN
		@	30MG/ML	A	075631	001	Jun 29, 2001	Apr CAHN
>A>		@ EUROHLTH INTL SARL	15MG/ML	A	075772	001	Jul 21, 2004	Jun CAHN
>A>		@	30MG/ML	A	075772	002	Jul 21, 2004	Jun CAHN
>D>		@ HIKMA MAPLE	15MG/ML	A	075772	001	Jul 21, 2004	Jun CAHN
>D>		@	30MG/ML	A	075772	002	Jul 21, 2004	Jun CAHN
	AP	MYLAN PHARMS INC	15MG/ML	A	078299	001	Jul 16, 2007	Apr CAHN
	AP		30MG/ML	A	078299	002	Jul 16, 2007	Apr CAHN

SPRAY, METERED;NASAL

SPRIX

	+	EGALET US INC	15.75MG/SPRAY	N	022382	001	May 14, 2010	Jan CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

OMIDRIA

	+	OMEROS	EQ 4.24MG BASE/ML;EQ 12.4MG BASE/ML	N	205388	001	May 30, 2014	Feb CPOT

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

		@ CLARIS PHARMASERVICE	5MG/ML	A	076051	001	Jul 05, 2002	Apr CAHN

TABLET;ORAL

LABETALOL HYDROCHLORIDE

	AB	MUTUAL PHARM	100MG	A	075215	001	Jul 29, 1999	Jan CMFD
	AB		200MG	A	075215	002	Jul 29, 1999	Jan CMFD
	AB		300MG	A	075215	003	Jul 29, 1999	Jan CMFD

LACTULOSE

SOLUTION;ORAL, RECTAL

LACTULOSE

	AA	BIO-PHARM INC	10GM/15ML	A	203762	001	Mar 27, 2015	Mar NEWA

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET;ORAL

DUTREBIS

	+	MERCK SHARP DOHME	150MG;EQ 300MG BASE	N	206510	001	Feb 06, 2015	Feb NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

	AB	STRIDES ARCOLAB LTD	150MG;300MG	A	079128	001	May 13, 2015	Apr NEWA

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

		@ HIKMA PHARMS	25MG	A	078134	001	Apr 19, 2011	May DISC
		@	100MG	A	078134	002	Apr 19, 2011	May DISC
		@	150MG	A	078134	003	Apr 19, 2011	May DISC
		@	200MG	A	078134	004	Apr 19, 2011	May DISC

LAPATINIB DITOSYLATE

TABLET;ORAL

TYKERB

	+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N	022059	001	Mar 13, 2007	Mar CAHN

LENVATINIB MESYLATE

CAPSULE;ORAL

LENVIMA

		EISAI INC	EQ 4MG BASE	N	206947	001	Feb 13, 2015	Feb NEWA
	+		EQ 10MG BASE	N	206947	002	Feb 13, 2015	Feb NEWA

LEVETIRACETAM

SOLUTION;ORAL

LEVETIRACETAM

	AA	PHARM ASSOC	100MG/ML	A	201157	001	Jun 04, 2015	May NEWA

		TABLET, EXTENDED RELEASE;ORAL					
		ELEPSIA XR					
		SPARC	1GM	N204417	001	Mar 02, 2015	Mar NEWA
			1.5GM	N204417	002	Mar 02, 2015	Mar NEWA
		LEVETIRACETAM					
		APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb NEWA
	AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May NEWA
	AB		750MG	A203468	002	May 21, 2015	May NEWA
		LEVOCARNITINE					
		INJECTABLE;INJECTION					
		LEVOCARNITINE					
		@ TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr DISC
		LEVOCETIRIZINE DIHYDROCHLORIDE					
		TABLET;ORAL					
		LEVOCETIRIZINE DIHYDROCHLORIDE					
	AB	APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb NEWA
>A>	AB	SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Jun NEWA
		LEVOFLOXACIN					
		INJECTABLE;INJECTION					
		LEVOFLOXACIN					
	AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr CAHN
		LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
	AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr CAHN
	AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr CAHN
	AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr CAHN
		TABLET;ORAL					
		LEVOFLOXACIN					
>A>	AB	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun NEWA
>A>	AB		500MG	A203613	002	Jun 19, 2015	Jun NEWA
		LEVOLEUCOVORIN CALCIUM					
		SOLUTION;IV (INFUSION)					
		LEVOLEUCOVORIN CALCIUM					
		SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb NEWA
		SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb NEWA
	+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar CRLD
		LEVONORGESTREL					
		INTRAUTERINE DEVICE;INTRAUTERINE					
		LILETTA					
		MEDICINES360	52MG	N206229	001	Feb 26, 2015	Feb NEWA
		LEVORPHANOL TARTRATE					
		TABLET;ORAL					
		LEVORPHANOL TARTRATE					
	+	SENTYNL THERAPS INC	2MG	A074278	001	Mar 31, 2000	Apr CAHN
		LIDOCAINE					
		PATCH;TOPICAL					
		LIDOCAINE					
	AB	ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar CAHN
		LIDOCAINE HYDROCHLORIDE					
		INJECTABLE;INJECTION					
		LIDOCAINE HYDROCHLORIDE					
		@ EUROHLTH INTL SARL	1%	A080407	001		Mar CAHN
		@	2%	A080407	002		Mar CAHN
	AP	MYLAN PHARMS INC	0.5%	A091056	001	Dec 08, 2010	May CAHN
	AP		0.5%	A091058	001	Sep 30, 2010	May CAHN
	AP		1%	A091056	002	Dec 08, 2010	May CAHN
	AP		1%	A091058	002	Sep 30, 2010	May CAHN
		LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
		@ EUROHLTH INTL SARL	1%	A084625	001		Feb CAHN
		@	2%	A084625	002		Feb CAHN
	AP	MYLAN PHARMS INC	2%	A090665	001	Sep 27, 2010	May CAHN

		JELLY;TOPICAL						
		ANESTACON						
		@ BANNER LIFE SCIENCES	2%	A080429	001			Jan CAHN
		LIDOCAINE HYDROCHLORIDE						
		@ G AND W LABS INC	2%	A081318	001	Apr 29, 1993		Apr CAHN
		LIDOCAINE; PRILOCAINE						
		CREAM;TOPICAL						
		EMLA						
	AB	+ ACTAVIS LABS UT INC	2.5%;2.5%	N019941	001	Dec 30, 1992		Feb CAHN
		LINACLOTIDE						
		CAPSULE;ORAL						
		LINZESS						
		FOREST LABS LLC	145MCG	N202811	001	Aug 30, 2012		Mar CAHN
		+	290MCG	N202811	002	Aug 30, 2012		Mar CAHN
		LINCOMYCIN HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		LINCOCIN						
	AP	+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317	001			May CFTG
		LINCOMYCIN						
	AP	X-GEN PHARMS INC	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015		May NEWA
		LINEZOLID						
		FOR SUSPENSION;ORAL						
		LINEZOLID						
	AB	ROXANE	100MG/5ML	A200068	001	Jun 03, 2015		May NEWA
		ZYVOX						
	AB	+ PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000		May CFTG
		SOLUTION;IV (INFUSION)						
		LINEZOLID						
>A>	AP	HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015		Jun NEWA
	AP	TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012		May CDFR
>A>		LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>A>		+ HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015		Jun NEWA
		ZYVOX						
		PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000		May CDFR
			400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000		May NEWA
	AP	+	600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000		May NEWA
		TABLET;ORAL						
		LINEZOLID						
	AB	TEVA PHARMS USA	600MG	A078061	001	May 18, 2015		May NEWA
		ZYVOX						
	AB	+ PHARMACIA AND UPJOHN	600MG	N021130	002	Apr 18, 2000		May CFTG
		LISINOPRIL						
		TABLET;ORAL						
		LISINOPRIL						
	AB	SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002		Apr CAHN
	AB		5MG	A075944	002	Jul 01, 2002		Apr CAHN
	AB		10MG	A075944	003	Jul 01, 2002		Apr CAHN
	AB		20MG	A075944	004	Jul 01, 2002		Apr CAHN
	AB		30MG	A075944	006	Feb 11, 2003		Apr CAHN
	AB		40MG	A075944	005	Jul 01, 2002		Apr CAHN
		ZESTRIL						
	AB	ALVOGEN IPCO SARL	2.5MG	N019777	005	Apr 29, 1993		Feb CAHN
	AB		5MG	N019777	001	May 19, 1988		Feb CAHN
	AB		10MG	N019777	002	May 19, 1988		Feb CAHN
	AB		20MG	N019777	003	May 19, 1988		Feb CAHN
	AB		30MG	N019777	006	Jan 20, 1999		Feb CAHN
	AB	+	40MG	N019777	004	May 19, 1988		Feb CAHN
		LITHIUM CARBONATE						
		TABLET, EXTENDED RELEASE;ORAL						
		LITHIUM CARBONATE						
	AB	ALEMBIC PHARMS LTD	300MG	A204445	001	Jun 10, 2015		May NEWA
		@ HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003		Feb DISC

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

AEGERION	EQ 30MG BASE	N203858	004	Apr 23, 2015	Apr	NEWA
	EQ 40MG BASE	N203858	005	Apr 23, 2015	Apr	NEWA
	EQ 60MG BASE	N203858	006	Apr 23, 2015	Apr	NEWA

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014	Jan	NEWA

LOPINAVIR; RITONAVIR

CAPSULE;ORAL

KALETRA

>D>	+	ABBVIE	133.3MG;33.3MG	N021226	001	Sep 15, 2000	Jun DISC
>A>		@	133.3MG;33.3MG	N021226	001	Sep 15, 2000	Jun DISC

LORAZEPAM

INJECTABLE;INJECTION

ATIVAN

>A> AP	+	EUROHLTH INTL SARL	2MG/ML	N018140	001			Jun CAHN
>A> AP	+		4MG/ML	N018140	002			Jun CAHN
>D> AP	+	HIKMA MAPLE	2MG/ML	N018140	001			Jun CAHN
>D> AP	+		4MG/ML	N018140	002			Jun CAHN

TABLET;ORAL

LORAZEPAM

AB	SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	Apr	CAHN
AB		1MG	A076045	002	Aug 29, 2001	Apr	CAHN
AB		2MG	A076045	003	Aug 29, 2001	Apr	CAHN

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB	WATSON LABS	25MG	A091129	001	Oct 06, 2010	Feb	CMFD
AB		50MG	A091129	002	Oct 06, 2010	Feb	CMFD
AB		100MG	A091129	003	Oct 06, 2010	Feb	CMFD

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

@	COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002	May	CAHN
		20MG	N021316	002	Jun 26, 2002	May	CAHN
		40MG	N021316	003	Jun 26, 2002	May	CAHN
+		60MG	N021316	004	Jun 26, 2002	May	CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL

LOXITANE C

@	ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001		Mar	CAHN

INJECTABLE;INJECTION

LOXITANE IM

@	ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001		Mar	CAHN

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB	ELITE LABS INC	EQ 5MG BASE	A076868	001	Aug 04, 2005	May	CAHN
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May	CAHN
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May	CAHN
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May	CAHN

LOXITANE

@	ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001		Mar	CAHN
@		EQ 10MG BASE	N017525	002		Mar	CAHN
@		EQ 25MG BASE	N017525	003		Mar	CAHN
@		EQ 50MG BASE	N017525	004		Mar	CAHN

TABLET;ORAL

LOXITANE

@	ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Mar	CAHN
@		EQ 25MG BASE	N017525	007		Mar	CAHN
@		EQ 50MG BASE	N017525	008		Mar	CAHN

LUCINACTANT

SUSPENSION;INTRATRACHEAL

SURFAXIN

		@	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	May DISC

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

		@	BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984	Mar DISC

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

	AP		EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr CDFR
	AP	+	FRESENIUS KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr CPOT
	AP	+	HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr CDFR
			HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr NEWA

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

		+	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr NEWA

MANNITOL

INJECTABLE;INJECTION

MANNITOL 25%

		@	IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar CAHN
		@		12.5GM/50ML	A089240	001	May 06, 1987	Mar CAHN

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

>D>	AA		VINTAGE PHARMS	12.5MG	A040179	001	Jan 30, 1997	Jun DISC
>A>		@		12.5MG	A040179	001	Jan 30, 1997	Jun DISC
>D>	AA			25MG	A040179	002	Jan 30, 1997	Jun DISC
>A>		@		25MG	A040179	002	Jan 30, 1997	Jun DISC

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMENDA XR

			FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar CAHN
				14MG	N022525	002	Jun 21, 2010	Mar CAHN
				21MG	N022525	003	Jun 21, 2010	Mar CAHN
		+		28MG	N022525	004	Jun 21, 2010	Mar CAHN

SOLUTION;ORAL

NAMENDA

		+	FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Mar CAHN

TABLET;ORAL

MEMANTINE

	AB		SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar CMFD
	AB			10MG	A090058	002	May 05, 2010	Mar CMFD

MEMANTINE HYDROCHLORIDE

	AB		AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar NEWA
	AB			10MG	A090041	002	Apr 10, 2015	Mar NEWA
>D>		@	DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun CMFD
>A>	AB			5MG	A090048	001	Apr 14, 2010	Jun CMFD
>D>		@		10MG	A090048	002	Apr 14, 2010	Jun CMFD
>A>	AB			10MG	A090048	002	Apr 14, 2010	Jun CMFD
	AB		LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar NEWA
	AB			10MG	A090051	002	Apr 10, 2015	Mar NEWA
>D>		@	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun CMFD
>A>	AB			5MG	A079225	001	Jan 30, 2015	Jun CMFD
		@		5MG	A079225	001	Jan 30, 2015	Mar DISC
	AB			5MG	A079225	001	Jan 30, 2015	Jan NEWA
>D>		@		10MG	A079225	002	Jan 30, 2015	Jun CMFD
>A>	AB			10MG	A079225	002	Jan 30, 2015	Jun CMFD
		@		10MG	A079225	002	Jan 30, 2015	Mar DISC
	AB			10MG	A079225	002	Jan 30, 2015	Jan NEWA
	AB		TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May CMFD
	AB			10MG	A090052	002	Oct 25, 2011	May CMFD

TABLET;ORAL
NAMENDA

AB		FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar CAHN
AB	+		10MG	N021487	002	Oct 16, 2003	Mar CAHN

MENOTROPINS (FSH;LH)
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
REPRONEX

	@	FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999	May DISC

MEPERIDINE HYDROCHLORIDE
INJECTABLE;INJECTION
MEPERIDINE HYDROCHLORIDE

AP		EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb CAHN
AP			50MG/ML	A080445	002		Feb CAHN
AP			75MG/ML	A080445	003		Feb CAHN
AP			100MG/ML	A080445	004		Feb CAHN
	@	IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May CAHN
	@		50MG/ML	A089782	001	Mar 31, 1989	Mar CAHN
	@		50MG/ML	A089783	001	Mar 31, 1989	Mar CAHN
	@		50MG/ML	A089784	001	Mar 31, 1989	Mar CAHN
	@		75MG/ML	A089785	001	Mar 31, 1989	Mar CAHN
	@		100MG/ML	A089786	001	Mar 31, 1989	Mar CAHN
	@		100MG/ML	A089787	001	Mar 31, 1989	Mar CAHN
	@		100MG/ML	A089788	001	Mar 31, 1989	Mar CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
INJECTABLE;INJECTION
MEPERGAN

>D>	@	BAXTER HLTHCARE CORP	25MG/ML;25MG/ML	N011730	001		Jun CAHN
>A>	@	EUROHLTH INTL SARL	25MG/ML;25MG/ML	N011730	001		Jun CAHN

MEROPENEM
POWDER;IV (INFUSION)
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

		B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	Apr NEWA
			1GM/VIAL	N202106	002	Apr 30, 2015	Apr NEWA

MESTRANOL; NORETHINDRONE
TABLET;ORAL-20
NORINYL

	@	ACTAVIS LABS UT INC	0.1MG;2MG	N013625	004		Mar CAHN

TABLET;ORAL-21
NORINYL 1+50 21-DAY

	@	ACTAVIS LABS UT INC	0.05MG;1MG	N013625	002		Mar CAHN

TABLET;ORAL-28
NORINYL 1+50 28-DAY

	+	ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001		Mar CAHN

METAPROTERENOL SULFATE
SOLUTION;INHALATION
METAPROTERENOL SULFATE

	@	MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	Apr DISC
	@		0.6%	A070804	001	Aug 17, 1987	Apr DISC
	@	WOCKHARDT	0.4%	A075586	001	May 30, 2002	Apr DISC
	@		0.6%	A075586	002	May 30, 2002	Apr DISC

SYRUP;ORAL
METAPROTERENOL SULFATE

	@	G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992	Apr CAHN
	@		10MG/5ML	A073034	001	Aug 30, 1991	Apr CAHN

METAXALONE
TABLET;ORAL
METAXALONE

		COREPHARMA	400MG	A040486	001	Feb 27, 2015	Feb NEWA
>A>			640MG	N022503	001	Jun 01, 2015	Jun NEWA

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

RIOMET

	+	SUN PHARM INDS LTD	500MG/5ML	N021591	001	Sep 11, 2003	Apr	CAHN

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

>D>		NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008	Jun	CFTG
>A>	AB		500MG;1MG	N022386	001	Jun 23, 2008	Jun	CFTG
>D>		+	500MG;2MG	N022386	002	Jun 23, 2008	Jun	CFTG
>A>	AB	+	500MG;2MG	N022386	002	Jun 23, 2008	Jun	CFTG

>A> REPAGLINIDE AND METFORMIN HYDROCHLORIDE

>A>	AB	LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015	Jun	NEWA
>A>	AB		500MG;2MG	A200624	002	Jul 15, 2015	Jun	NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

	@	SB PHARMCO	500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	May	DISC
	@		500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	May	DISC
	@		1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	May	DISC
	@		1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	May	DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

		TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014	May	CTEC
			500MG;EQ 4MG BASE	A077337	002	May 07, 2014	May	CTEC
	+		1GM;EQ 4MG BASE	A077337	004	May 07, 2014	May	CRLD
			1GM;EQ 2MG BASE	A077337	003	May 07, 2014	May	CTEC

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

	AB	HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar	CAHN
	AB		10MG	A040734	002	Dec 14, 2007	Mar	CAHN

METHOCARBAMOL

SOLUTION;IM-IV

ROBAXIN

>A>	AP	+ EUROHLTH INTL SARL	1GM/10ML (100MG/ML)	N011790	001		Jun	CAHN
>D>	AP	+ HIKMA MAPLE	1GM/10ML (100MG/ML)	N011790	001		Jun	CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE PRESERVATIVE FREE

	AP	FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	May	CMFD

METHOTREXATE SODIUM PRESERVATIVE FREE

	AP	MYLAN PHARMS INC	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	May	CAHN

TABLET;ORAL

METHOTREXATE SODIUM

	AB	ORION CORP ORION	EQ 2.5MG BASE	A201749	001	May 21, 2015	May	NEWA

METHOXSALEN

CAPSULE;ORAL

METHOXSALEN

	AB	ACTAVIS INC	10MG	A202603	001	Jun 09, 2015	May	NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

APTENSIO XR

		RHODES PHARMS	10MG	N205831	001	Apr 17, 2015	Apr	NEWA
			15MG	N205831	002	Apr 17, 2015	Apr	NEWA
			20MG	N205831	003	Apr 17, 2015	Apr	NEWA
			30MG	N205831	004	Apr 17, 2015	Apr	NEWA
			40MG	N205831	005	Apr 17, 2015	Apr	NEWA
			50MG	N205831	006	Apr 17, 2015	Apr	NEWA
	+		60MG	N205831	007	Apr 17, 2015	Apr	NEWA

RITALIN LA

	AB1	NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb	CRLD
	+		60MG	N021284	005	Oct 27, 2014	Feb	CRLD

		TABLET, CHEWABLE;ORAL						
		METHYLIN						
	AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb	CFTG
	AB		5MG	N021475	002	Apr 15, 2003	Feb	CFTG
	AB +		10MG	N021475	003	Apr 15, 2003	Feb	CFTG
		METHYLPHENIDATE HYDROCHLORIDE						
	AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb	NEWA
	AB		5MG	A204115	002	Feb 25, 2015	Feb	NEWA
	AB		10MG	A204115	003	Feb 25, 2015	Feb	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
		METHYLIN ER						
	AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May	CTEC
		METHYLPHENIDATE HYDROCHLORIDE						
	AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May	NEWA
	AB		20MG	A207488	002	Jun 09, 2015	May	NEWA
		METOPROLOL TARTRATE						
		INJECTABLE;INJECTION						
		METOPROLOL TARTRATE						
	AP	CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr	CAHN
		TABLET;ORAL						
		METOPROLOL TARTRATE						
		MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar	NEWA
			75MG	A076704	005	Mar 18, 2015	Mar	NEWA
		METRONIDAZOLE						
		CREAM;TOPICAL						
		NORITATE						
	+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb	CAHN
		GEL;VAGINAL						
		METRONIDAZOLE						
	+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CAHN
		NUVESSA						
	+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CTNA
		INJECTABLE;INJECTION						
		METRONIDAZOLE IN PLASTIC CONTAINER						
	AP	CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr	CAHN
		TABLET;ORAL						
		METRONIDAZOLE						
	AB	AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May	NEWA
	AB		500MG	A203974	002	May 29, 2015	May	NEWA
		MICONAZOLE						
		TABLET;BUCCAL						
		ORAVIG						
	+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr	CAHN
		MIDAZOLAM HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		MIDAZOLAM HYDROCHLORIDE						
	@	CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr	CAHN
	@		EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr	CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun	CAHN
>A>	AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun	CAHN
>D>	AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun	CAHN
>D>	AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun	CAHN
	@	IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000	Apr	CAHN
	@	WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar	DISC
	@		EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar	DISC
	@		EQ 5MG BASE/ML	A078141	002	May 30, 2008	Mar	DISC
	@		EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Mar	DISC
		SYRUP;ORAL						
		MIDAZOLAM HYDROCHLORIDE						
	AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	Apr	CAHN
		MIGLITOL						
		TABLET;ORAL						
		GLYSET						
	AB	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Mar	CTEC
	AA		25MG	N020682	001	Dec 18, 1996	Feb	CFTG
	AB		50MG	N020682	002	Dec 18, 1996	Mar	CTEC

TABLET;ORAL
GLYSET

AA		50MG	N020682	002	Dec 18, 1996	Feb	CFTG
AB	+	100MG	N020682	003	Dec 18, 1996	Mar	CTEC
AA	+	100MG	N020682	003	Dec 18, 1996	Feb	CFTG

MIGLITOL

AB	ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015	Mar	CTEC
AA		25MG	A203965	001	Feb 24, 2015	Feb	NEWA
AB		50MG	A203965	002	Feb 24, 2015	Mar	CTEC
AA		50MG	A203965	002	Feb 24, 2015	Feb	NEWA
AB		100MG	A203965	003	Feb 24, 2015	Mar	CTEC
AA		100MG	A203965	003	Feb 24, 2015	Feb	NEWA

MILRINONE LACTATE

INJECTABLE;INJECTION
MILRINONE LACTATE

AP	BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan	CRLD
>A> AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jun	CAHN
AP	+ HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03, 2010	Jan	CRLD
>D> AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jun	CAHN

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL
MINOCYCLINE HYDROCHLORIDE

>D> AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun	CAHN
AB		EQ 50MG BASE	A065062	001	Nov 30, 2000	Apr	CAHN
>D> AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun	CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Apr	CAHN
>D> AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun	CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Apr	CAHN
>A> AB	TORRENT PHARMA INC	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun	CAHN
>A> AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun	CAHN
>A> AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun	CAHN

CAPSULE, EXTENDED RELEASE;ORAL
XIMINO

@	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr	CAHN
@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Apr	CAHN
@		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr	CAHN
@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Apr	CAHN
@		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr	CAHN

TABLET;ORAL
MINOCYCLINE HYDROCHLORIDE

>D> AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun	CAHN
AB		EQ 50MG BASE	A065156	001	Jan 06, 2004	Apr	CAHN
>D> AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun	CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Apr	CAHN
>D> AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun	CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Apr	CAHN
>A> AB	TORRENT PHARMA INC	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun	CAHN
>A> AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun	CAHN
>A> AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Apr	CAHN
AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Apr	CAHN
AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Apr	CAHN
AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr	CAHN
AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr	CAHN

MIVACURIUM CHLORIDE

INJECTABLE;INJECTION
MIVACURIUM CHLORIDE

@	MYLAN PHARMS INC	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	May	CAHN

SOLUTION;INTRAVENOUS
MIVACRON

	ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jan	NEWA
+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jan	NEWA

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

			COREPHARMA	5MG	A090453	001	Mar 20, 2015	Mar NEWA
				10MG	A090453	002	Mar 20, 2015	Mar NEWA
		+		25MG	A090453	003	Mar 20, 2015	Mar NEWA

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

	AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A201522	001	Aug 03, 2012	Mar CAHN

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

	AB		HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May NEWA
	AB			EQ 5MG BASE	A204093	002	May 22, 2015	May NEWA
	AB		JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA
	AB			EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA
	AB		KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN
	AB			EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN
	AB		MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA
	AB			EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN

	AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar CAHN
	AB1			20MG	N020616	001	Jul 03, 1996	Mar CAHN
	AB1			30MG	N020616	004	Mar 09, 2001	Mar CAHN
	AB1			40MG	N020616	009	Jul 09, 2012	May CTEC
				40MG	N020616	009	Jul 09, 2012	Mar CAHN
	AB1			50MG	N020616	002	Jul 03, 1996	Mar CAHN
	AB1			60MG	N020616	005	Mar 09, 2001	Mar CAHN
	AB1			70MG	N020616	010	Jul 09, 2012	May CTEC
				70MG	N020616	010	Jul 09, 2012	Mar CAHN
	AB1			80MG	N020616	006	Oct 27, 2006	Mar CAHN
	AB1	+		100MG	N020616	003	Jul 03, 1996	Mar CAHN
				130MG	N020616	011	Jul 09, 2012	Mar CAHN
				150MG	N020616	012	Jul 09, 2012	Mar CAHN
	AB1	+		200MG	N020616	007	Feb 27, 2007	Mar CAHN

MORPHINE SULFATE

	AB1		TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May NEWA
	AB1			70MG	A202718	008	Jun 03, 2015	May NEWA

INJECTABLE;INJECTION

DURAMORPH PF

>A>	AP	+	EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Jun CAHN
>A>	AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun CAHN
>D>	AP	+	HIKMA MAPLE	0.5MG/ML	N018565	001	Sep 18, 1984	Jun CAHN
>D>	AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun CAHN

INFUMORPH

>A>		+	EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Jun CAHN
>A>		+		25MG/ML	N018565	004	Jul 19, 1991	Jun CAHN
>D>		+	HIKMA MAPLE	10MG/ML	N018565	003	Jul 19, 1991	Jun CAHN
>D>		+		25MG/ML	N018565	004	Jul 19, 1991	Jun CAHN

MORPHINE SULFATE

	AP		EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May NEWA
	AP			8MG/ML	A205758	002	May 21, 2015	May NEWA
	AP			10MG/ML	A205758	003	May 21, 2015	May NEWA
	AP	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May CFTG
	AP	+		8MG/ML	N202515	003	Nov 14, 2011	May CFTG
	AP	+		10MG/ML	N202515	004	Nov 14, 2011	May CFTG

SOLUTION;ORAL

MORPHINE SULFATE

	AA		TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May NEWA
	AA			100MG/5ML	A203518	002	May 12, 2015	May NEWA

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar NEWA
	AB			30MG	A203849	002	Apr 06, 2015	Mar NEWA
	AB			60MG	A203849	003	Apr 06, 2015	Mar NEWA
	AB			100MG	A203849	004	Apr 06, 2015	Mar NEWA
	AB			200MG	A203849	005	Apr 06, 2015	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

AB		SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr CAHN
AB			30MG	A078761	002	May 11, 2012	Apr CAHN
AB			60MG	A078761	003	May 11, 2012	Apr CAHN
AB			100MG	A078761	004	May 11, 2012	Apr CAHN
AB			200MG	A078761	005	May 11, 2012	Apr CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)
MOXIFLOXACIN HYDROCHLORIDE

+		FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr NEWA

SOLUTION/DROPS;OPHTHALMIC
MOXEZA

AT2	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May CFTG

MOXIFLOXACIN HYDROCHLORIDE

AT1		LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May CTEC
AT2			EQ 0.5% BASE	A204079	001	May 28, 2015	May NEWA
AT1		WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May CTEC
AT			EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb NEWA

VIGAMOX

AT1	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May CTEC

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION
NALBUPHINE HYDROCHLORIDE

@		IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar CAHN
@			10MG/ML	A072071	001	Apr 10, 1989	Mar CAHN
@			10MG/ML	A072072	001	Apr 10, 1989	Mar CAHN
@			20MG/ML	A072073	001	Apr 10, 1989	Mar CAHN
@			20MG/ML	A072074	001	Apr 10, 1989	Mar CAHN
@			20MG/ML	A072075	001	Apr 10, 1989	Mar CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE;INJECTION
REVEX

>D>	@	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun CAHN
>D>	@		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun CAHN
>A>	@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun CAHN
>A>	@		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION
NALOXONE

@		EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar CAHN

NALOXONE HYDROCHLORIDE

@		IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar CAHN
@			0.02MG/ML	A072083	001	Apr 11, 1989	Mar CAHN
@			0.02MG/ML	A072084	001	Apr 11, 1989	Mar CAHN
@			0.02MG/ML	A072085	001	Apr 11, 1989	Mar CAHN
@			0.4MG/ML	A072086	001	Apr 11, 1989	Mar CAHN
@			0.4MG/ML	A072087	001	Apr 11, 1989	Mar CAHN
@			0.4MG/ML	A072088	001	Apr 11, 1989	Mar CAHN
@			0.4MG/ML	A072089	001	Apr 11, 1989	Mar CAHN
@			0.4MG/ML	A072090	001	Apr 11, 1989	Mar CAHN
@			1MG/ML	A072091	001	Apr 11, 1989	Mar CAHN
@			1MG/ML	A072092	001	Apr 11, 1989	Mar CAHN
@			1MG/ML	A072093	001	Apr 11, 1989	Mar CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Apr CAHN

NAPROXEN

SUSPENSION;ORAL
NAPROSYN

AB	+	PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Apr CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

>A>		PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jun	NEWA

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

>A>		ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun	NEWA
>A>	@		EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun	DISC
>A>			EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun	NEWA
>A>	@		EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun	DISC
>A>			EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun	NEWA
>A>	@		EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun	DISC
>A>			EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun	NEWA
>A>	@		EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun	DISC
	@	AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Apr	DISC
AB			EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Mar	NEWA
	@		EQ 5MG BASE	A203659	002	Apr 16, 2015	Apr	DISC
AB			EQ 5MG BASE	A203659	002	Apr 16, 2015	Mar	NEWA
	@		EQ 10MG BASE	A203659	003	Apr 16, 2015	Apr	DISC
AB			EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar	NEWA
	@		EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr	DISC
AB			EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar	NEWA

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

	@	IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr	CAHN
	@		100MG	A076072	002	Sep 16, 2003	Apr	CAHN
	@		150MG	A076072	003	Sep 16, 2003	Apr	CAHN
	@		200MG	A076072	004	Sep 16, 2003	Apr	CAHN
	@		250MG	A076072	005	Sep 16, 2003	Apr	CAHN
AB		SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr	CAHN
AB			100MG	A076409	002	Sep 16, 2003	Apr	CAHN
AB			150MG	A076409	003	Sep 16, 2003	Apr	CAHN
AB			200MG	A076409	004	Sep 16, 2003	Apr	CAHN
AB			250MG	A076409	005	Sep 16, 2003	Apr	CAHN

NELARABINE

INJECTABLE;IV (INFUSION)

ARRANON

	+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar	CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

		FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan	NEWA
			10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

>A>	AB	ALVOGEN PINE BROOK	400MG	A204621	001	Jul 10, 2015	Jun	NEWA

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB		HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar	CAHN
AB			20MG	A202644	002	Apr 25, 2013	Mar	CAHN

NILUTAMIDE

TABLET;ORAL

NILANDRON

	@	CONCORDIA PHARMS INC	50MG	N020169	001	Sep 19, 1996	Apr	CAHN
	+		150MG	N020169	002	Apr 30, 1999	Apr	CAHN

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB	+	BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008	Jan CAHN

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

		BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar CAIN
	+		EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar CAIN

NITRIC OXIDE

GAS;INHALATION

INOMAX

>D>		INO	100PPM	N020845	002	Dec 23, 1999	Jun DISC
>A>	@		100PPM	N020845	002	Dec 23, 1999	Jun DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

>D>		ALVOGEN INC	25MG	N016620	003		Jun CTEC
>A>	AB		25MG	N016620	003		Jun CTEC

NITROFURANTOIN

>A>	AB	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Jun NEWA
>A>	AB		50MG	A091095	002	Jun 18, 2015	Jun NEWA
>A>	AB		100MG	A091095	003	Jun 18, 2015	Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>A>	AB	WATSON LABS INC	75MG;25MG	A202250	001	Jul 08, 2015	Jun NEWA

NORETHINDRONE

TABLET;ORAL-28

NOR-QD

AB1	+	ACTAVIS LABS UT INC	0.35MG	N017060	001		Mar CAHN

NORGESTREL

TABLET;ORAL

OVRETTE

>A>	@	LABORATOIRE HRA	0.075MG	N017031	001		Jun CAHN
>D>	@	WYETH PHARMS	0.075MG	N017031	001		Jun CAHN

NYSTATIN

CREAM;TOPICAL

NYSTATIN

>D>	@	G AND W LABS INC	100,000 UNITS/GM	A061966	001		Jun CMFD
>A>	AT		100,000 UNITS/GM	A061966	001		Jun CMFD

SUSPENSION;ORAL

NYSTATIN

AA		G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Apr CAHN
	@		100,000 UNITS/ML	A062776	001	Dec 17, 1987	Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

AT		G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Mar CMFD

OINTMENT;TOPICAL

MYKACET

AT		G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Mar CMFD

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB		IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB		MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015	Feb NEWA
AB			10MG	A203044	002	Feb 20, 2015	Feb NEWA
AB			15MG	A203044	003	Feb 20, 2015	Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB		20MG	A203044	004	Feb 20, 2015	Feb	NEWA
AB	ORCHID HLTHCARE	5MG	A202937	001	Mar 02, 2015	Feb	NEWA
AB		10MG	A202937	002	Mar 02, 2015	Feb	NEWA
AB		15MG	A202937	003	Mar 02, 2015	Feb	NEWA
AB		20MG	A202937	004	Mar 02, 2015	Feb	NEWA

OLAPARIB
CAPSULE;ORAL
LYNPARZA

	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Jan	CTNA

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE
SPRAY, METERED;INHALATION
STIOLTO RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015	May	NEWA

OLOPATADINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>A>			EQ 0.2% BASE	A090848	001	Jul 13, 2015	Jun	NEWA
>A>	AT	BARR LABS INC						

PATADAY

>D>	+	ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun	CFTG
>A>	AT +		EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun	CFTG

PAZEO

+	ALCON RES LTD	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jan	NEWA

ONDANSETRON
TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

AB	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Apr	CAHN
AB		8MG	A078602	002	Feb 24, 2011	Apr	CAHN

ZOFRAN ODT

AB	NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar	CAHN
AB +		8MG	N020781	002	Jan 27, 1999	Mar	CAHN

ONDANSETRON HYDROCHLORIDE
INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

>A>	AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206846	001	Jul 13, 2015	Jun	NEWA
	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr	CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun	CAHN
>D>	AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun	CAHN
	AP	MYLAN PHARMS INC	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	May	CAHN

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr	CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun	CAHN
>D>	AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun	CAHN
	AP	MYLAN PHARMS INC	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Apr	CAHN
	@	TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan	DISC

ZOFRAN

AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar	CAHN

ZOFRAN PRESERVATIVE FREE

AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar	CAHN

SOLUTION;ORAL
ZOFRAN

AA	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar	CAHN

TABLET;ORAL
ZOFRAN

AB		NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar	CAHN
AB			EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar	CAHN
AB	+		EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar	CAHN

ORPHENADRINE CITRATE
INJECTABLE;INJECTION
NORFLEX

@	IGI LABS INC	30MG/ML	N013055	001			Apr CAHN
@	MEDICIS	30MG/ML	N013055	001			Mar DISC

		INJECTABLE;INJECTION						
		ORPHENADRINE CITRATE						
AP	+	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar	CRLD
		OXCARBAZEPINE						
		SUSPENSION;ORAL						
		OXCARBAZEPINE						
AB		SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr	CAHN
		OXYBUTYNIN						
		FILM, EXTENDED RELEASE;TRANSDERMAL						
		OXYTROL						
AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar	CAHN
		GEL, METERED;TRANSDERMAL						
		GELNIQUE 3%						
	+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar	CAHN
		OXYBUTYNIN CHLORIDE						
		GEL;TRANSDERMAL						
		GELNIQUE						
	+	ACTAVIS LABS UT INC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Mar	CAHN
		OXYCODONE HYDROCHLORIDE						
		SOLUTION;ORAL						
		OXYCODONE HYDROCHLORIDE						
AA		ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May	NEWA
AA		NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr	NEWA
>A> AA		WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Jun	NEWA
		TABLET;ORAL						
		OXAYDO						
		ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	Mar	CTNA
			7.5MG	N202080	002	Jun 17, 2011	Mar	CTNA
		EGALET LTD	5MG	N202080	001	Jun 17, 2011	May	CAHN
			7.5MG	N202080	002	Jun 17, 2011	May	CAHN
		OXYCODONE HYDROCHLORIDE						
AB		ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar	NEWA
AB		VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar	NEWA
AB			20MG	A077712	005	Apr 13, 2015	Mar	NEWA
		OXYMORPHONE HYDROCHLORIDE						
		TABLET, EXTENDED RELEASE;ORAL						
		OXYMORPHONE HYDROCHLORIDE						
AB		SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Apr	NEWA
AB			7.5MG	A203506	002	Apr 24, 2015	Apr	NEWA
AB			10MG	A203506	003	Apr 24, 2015	Apr	NEWA
AB			15MG	A203506	004	Apr 24, 2015	Apr	NEWA
AB			20MG	A203506	005	Apr 24, 2015	Apr	NEWA
AB			30MG	A203506	006	Apr 24, 2015	Apr	NEWA
AB			40MG	A203506	007	Apr 24, 2015	Apr	NEWA
		OXYTOCIN						
		INJECTABLE;INJECTION						
		OXYTOCIN						
AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Feb	CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Feb	CAHN
		PACLITAXEL						
		INJECTABLE;INJECTION						
		PACLITAXEL						
AP		MYLAN PHARMS INC	6MG/ML	A091540	001	Sep 29, 2011	Apr	CAHN
		PALBOCICLIB						
		CAPSULE;ORAL						
		IBRANCE						
		PFIZER INC	75MG	N207103	001	Feb 03, 2015	Feb	NEWA
			100MG	N207103	002	Feb 03, 2015	Feb	NEWA
	+		125MG	N207103	003	Feb 03, 2015	Feb	NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA TRINZA

	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	May	NEWA
		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	May	NEWA
		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	May	NEWA
+		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015	May	NEWA

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

AP	MYLAN PHARMS INC	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	Apr	CAHN
AP		90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	Apr	CAHN

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

@	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988	Mar	CAHN
@		2MG/ML	A072211	001	Mar 31, 1988	Mar	CAHN
@		2MG/ML	A072212	001	Mar 31, 1988	Mar	CAHN
@		2MG/ML	A072213	001	Mar 31, 1988	Mar	CAHN

PANOBINOSTAT

CAPSULE;ORAL

FARYDAK

	NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Feb	NEWA
		15MG	N205353	002	Feb 23, 2015	Feb	NEWA
+		20MG	N205353	003	Feb 23, 2015	Feb	NEWA

PANOBINOSTAT LACTATE

CAPSULE;ORAL

FARYDAK

	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar	CAIN
		EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar	CPOT
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar	CAIN
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar	CPOT
+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar	CAIN
+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar	CPOT

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUM

>A> AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Jun	NEWA

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar	CAHN
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar	CAHN
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr	CAHN

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan	CAHN

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar	CAHN
		EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb	CAHN

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

BONTRIL

	@	VALEANT	105MG	A088021	001	Sep 21, 1982	Jan DISC

PHENDIMETRAZINE TARTRATE

	+	SANDOZ	105MG	N018074	001		Jan CTEC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIBENZYLINE

>A> AB	+	CONCORDIA PHARMS INC	10MG	N008708	001		Jun CAHN
>D> AB	+	COVIS PHARMA SARL	10MG	N008708	001		Jun CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

>D>		@ MIKAH PHARMA LLC	37.5MG	A040228	001	Jun 19, 1997	Jun CMFD
>A> AA			37.5MG	A040228	001	Jun 19, 1997	Jun CMFD

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

		AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan NEWA
			10%	N207926	002	Jan 15, 2015	Jan NEWA

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

>D> AB		WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007	Jun DISC
>A>		@	30MG EXTENDED	A040759	001	Dec 18, 2007	Jun DISC
>D> AB		WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008	Jun DISC
>A>		@	100MG EXTENDED	A040732	001	Jan 30, 2008	Jun DISC

PHENYTOIN SODIUM

AB		AUROBINDO PHARMA LTD	100MG EXTENDED	A204309	001	Jun 10, 2015	May NEWA

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP	+	EUROHLTH INTL SARL	50MG/ML	A084307	001		Feb CAHN

PHYTONADIONE

INJECTABLE;INJECTION

AQUAMEPHYTON

	@	IGI LABS INC	1MG/0.5ML	N012223	002		Apr CAHN
	@		10MG/ML	N012223	001		Apr CAHN

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004	Mar CAHN

PINDOLOL

TABLET;ORAL

PINDOLOL

	@	G AND W LABS INC	5MG	A073661	001	Oct 31, 1993	Apr CAHN
	@		5MG	A073687	001	Feb 26, 1993	Apr CAHN
	@		5MG	A074123	001	Apr 17, 1997	Apr CAHN
	@		10MG	A073661	002	Oct 31, 1993	Apr CAHN
	@		10MG	A073687	002	Feb 26, 1993	Apr CAHN
	@		10MG	A074123	002	Apr 17, 1997	Apr CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		AGILA SPECLTS	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Mar CPOT

PIRBUTEROL ACETATE

AEROSOL, METERED;INHALATION

MAXAIR

	@	MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	Jan DISC

PIRFENIDONE
CAPSULE;ORAL
ESBRIET
+ GENENTECH INC 267MG N022535 001 Oct 15, 2014 Feb CAHN

PIROXICAM
CAPSULE;ORAL
PIROXICAM
AB MYLAN PHARMS INC 10MG A074116 001 Jun 15, 1993 May CAHN
AB 20MG A074118 001 Jun 15, 1993 May CAHN

PODOFILOX
GEL;TOPICAL
CONDYLOX
+ ACTAVIS LABS UT INC 0.5% N020529 001 Mar 13, 1997 Feb CAHN
SOLUTION;TOPICAL
CONDYLOX
AT + ACTAVIS LABS UT INC 0.5% N019795 001 Dec 13, 1990 Jan CAHN
PODOFILOX
AT BAUSCH AND LOMB INC 0.5% A090184 001 Jul 21, 2010 May CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE
SOLUTION/DROPS;OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
AT ALCON RES LTD 10,000 UNITS/ML;EQ 1MG BASE/ML A064211 001 Apr 13, 1998 Jan CAHN

PONATINIB HYDROCHLORIDE
TABLET;ORAL
ICLUSIG
ARIAD EQ 30MG BASE N203469 003 Apr 23, 2015 Apr NEWA

POTASSIUM CHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
>A> KLOR-CON
>A> AB UPSHER SMITH 8MEQ A203106 001 Jul 10, 2015 Jun NEWA
>A> AB 10MEQ A203106 002 Jul 10, 2015 Jun NEWA
TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE
AB2 MYLAN PHARMS INC 8MEQ A204662 001 Aug 21, 2014 Feb CPOT
AB2 10MEQ A204662 002 Aug 21, 2014 Feb CPOT

PREDNICARBATE
OINTMENT;TOPICAL
DERMATOP
AB + VALEANT PHARMS NORTH 0.1% N019568 001 Sep 23, 1991 Apr CAHN

PREGABALIN
CAPSULE;ORAL
LYRICA
PF PRISM CV 25MG N021446 001 Dec 30, 2004 Apr CTEC
50MG N021446 002 Dec 30, 2004 Apr CTEC
75MG N021446 003 Dec 30, 2004 Apr CTEC
100MG N021446 004 Dec 30, 2004 Apr CTEC
150MG N021446 005 Dec 30, 2004 Apr CTEC
200MG N021446 006 Dec 30, 2004 Apr CTEC
225MG N021446 007 Dec 30, 2004 Apr CTEC
+ 300MG N021446 008 Dec 30, 2004 Apr CTEC

PROCAINAMIDE HYDROCHLORIDE
CAPSULE;ORAL
PROCAINAMIDE HYDROCHLORIDE
>A> @ IDT AUSTRALIA LTD 250MG A089219 001 Jul 01, 1986 Jun CAHN
>A> @ 500MG A089221 001 Jul 01, 1986 Jun CAHN
>D> @ SANDOZ 250MG A089219 001 Jul 01, 1986 Jun CAHN
>D> @ 500MG A089221 001 Jul 01, 1986 Jun CAHN
TABLET, EXTENDED RELEASE;ORAL
PROCAINAMIDE HYDROCHLORIDE
>A> @ IDT AUSTRALIA LTD 250MG A089369 001 Aug 14, 1987 Jun CAHN
>A> @ 500MG A089370 001 Jan 09, 1987 Jun CAHN
>A> @ 750MG A089371 001 Aug 14, 1987 Jun CAHN
>D> @ SANDOZ 250MG A089369 001 Aug 14, 1987 Jun CAHN

			TABLET, EXTENDED RELEASE;ORAL						
			PROCAINAMIDE HYDROCHLORIDE						
>D>			@	500MG	A089370	001	Jan 09, 1987	Jun	CAHN
>D>			@	750MG	A089371	001	Aug 14, 1987	Jun	CAHN
			PROCHLORPERAZINE EDISYLATE						
			INJECTABLE;INJECTION						
			PROCHLORPERAZINE EDISYLATE						
	AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb	CAHN
			PROGESTERONE						
			CAPSULE;ORAL						
			PROGESTERONE						
	AB		BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan	CAHN
	AB			200MG	A200900	002	Aug 16, 2013	Jan	CAHN
			GEL;VAGINAL						
			CRINONE						
			ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Feb	CAHN
		+		8%	N020701	002	Jul 31, 1997	Feb	CAHN
			INJECTABLE;INJECTION						
			PROGESTERONE						
	AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar	CAHN
			PROMETHAZINE HYDROCHLORIDE						
			INJECTABLE;INJECTION						
			PROMETHAZINE HYDROCHLORIDE						
>A>	AP	+	EUROHLTH INTL SARL	25MG/ML	A083312	001		Jun	CAHN
>A>	AP	+		50MG/ML	A083312	002		Jun	CAHN
>D>	AP	+	HIKMA MAPLE	25MG/ML	A083312	001		Jun	CAHN
>D>	AP	+		50MG/ML	A083312	002		Jun	CAHN
			SUPPOSITORY;RECTAL						
			PHENERGAN						
			@ DELCOR ASSET CORP	12.5MG	N010926	002		Apr	CAHN
			@	25MG	N010926	001		Apr	CAHN
			TABLET;ORAL						
			PROMETHAZINE HYDROCHLORIDE						
	AB		HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar	CAHN
	AB			25MG	A040673	002	Mar 05, 2008	Mar	CAHN
	AB			50MG	A040673	003	Mar 05, 2008	Mar	CAHN
			PYRIDOSTIGMINE BROMIDE						
			TABLET;ORAL						
			PYRIDOSTIGMINE BROMIDE						
>A>	AB		ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015	Jun	NEWA
			TABLET, EXTENDED RELEASE;ORAL						
			MESTINON						
>D>		+	VALEANT PHARMS LLC	180MG	N011665	001		Jun	CFTG
>A>	AB	+		180MG	N011665	001		Jun	CFTG
>A>			PYRIDOSTIGMINE BROMIDE						
>A>	AB		ALVOGEN INC	180MG	A204737	001	Jun 26, 2015	Jun	NEWA
>D>			QUAZEPAM						
>D>			TABLET;ORAL						
>D>			DORAL						
>D>		+	SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985	Jun	DISC
>A>			@	15MG	N018708	001	Dec 27, 1985	Jun	DISC
			QUETIAPINE FUMARATE						
			TABLET;ORAL						
			SEROQUEL						
	AB	+	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May	CAHN
	AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May	CAHN
	AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May	CAHN
			@	EQ 150MG BASE	N020639	004	Dec 20, 1998	May	CAHN
	AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	May	CAHN
	AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	May	CAHN
	AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	May	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

	AB		SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr CAHN
	AB			EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr CAHN
	AB			EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr CAHN
	AB			EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

>A>		@	CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984	Jun CAHN
>D>		@	ROXANE	324MG	A088431	001	Jan 06, 1984	Jun CAHN

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

>A>		@	CYCLE PHARMS LTD	200MG	A083640	001		Jun CAHN
>A>		@		300MG	A085632	001		Jun CAHN
>D>		@	ROXANE	200MG	A083640	001		Jun CAHN
>D>		@		300MG	A085632	001		Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE SULFATE

		+	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr CAHN

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

>A>	AB		AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015	Jun NEWA
	AB		LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr NEWA

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

	AB		WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

>A>	AP	+	CONCORDIA PHARMS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun CAHN
>D>	AP	+	COVIS INJECTABLES	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun CAHN

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

		@	SUN PHARM INDS LTD	EQ 150MG BASE	A075439	001	Apr 19, 2000	Apr CAHN
		@		EQ 300MG BASE	A075439	002	Apr 19, 2000	Apr CAHN

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

	AB		STANDARD CHEM PHARM	0.5MG	A091517	001	Apr 24, 2015	Apr NEWA
	AB			1MG	A091517	002	Apr 24, 2015	Apr NEWA
	AB			2MG	A091517	003	Apr 24, 2015	Apr NEWA

RIBAVIRIN

CAPSULE;ORAL

REBETOL

>D>		+	MERCK SHARP DOHME	200MG	N020903	001	Jun 03, 1998	Jun DISC
>A>		@		200MG	N020903	001	Jun 03, 1998	Jun DISC

RIFAMPIN

INJECTABLE;INJECTION

RIFAMPIN

	AP		MYLAN PHARMS INC	600MG/VIAL	A065421	001	May 22, 2008	Apr CAHN

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL

ATELVIA

	AB	+	WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010	May CFTG

RISEDRONATE SODIUM

	AB		TEVA PHARMS USA	35MG	A203217	001	May 18, 2015	May NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB		SUN PHARM INDS LTD	0.5MG	A077542	001	Aug 06, 2010	Apr CAHN
AB			1MG	A077542	002	Aug 06, 2010	Apr CAHN
AB			2MG	A077542	003	Aug 06, 2010	Apr CAHN
AB			3MG	A078474	001	Aug 06, 2010	Apr CAHN
AB			4MG	A078474	002	Aug 06, 2010	Apr CAHN

RIVAROXABAN

TABLET;ORAL

XARELTO

		JANSSEN PHARMS	10MG	N022406	001	Jul 01, 2011	Apr CRLD

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB		ORCHID HLTHCARE	EQ 1.5MG BASE	A090879	001	Jun 10, 2015	May NEWA
AB			EQ 3MG BASE	A090879	002	Jun 10, 2015	May NEWA
AB			EQ 4.5MG BASE	A090879	003	Jun 10, 2015	May NEWA
AB			EQ 6MG BASE	A090879	004	Jun 10, 2015	May NEWA

ROFLUMILAST

TABLET;ORAL

DALIRESP

	+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011	Mar CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr CAHN
AB			EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr CAHN
AB			EQ 1MG BASE	A077460	003	May 05, 2008	Apr CAHN
AB			EQ 2MG BASE	A077460	004	May 05, 2008	Apr CAHN
AB			EQ 3MG BASE	A077460	005	May 05, 2008	Apr CAHN
AB			EQ 4MG BASE	A077460	006	May 05, 2008	Apr CAHN
AB			EQ 5MG BASE	A077460	007	May 19, 2008	Apr CAHN

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

AB		PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar CAHN
AB		PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan NEWA

TRANSDERM SCOP

AB	+	NOVARTIS	1MG/72HR	N017874	001		Jan CFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

	@	G AND W LABS INC	5MG	A074537	001	Aug 02, 1996	Apr CAHN
	@		5MG	A074744	001	Jan 27, 1997	Apr CAHN
	@		5MG	A074756	001	Nov 25, 1998	Apr CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	@	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009	May DISC
	@		EQ 50MG BASE	A077864	002	Aug 10, 2009	May DISC
	@		EQ 100MG BASE	A077864	003	Aug 10, 2009	May DISC
AB		SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Apr CAHN
AB			EQ 50MG BASE	A077977	002	Feb 06, 2007	Apr CAHN
AB			EQ 100MG BASE	A077977	003	Feb 06, 2007	Apr CAHN
			EQ 150MG BASE	A077977	004	Feb 06, 2007	Apr CAHN
			EQ 200MG BASE	A077977	005	Feb 06, 2007	Apr CAHN

SILDENAFIL CITRATE

SOLUTION;INTRAVENOUS

REVATIO

AP	+	PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar CFTG

		SOLUTION;INTRAVENOUS							
		SILDENAFIL CITRATE							
	AP	AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar NEWA		
		SILODOSIN							
		CAPSULE;ORAL							
		RAPAFLO							
	+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar CAHN		
			8MG	N022206	002	Oct 08, 2008	Mar CAHN		
		SIMVASTATIN							
		TABLET;ORAL							
		SIMVASTATIN							
	AB	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Apr CAHN		
	AB		10MG	A076285	002	Dec 20, 2006	Apr CAHN		
	AB		20MG	A076285	003	Dec 20, 2006	Apr CAHN		
	AB		40MG	A076285	004	Dec 20, 2006	Apr CAHN		
	AB		80MG	A076285	005	Jun 23, 2006	Apr CAHN		
		SODIUM CHLORIDE							
		INJECTABLE;INJECTION							
		SODIUM CHLORIDE 0.9%							
	AP	EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb CAHN		
		SODIUM CHLORIDE 0.9%							
		EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb CAHN		
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	+	LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CAHN		
			112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CAHN		
	+		405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CPOT		
			1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CPOT		
		SODIUM FERRIC GLUCONATE COMPLEX							
		INJECTABLE;INJECTION							
		SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE							
>A>	AB	EUROHLTH INTL SARL	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun CAHN		
>D>	AB	HIKMA PHARMS	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun CAHN		
		SODIUM FLUORIDE F-18							
		INJECTABLE;INTRAVENOUS							
		SODIUM FLUORIDE F-18							
	AP	PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb NEWA		
	AP	SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr NEWA		
	AP	UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr NEWA		
		SODIUM IODIDE I-123							
		CAPSULE;ORAL							
		SODIUM IODIDE I 123							
	AA +	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr CAHN		
	AA +		200uCi	N018671	002	May 27, 1982	Apr CAHN		
	@		400uCi	N018671	003	May 27, 1982	Apr CAHN		
		SODIUM POLYSTYRENE SULFONATE							
		POWDER;ORAL, RECTAL							
		KALEXATE							
		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015	Mar NEWA		
		KAYEXALATE							
	AA +	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr CAHN		
		SOMATROPIN RECOMBINANT							
		INJECTABLE;INJECTION							
		NORDITROPIN FLEXPRO							
		NOVO NORDISK INC	30MG/3ML	N021148	011	Jan 23, 2015	Jan NEWA		
		NORDITROPIN NORDIFLEX							
		NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009	Mar CMFD		
	@		30MG/3ML	N021148	007	Mar 10, 2009	Jan DISC		
>D>		NUTROPIN							
>D>	BX	GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Jun DISC		
>A>	@		5MG/VIAL	N020168	001	Nov 17, 1993	Jun DISC		
>D>	BX +		10MG/VIAL	N020168	002	Nov 17, 1993	Jun DISC		
>A>	@		10MG/VIAL	N020168	002	Nov 17, 1993	Jun DISC		
	BX +		10MG/VIAL	N020168	002	Nov 17, 1993	Mar CTEC		

			INJECTABLE;INJECTION						
>D>			NUTROPIN AQ						
>D>		+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Jun	CTNA
>D>		+		10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Jun	DISC
>A>		@		10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Jun	DISC
>D>		+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Jun	CTNA
>A>			NUTROPIN AQ NUSPIN						
>A>		+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Jun	CTNA
>A>		+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Jun	NEWA
>A>		+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Jun	CTNA
>A>			NUTROPIN AQ PEN						
>A>		+	GENENTECH	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun	NEWA
			ZOMACTON						
	BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar	CTNA
	BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr	CRLD
	BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar	NEWA
			SOTALOL HYDROCHLORIDE						
			SOLUTION;INTRAVENOUS						
			SOTALOL HYDROCHLORIDE						
		+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr	CAHN
			TABLET;ORAL						
			BETAPACE						
	AB1		COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar	CAHN
	AB1			120MG	N019865	005	Apr 20, 1994	Mar	CAHN
	AB1	+		160MG	N019865	002	Oct 30, 1992	Mar	CAHN
	AB1			240MG	N019865	003	Oct 30, 1992	Mar	CAHN
		@		320MG	N019865	004	Oct 30, 1992	Mar	CAHN
			SUCCINYLCHOLINE CHLORIDE						
			INJECTABLE;INJECTION						
			QUELICIN PRESERVATIVE FREE						
>D>		+	HOSPIRA	100MG/ML	N008845	004		Jun	DISC
>A>		@		100MG/ML	N008845	004		Jun	DISC
			SUCRALFATE						
			TABLET;ORAL						
			SUCRALFATE						
	AB		MYLAN PHARMS INC	1GM	A074415	001	Jun 08, 1998	May	CAHN
			SUFENTANIL CITRATE						
			INJECTABLE;INJECTION						
			SUFENTANIL CITRATE						
>A>	AP		EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Jun	CAHN
>D>	AP		HIKMA MAPLE	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Jun	CAHN
			SULFACETAMIDE SODIUM						
			LOTION;TOPICAL						
			KLARON						
	AB	+	VALEANT PHARMS NORTH	10%	N019931	001	Dec 23, 1996	Mar	CAHN
			SOLUTION/DROPS;OPHTHALMIC						
			SULFACETAMIDE SODIUM						
	AT		AKORN	10%	A040215	001	May 25, 1999	Mar	CMFD
			SULFANILAMIDE						
			CREAM;VAGINAL						
			SULFANILAMIDE						
		@	G AND W LABS INC	15%	A088718	001	Sep 19, 1985	Apr	CAHN
			SUMATRIPTAN SUCCINATE						
			TABLET;ORAL						
			SUMATRIPTAN SUCCINATE						
	AB		SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009	Apr	CAHN
	AB			EQ 50MG BASE	A076554	002	Aug 10, 2009	Apr	CAHN
	AB			EQ 100MG BASE	A076572	001	Feb 09, 2009	Apr	CAHN

TAPENTADOL HYDROCHLORIDE

	SOLUTION;ORAL						
	NUCYNTA						
	+ DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May	CAHN
	TABLET;ORAL						
	NUCYNTA						
	DEPOMED INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	May	CAHN
		EQ 75MG BASE	N022304	002	Nov 20, 2008	May	CAHN
	+	EQ 100MG BASE	N022304	003	Nov 20, 2008	May	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	NUCYNTA ER						
	DEPOMED INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	May	CAHN
		EQ 100MG BASE	N200533	002	Aug 25, 2011	May	CAHN
		EQ 150MG BASE	N200533	003	Aug 25, 2011	May	CAHN
		EQ 200MG BASE	N200533	004	Aug 25, 2011	May	CAHN
	+	EQ 250MG BASE	N200533	005	Aug 25, 2011	May	CAHN

TELAPREVIR

	TABLET;ORAL						
	INCIVEK						
	@ VERTEX PHARMS	375MG	N201917	001	May 23, 2011	Jan	DISC

TEMAZEPAM

	CAPSULE;ORAL						
	TEMAZEPAM						
AB	VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015	May	NEWA
AB		15MG	A201781	002	Jun 04, 2015	May	NEWA
AB		22.5MG	A201781	003	Jun 04, 2015	May	NEWA
AB		30MG	A201781	004	Jun 04, 2015	May	NEWA

TEMOZOLOMIDE

	CAPSULE;ORAL						
	TEMOZOLOMIDE						
AB	AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr	NEWA
AB		20MG	A203691	002	May 08, 2015	Apr	NEWA
AB		100MG	A203691	003	May 08, 2015	Apr	NEWA
AB		140MG	A203691	004	May 08, 2015	Apr	NEWA
AB		180MG	A203691	005	May 08, 2015	Apr	NEWA
AB		250MG	A203691	006	May 08, 2015	Apr	NEWA

TENOFOVIR DISOPROXIL FUMARATE

	TABLET;ORAL						
	TENOFOVIR DISOPROXIL FUMARATE						
AB	TEVA PHARMS USA	300MG	A091612	001	Mar 18, 2015	Mar	NEWA
	VIREAD						
AB	+ GILEAD SCIENCES INC	300MG	N021356	001	Oct 26, 2001	Mar	CFTG

TERBINAFINE HYDROCHLORIDE

	TABLET;ORAL						
	TERBINAFINE HYDROCHLORIDE						
	@ WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb	DISC

TESTOSTERONE

	GEL;TRANSDERMAL						
	ANDROGEL						
AB1	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan	CTEC
AB1	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan	CTEC
	TESTIM						
AB2	+ AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan	CTEC
	TESTOSTERONE						
	@ ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar	CAHN
	@	1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar	CAHN
BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May	CAHN
BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May	CAHN
AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan	CTEC
AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan	CTEC
	VOGELXO						
AB2	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan	CTEC

TETRABENAZINE

TABLET;ORAL

XENAZINE

		VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Feb	CAHN
	+		25MG	N021894	002	Aug 15, 2008	Feb	CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

AB	+	HERITAGE PHARMS INC	500MG	N050278	001		Apr	CRLD

TETRACYCLINE HYDROCHLORIDE

	@	IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr	DISC
	@		500MG	A060704	002		Apr	DISC

THEOPHYLLINE

TABLET;ORAL

THEOLAIR

	@	MEDICIS	125MG	A086399	001		Mar	DISC
	@		250MG	A086399	002		Mar	DISC

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB		MYLAN PHARMS INC	400MG	A040595	001	Apr 21, 2006	May	CAHN
AB	+		600MG	A040560	002	Apr 21, 2006	May	CAHN

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

	+	EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	May	CRLD

TIGECYCLINE

INJECTABLE;IV (INFUSION)

TIGECYCLINE

AP		SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	May	NEWA

TYGACIL

AP	+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	May	CFTG

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

ISTALOL

AT2	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	Apr	CFTG

TIMOLOL MALEATE

AT1		AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Apr	CTEC
AT1			EQ 0.5% BASE	A074516	001	Mar 25, 1997	Apr	CTEC
AT1		ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr	CTEC
AT2		APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015	Apr	NEWA
AT1		BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr	CTEC
AT1		FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr	CTEC
AT1		HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr	CTEC
AT1		PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr	CTEC
AT1		WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr	CTEC

TIMOPTIC

AT1	+	ATON	EQ 0.5% BASE	N018086	002		Apr	CTEC

TOBRAMYCIN

SOLUTION;INHALATION

KITABIS PAK

AN		PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014	Feb	CTEC

TOBRAMYCIN

>A> AN		AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	Jun	NEWA

SOLUTION/DROPS;OPHTHALMIC

TOBREX

AT	+	ALCON LABS INC	0.3%	N050541	001		Mar	CAHN

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

	@	IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994	Mar	CAHN
	@		EQ 40MG BASE/ML	A063120	001	Oct 31, 1994	Mar	CAHN
	@		EQ 40MG BASE/ML	A063121	001	Oct 31, 1994	Mar	CAHN
	@		EQ 40MG BASE/ML	A063122	001	Oct 31, 1994	Mar	CAHN
AP		MYLAN PHARMS INC	EQ 40MG BASE/ML	A065407	001	Mar 11, 2008	Apr	CAHN

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@	G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr	CAHN
@		250MG	N018894	002	Nov 02, 1984	Apr	CAHN
@		500MG	N018894	003	Nov 02, 1984	Apr	CAHN

TOLCAPONE

TABLET;ORAL

TASMAR

AB	+	VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar	CFTG

TOLCAPONE

AB		PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	NEWA

TOLMETIN SODIUM

TABLET;ORAL

TOLMETIN SODIUM

@	G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May	CAHN
@		EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr	CAHN

TOLTERODINE TARTRATE

TABLET;ORAL

TOLTERODINE TARTRATE

AB		IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb	NEWA
AB			2MG	A077006	002	Feb 23, 2015	Feb	NEWA

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

AB		SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr	CAHN
AB			100MG	A076327	002	Mar 27, 2009	Apr	CAHN
AB			200MG	A076327	003	Mar 27, 2009	Apr	CAHN
@		WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr	DISC
@			50MG	A090353	002	Sep 01, 2010	Apr	DISC
@			100MG	A090353	003	Sep 01, 2010	Apr	DISC
@			200MG	A090353	004	Sep 01, 2010	Apr	DISC

TOPIRAMATE

@		HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May	DISC
@			50MG	A091185	002	Nov 25, 2013	May	DISC
@			100MG	A091185	003	Nov 25, 2013	May	DISC
@			200MG	A091185	004	Nov 25, 2013	May	DISC

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL

HYCAMTIN

		NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar	CAHN
	+		EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar	CAHN

INJECTABLE;INJECTION

HYCAMTIN

AP	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar	CAHN

TOPOTECAN HYDROCHLORIDE

AP		CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May	CAHN

TORSEMIDE

INJECTABLE;INJECTION

TORSEMIDE

@		EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan	DISC
@			50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan	DISC
@		LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan	DISC
@			50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan	DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

		NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar	CAHN
			EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar	CAHN
	+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar	CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP		FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD

TRANYLCYPROMINE SULFATE

TABLET;ORAL

PARNATE

>A>	AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun	CAHN
>D>	AB	+	COVIS PHARMA	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun	CAHN

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVATAN Z

>D>		+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Jun	CTEC
>A>	AT	+		0.004%	N021994	001	Sep 21, 2006	Jun	CTEC

TRAVOPROST

>A>	AT		APOTEX INC	0.004%	A203431	001	Jul 10, 2015	Jun	NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

DESYREL

		@	PRAGMA PHARMS LLC	50MG	N018207	001		May	CAHN
		@		100MG	N018207	002		May	CAHN
		@		150MG	N018207	003	Mar 25, 1985	May	CAHN
		@		300MG	N018207	004	Nov 07, 1988	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

OLEPTRO

		@	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Mar	DISC
		@		300MG	N022411	002	Feb 02, 2010	Mar	DISC

TRETINOIN

CREAM;TOPICAL

RENOVA

		+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr	CAHN
	AB2	+		0.05%	N019963	001	Dec 29, 1995	Apr	CAHN

RETIN-A

	AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr	CAHN

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

	AT		G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr	CMFD
	AT			0.1%	A089798	001	May 31, 1991	Apr	CMFD

TRIDERM

	AT		CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar	NEWA
	AT			0.5%	A088042	003	Mar 25, 2015	Mar	NEWA

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

	AT		G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar	CMFD

OINTMENT;TOPICAL

KENALOG

	AT		DELCOR ASSET CORP	0.025%	N011600	003		Mar	CMFD
	AT			0.1%	N011600	001		Mar	CMFD

SPRAY;TOPICAL

KENALOG

	AT	+	RANBAXY	0.147MG/GM	N012104	001		Mar	CFTG

TRIAMCINOLONE ACETONIDE

	AT		PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015	Mar	NEWA

TRIAMTERENE

CAPSULE;ORAL

DYRENIUM

			CONCORDIA PHARMS INC	50MG	N013174	001		Apr	CAHN
		+		100MG	N013174	002		Apr	CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

SURMONTIL

>D>	AB		ODYSSEY PHARMS	EQ 50MG BASE	N016792	002		Jun CRLD
>A>	AB	+		EQ 50MG BASE	N016792	002		Jun CRLD
>D>	AB	+		EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun CRLD
>A>	AB			EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun CRLD

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR

TRELSTAR

		+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Jan CAHN
		+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Jan CAHN
		+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Jan CAHN

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

SANCTURA XR

		@	ALLERGAN	60MG	N022103	001	Aug 03, 2007	May DISC

TROSPIUM CHLORIDE

>D>	AB	+	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Jun CRLD
>A>	AB			60MG	A091289	001	Oct 12, 2012	Jun CRLD
	AB	+		60MG	A091289	001	Oct 12, 2012	May CRLD
	AB		SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr NEWA

TABLET;ORAL

SANCTURA

		@	ALLERGAN	20MG	N021595	001	May 28, 2004	May DISC

TROSPIUM CHLORIDE

>D>	AB	+	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Jun CRLD
>A>	AB			20MG	A091575	001	Aug 13, 2010	Jun CRLD
	AB	+		20MG	A091575	001	Aug 13, 2010	May CRLD

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC

RESCULA

		+	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	May CAHN
		+	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Jan CAHN

URSODIOL

CAPSULE;ORAL

ACTIGALL

		@	ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987	Mar CAHN
	AB	+		300MG	N019594	002	Dec 31, 1987	Mar CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

	AB		HETERO LABS LTD V	EQ 500MG BASE	A203047	001	Apr 08, 2015	Mar NEWA
	AB			EQ 1GM BASE	A203047	002	Apr 08, 2015	Mar NEWA
	AB		SUN PHARM INDS LTD	EQ 500MG BASE	A076588	001	Jan 31, 2007	Apr CAHN
	AB			EQ 1GM BASE	A076588	002	Jan 31, 2007	Apr CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

	AB		BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan CAHN

CAPSULE, DELAYED RELEASE;ORAL

STAVZOR

		@	BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan CAHN
		@		250MG	N022152	002	Jul 29, 2008	Jan CAHN
		@		500MG	N022152	003	Jul 29, 2008	Jan CAHN

VALSARTAN

TABLET;ORAL

VALSARTAN

	AB		PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May NEWA
	AB			80MG	A204821	002	Jun 09, 2015	May NEWA
	AB			160MG	A204821	003	Jun 09, 2015	May NEWA
	AB			320MG	A204821	004	Jun 09, 2015	May NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

AB		LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan NEWA
AB			EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan NEWA

INJECTABLE;INJECTION

VANCOLED

>A>		@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Jun CAHN
>A>		@	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Jun CAHN
>A>		@	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Jun CAHN
>A>		@	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Jun CAHN
>A>		@	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Jun CAHN
>D>		@ HIKMA MAPLE	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Jun CAHN
>D>		@	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Jun CAHN
>D>		@	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Jun CAHN
>D>		@	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Jun CAHN
>D>		@	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Jun CAHN

VANCOMYCIN HYDROCHLORIDE

AP		MYLAN PHARMS INC	EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	Apr CAHN
AP			EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	Apr CAHN
AP			EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	May CAHN

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

AB	+	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr CFTG

VARDENAFIL HYDROCHLORIDE

AB		WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr NEWA

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

AP		MYLAN PHARMS INC	10MG/VIAL	A090243	001	May 11, 2010	Apr CAHN
AP			20MG/VIAL	A090243	002	May 11, 2010	Apr CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb CAHN
AB			EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb CAHN
AB			EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May NEWA
AB			EQ 37.5MG BASE	A202036	002	May 28, 2015	May NEWA
AB			EQ 50MG BASE	A202036	003	May 28, 2015	May NEWA
AB			EQ 75MG BASE	A202036	004	May 28, 2015	May NEWA
AB			EQ 100MG BASE	A202036	005	May 28, 2015	May NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB		RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr CAHN
AB			180MG	N019614	003	Jan 09, 1992	Apr CAHN
AB			240MG	N019614	002	May 29, 1990	Apr CAHN
	+		360MG	N019614	004	May 10, 1996	Apr CAHN

VERELAN PM

AB		RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr CAHN
AB			200MG	N020943	002	Nov 25, 1998	Apr CAHN
AB	+		300MG	N020943	003	Nov 25, 1998	Apr CAHN

INJECTABLE;INJECTION

ISOPTIN

		@ MT ADAMS	2.5MG/ML	N018485	001		Apr CAHN

TABLET;ORAL

ISOPTIN

		@ MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr CAHN
		@	80MG	N018593	001	Mar 08, 1982	Apr CAHN
		@	120MG	N018593	002	Mar 08, 1982	Apr CAHN

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar	CAHN

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar	CAHN
		20MG	N022567	002	Jan 21, 2011	Mar	CAHN
		40MG	N022567	003	Jan 21, 2011	Mar	CAHN

ZAFIRLUKAST

TABLET;ORAL

ACCOLATE

AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb	CAHN
AB +		20MG	N020547	001	Sep 26, 1996	Feb	CAHN

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr	NEWA
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar	NEWA
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CPOT

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

@	HIKMA	5MG	A078129	001	Apr 30, 2008	Mar	DISC
@		10MG	A078129	002	Apr 30, 2008	Mar	DISC
AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr	CAHN
AB		10MG	A078055	002	Apr 23, 2007	Apr	CAHN

TABLET;SUBLINGUAL

INTERMEZZO

AB	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	May	CFTG
AB +		3.5MG	N022328	002	Nov 23, 2011	May	CFTG

ZOLPIDEM TARTRATE

AB	NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015	May	NEWA
AB		3.5MG	A204299	002	Jun 03, 2015	May	NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB	BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan	CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan	CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan	CAHN

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL						
ACETAMINOPHEN						
SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011	Apr	CAHN
@	650MG	A090205	001	Nov 18, 2009	Apr	CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL						
SHADE UVAGUARD						
+ BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992	Mar	CAHN

BUDESONIDE

SPRAY, METERED;NASAL						
RHINOCORT ALLERGY						
+ ASTRAZENECA PHARMS	0.032MG/SPRAY	N020746	003	Mar 23, 2015	Mar	NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL						
LOTRIMIN ULTRA						
+ BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001	Mar	CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL						
CETIRIZINE HYDROCHLORIDE ALLERGY						
BANNER LIFE SCIENCES	5MG	N022429	001	Jul 23, 2009	Jan	CAHN
+	10MG	N022429	004	Jul 23, 2009	Jan	CAHN
CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
BANNER LIFE SCIENCES	5MG	N022429	003	Jul 23, 2009	Jan	CAHN
+	10MG	N022429	002	Jul 23, 2009	Jan	CAHN
TABLET;ORAL						
CETIRIZINE HYDROCHLORIDE ALLERGY						
SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007	Apr	CAHN
	10MG	A077498	002	Dec 27, 2007	Apr	CAHN
CETIRIZINE HYDROCHLORIDE HIVES						
SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007	Apr	CAHN
	10MG	A077498	004	Dec 27, 2007	Apr	CAHN
TABLET, CHEWABLE;ORAL						
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY						
JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015	Feb	NEWA
	10MG	A091116	002	Feb 19, 2015	Feb	NEWA
SANDOZ	5MG	A078692	001	Feb 14, 2008	Feb	CTNA
+	10MG	A078692	002	Feb 14, 2008	Feb	CTNA
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015	Feb	NEWA
	10MG	A091116	004	Feb 19, 2015	Feb	NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL						
CHLOR-TRIMETON						
@ BAYER HEALTHCARE LLC	8MG	N007638	001		Mar	CAHN
+	12MG	N007638	002		Mar	CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL						
CHLOR-TRIMETON						
+ BAYER HEALTHCARE LLC	8MG;120MG	N018397	001		Mar	CAHN

CLOTRIMAZOLE

CREAM;VAGINAL						
GYNE-LOTRIMIN						
+ BAYER HEALTHCARE LLC	1%	N018052	002	Nov 30, 1990	Mar	CAHN
GYNE-LOTRIMIN 3						
+ BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998	Mar	CAHN
CREAM, TABLET;TOPICAL, VAGINAL						
GYNE-LOTRIMIN COMBINATION PACK						
+ BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993	Mar	CAHN
TABLET;VAGINAL						
GYNE-LOTRIMIN						
+ BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990	Mar	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER LIFE SCIENCES	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan	CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr	CAHN
	20MG	A090283	002	Nov 17, 2009	Apr	CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL	60MG;120MG	A090818	001	Jan 29, 2015	Jan	NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC	600MG;60MG	A091071	001	May 27, 2015	May	NEWA
	1.2GM;120MG	A091071	002	May 27, 2015	May	NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BANNER LIFE SCIENCES	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan	CAHN

MIDOL LIQUID GELS

+	BANNER LIFE SCIENCES	200MG	N021472	001	Oct 18, 2002	Jan	CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH AND LOMB	EQ 0.035% BASE	N021996	002	Feb 11, 2015	Feb	NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

LOTUS PHARM CO LTD	1.5MG	A202246	001	Jun 05, 2015	May	NEWA
OC PHARMA	1.5MG	A202380	001	May 29, 2015	May	NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

	BANNER LIFE SCIENCES	1MG	N021855	001	Aug 04, 2005	Jan	CAHN
+		2MG	N021855	002	Aug 04, 2005	Jan	CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006	Apr	CAHN

LORATADINE

CAPSULE;ORAL

CLARITIN

+	BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008	Mar	CAHN

SYRUP;ORAL

CLARITIN

+	BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002	Mar	CAHN

CLARITIN HIVES RELIEF

@	BAYER HEALTHCARE LLC	1MG/ML	N020641	003	Nov 19, 2003	Mar	CAHN

TABLET;ORAL

LORATADINE

SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003	Apr	CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006	Mar	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
CLARITIN REDITABS
+ BAYER HEALTHCARE LLC 5MG N021993 001 Dec 12, 2006 Mar CAHN
LORATADINE REDIDOSE
SUN PHARM INDS LTD 10MG A077153 001 Apr 11, 2007 Apr CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE
TABLET, EXTENDED RELEASE;ORAL
CLARITIN-D
+ BAYER HEALTHCARE LLC 5MG;120MG N019670 002 Nov 27, 2002 Mar CAHN
CLARITIN-D 24 HOUR
+ BAYER HEALTHCARE LLC 10MG;240MG N020470 002 Nov 27, 2002 Mar CAHN
LORATADINE AND PSEUDOEPHEDRINE SULFATE
SUN PHARM INDS LTD 10MG;240MG A076557 001 Sep 22, 2004 Apr CAHN

NAPROXEN SODIUM
CAPSULE;ORAL
NAPROXEN SODIUM
+ BANNER LIFE SCIENCES EQ 200MG BASE N021920 001 Feb 17, 2006 Jan CAHN
>D> CATALENT EQ 200MG BASE A202807 001 Feb 13, 2015 Jun CAHN
EQ 200MG BASE A202807 001 Feb 13, 2015 Feb NEWA
>A> OHM LABS INC EQ 200MG BASE A202807 001 Feb 13, 2015 Jun CAHN
TABLET;ORAL
NAPROXEN SODIUM
SUN PHARM INDS LTD EQ 200MG BASE A091183 001 May 20, 2011 Apr CAHN

NICOTINE POLACRILEX
GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX
@ IVAX SUB TEVA PHARMS EQ 2MG BASE A076880 001 Feb 18, 2009 Mar DISC
@ EQ 4MG BASE A077850 001 Feb 18, 2009 Mar DISC

OMEPRAZOLE; SODIUM BICARBONATE
CAPSULE;ORAL
ZEGERID OTC
+ BAYER HEALTHCARE LLC 20MG;1.1GM N022281 001 Dec 01, 2009 Mar CAHN
FOR SUSPENSION;ORAL
ZEGERID OTC
+ BAYER HEALTHCARE LLC 20MG/PACKET;1.68GM/PACKET N022283 001 Jun 17, 2013 Mar CAHN

OXYMETAZOLINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
OCUCLEAR
BAYER HEALTHCARE LLC 0.025% N018471 001 May 30, 1986 Mar CAHN

POLYETHYLENE GLYCOL 3350
FOR SOLUTION;ORAL
MIRALAX
+ BAYER HEALTHCARE LLC 17GM/SCOOPFUL N022015 001 Oct 06, 2006 Mar CAHN
POLYETHYLENE GLYCOL 3350
RARITAN PHARMS INC 17GM/SCOOPFUL A202071 001 Dec 28, 2012 Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE
SUN PHARM INDS LTD 120MG A077442 001 Sep 28, 2005 Apr CAHN

RANITIDINE HYDROCHLORIDE
TABLET;ORAL
RANITIDINE HYDROCHLORIDE
@ SUN PHARM INDS LTD EQ 75MG BASE A075132 001 Jan 14, 2000 Apr CAHN
@ WOCKHARDT EQ 75MG BASE A078884 001 Jul 31, 2008 Jan DISC

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE 2015

NO JUNE 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE - ZIAGEN								
N 020977 001							D-147	Mar 23, 2018
ABACAVIR SULFATE - ZIAGEN								
N 020978 001							D-147	Mar 23, 2018
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ								
N 205551 001		6417191	Mar 28, 2016		DP U-1572			
		6417191*PED	Sep 28, 2016					
ABACAVIR SULFATE; LAMIVUDINE - EPZICOM								
N 021652 001		6417191	Mar 28, 2016		DP U-257			
		6417191*PED	Sep 28, 2016					
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR								
N 204031 001		8980319	Dec 21, 2030		DP			
		8992975	May 16, 2032		DP			
	>A>	9050335	May 16, 2032		DP			
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR								
N 202450 001	>A>	9056100	Jul 07, 2020		DP U-1263			
ACYCLOVIR; HYDROCORTISONE - XERESE								
N 022436 001		7223387	Jul 24, 2021		DP U-1006			
		7223387	Jul 24, 2021		DP U-1484			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO								
N 022320 001		8936800	Dec 23, 2022		DP U-1078			
ALBUTEROL SULFATE - PROAIR RESPICLICK								
N 205636 001		6446627	Dec 18, 2017		DP		NP	Mar 12, 2018
		6701917	Jun 23, 2021		DP			
		6718972	Jun 23, 2021		DP			
		6748947	Jun 23, 2021		DP			
		6871646	Jun 23, 2021		DP			
		7540282	May 06, 2023		DP			
		8006690	Jun 23, 2021		DP			
		8651103	Mar 26, 2028		DP			
ALVIMOPAN - ENTEREG								
N 021775 001		8946262	Feb 12, 2030		U-1655			
AMOXICILLIN - MOXATAG								
N 050813 001	>A>	8778924	Dec 08, 2026	DS	DP U-897			
APREMILAST - OTEZLA								
N 205437 001		9018243	Mar 19, 2023		U-1505			
		9018243	Mar 19, 2023		U-1595			
APREMILAST - OTEZLA								
N 205437 002		9018243	Mar 19, 2023		U-1505			
		9018243	Mar 19, 2023		U-1595			
APREMILAST - OTEZLA								
N 205437 003		9018243	Mar 19, 2023		U-1505			
		9018243	Mar 19, 2023		U-1595			
ARIPIPRAZOLE - ABILIFY								
N 021436 001							ODE	Dec 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 002					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY						
N 021436 003					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY						
N 021436 004					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY						
N 021436 005					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY						
N 021436 006					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
ARIPIPRAZOLE - ABILIFY						
N 021729 002					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY						
N 021729 003					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY						
N 021729 004					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY						
N 021729 005					ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY						
N 021866 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-763			
	5006528*PED	Apr 20, 2015				
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 001	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	002	8338428	Aug 06, 2023	DP U-1633			
		8399469	Jun 29, 2025	DS			
		8759351	Aug 06, 2023	DP U-1530			
		8759351	Aug 06, 2023	DP U-1633			
		8993761	Sep 25, 2022	DS			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	003	5006528	Oct 20, 2014	DS DP U-543			
		5006528	Oct 20, 2014	DS DP U-1632			
		5006528*PED	Apr 20, 2015				
		8030313	Oct 19, 2024	U-543			
		8030313	Oct 19, 2024	U-1632			
		8338427	Mar 15, 2025	DP U-543			
		8338427	Mar 15, 2025	DP U-1633			
		8338428	Aug 06, 2023	DP U-543			
		8338428	Aug 06, 2023	DP U-1633			
		8399469	Jun 29, 2025	DS			
		8759351	Aug 06, 2023	DP U-1530			
		8759351	Aug 06, 2023	DP U-1633			
		8993761	Sep 25, 2022	DS			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	004	5006528	Oct 20, 2014	DS DP U-543			
		5006528	Oct 20, 2014	DS DP U-1632			
		5006528*PED	Apr 20, 2015				
		8030313	Oct 19, 2024	U-543			
		8030313	Oct 19, 2024	U-1632			
		8338427	Mar 15, 2025	DP U-543			
		8338427	Mar 15, 2025	DP U-1633			
		8338428	Aug 06, 2023	DP U-543			
		8338428	Aug 06, 2023	DP U-1633			
		8399469	Jun 29, 2025	DS			
		8759351	Aug 06, 2023	DP U-1530			
		8759351	Aug 06, 2023	DP U-1633			
		8993761	Sep 25, 2022	DS			
ASENAPINE MALEATE - SAPHRIS							
N 022117	001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
		5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
		7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
		7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS							
N 022117	002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
		5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
		7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
		7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ATAZANAVIR SULFATE - REYATAZ							
N 021567	001	>A> 5849911	Jun 20, 2017	DS DP U-167			
		>A> 5849911*PED	Dec 20, 2017				
		>A> 6087383	Dec 21, 2018	DS DP			
		>A> 6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 021567	002	>A> 5849911	Jun 20, 2017	DS DP U-167			
		>A> 5849911*PED	Dec 20, 2017				
		>A> 6087383	Dec 21, 2018	DS DP			
		>A> 6087383*PED	Jun 21, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ATAZANAVIR SULFATE - REYATAZ							
N 021567	003	>A> 5849911	Jun 20, 2017	DS DP U-167			
		>A> 5849911*PED	Dec 20, 2017				
		>A> 6087383	Dec 21, 2018	DS DP			
		>A> 6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 021567	004	>A> 5849911	Jun 20, 2017	DS DP U-167			
		>A> 5849911*PED	Dec 20, 2017				
		>A> 6087383	Dec 21, 2018	DS DP			
		>A> 6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 206352	001	>A> 5849911	Jun 20, 2017	DS DP U-167		>A> NP	Jun 02, 2017
		>A> 5849911*PED	Dec 20, 2017			>A> PED	Dec 02, 2017
		>A> 6087383	Dec 21, 2018	DS DP			
ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ							
N 206353	001	>A> 5849911	Jun 20, 2017	DS DP U-167			
		>A> 5849911*PED	Dec 20, 2017				
		>A> 6087383	Dec 21, 2018	DS DP			
		>A> 6087383*PED	Jun 21, 2019				
		8148374	Sep 03, 2029	DS DP U-1279			
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ							
N 206494	001	7112592	Feb 24, 2022	DS DP U-282			
		7612087	Nov 12, 2026	DP			
		8178554	Jul 24, 2021	DS DP U-282			
		8471025	Aug 12, 2031	DS			
		8835455	Oct 08, 2030	DP			
		8969566	Jun 15, 2032	DS			
AZELASTINE HYDROCHLORIDE - ASTEPRO							
N 022203	001					NPP	Feb 20, 2018
						NPP	Feb 20, 2018
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA							
N 202236	001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
		8163723	Aug 29, 2023	U-81			
		8163723	Aug 29, 2023	U-644			
		8163723	Aug 29, 2023	U-707			
		8163723	Aug 29, 2023	U-1667			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA							
N 050819	001	8895070	Jun 03, 2029	U-124			
BESIFLOXACIN HYDROCHLORIDE - BESIVANCE							
N 022308	001	8937062	Nov 13, 2029	U-80			
BIMATOPROST - LUMIGAN							
N 022184	001	8933120	Mar 16, 2025	DP			
		8933127	Mar 16, 2025	DP			
BIMATOPROST - LATISSE							
N 022369	001	7351404	May 25, 2024	U-939	Y		
		7388029	Jan 21, 2022	U-938	Y		
		8541466	Jan 31, 2021	U-1217			
		8986715	Jan 15, 2023	U-1217			
BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA							
N 204251	001	9044484	Oct 30, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BROMOCRIPTINE MESYLATE - CYCLOSET							
N 020866 001	>A>	8877708	Jun 07, 2030	DP U-1706			
BUDESONIDE - UCERIS							
N 205613 001		5914122	Dec 19, 2015	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242 001		8470361	May 22, 2030	DP U-1425			
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242 002		8470361	May 22, 2030	DP U-1425			
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242 003		8470361	May 22, 2030	DP U-1425			
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242 004		8470361	May 22, 2030	DP U-1425			
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242 005	>A>	8454996	Sep 24, 2019	U-1421			
	>A>	8470361	May 22, 2030	DP U-1425			
	>A>	8658198	Dec 03, 2027	DP U-1494			
	>A>	8940330	Sep 18, 2032	DP			
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE							
N 200063 001		8916195	Feb 02, 2030	U-1639			
CALCIUM ACETATE - PHOSLO GELCAPS							
N 021160 003		6875445	Jul 30, 2021	DP			
CANGRELOR - KENGREAL							
N 204958 001					>A>	NCE	Jun 22, 2020
CARBIDOPA; LEVODOPA - RYTARY							
N 203312 001		7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
		8377474	Dec 26, 2028	DP U-219			
		8377474	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-219			
		8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8557283	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312 002		7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
		8377474	Dec 26, 2028	DP U-219			
		8377474	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-219			
		8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8557283	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
CARBIDOPA; LEVODOPA - DUOPA						
N 203952 001					NP	Jan 09, 2018
					ODE	Jan 09, 2022
CEFTAROLINE FOSAMIL - TEFLARO						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			
CEFTAROLINE FOSAMIL - TEFLARO						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
CELECOXIB - CELECOXIB						
A 076898 002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 076898 003					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 076898 004					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 078857 002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 078857 003					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 078857 004					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 200562 002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 200562 003					PC	Jun 02, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CELECOXIB - CELECOXIB						
A 200562 004					PC	Jun 02, 2015
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
CHOLIC ACID - CHOLBAM						
N 205750 001					ODE	Mar 17, 2022
CHOLIC ACID - CHOLBAM						
N 205750 002					ODE	Mar 17, 2022
CICLESONIDE - ALVESCO						
N 021658 002	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - ALVESCO						
N 021658 003	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - OMNARIS						
N 022004 001	8371292	Feb 01, 2028	U-1356			
CICLESONIDE - ZETONNA						
N 202129 001	8371292	Feb 01, 2028	U-1357			
CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE						
A 090898 001					PC	Jul 01, 2015
CLOBETASOL PROPIONATE - OLUX E						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
COLCHICINE - MITIGARE						
N 204820 001	8927607	Aug 22, 2033	U-1020			
CRIZOTINIB - XALKORI						
N 202570 001	7230098	Aug 26, 2025	DS			
CRIZOTINIB - XALKORI						
N 202570 002	7230098	Aug 26, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CROFELEMER - FULYZAQ							
N 202292 001		8962680	Oct 31, 2031	U-1319			
CYANOCOBALAMIN - NASCOBAL							
N 021642 001		7229636	Aug 01, 2024	DP U-817			
		7879349	Aug 01, 2024	DP U-1152			
		8003353	Aug 01, 2024	U-817			
		8940714	Feb 26, 2024	U-1152			
DABRAFENIB MESYLATE - TAFINLAR							
N 202806 001	>A>	8703781	Oct 15, 2030	DS DP U-1713			
DABRAFENIB MESYLATE - TAFINLAR							
N 202806 002	>A>	8703781	Oct 15, 2030	DS DP U-1713			
DANTROLENE SODIUM - RYANODEX							
N 205579 001						ODE	Jul 22, 2021
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA							
N 202293 001						M-157	Mar 11, 2018
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA							
N 202293 002						M-157	Mar 11, 2018
DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)							
N 206619 001		6037157	Jun 26, 2016	U-1635			
		6703403	Jun 26, 2016	U-1635			
		7148359	Jul 19, 2019	DP			
		7364752	Nov 10, 2020	DP			
		8188104	May 17, 2029	DS DP U-1636			
		8268349	Aug 25, 2024	DP			
		8399015	Aug 25, 2024	DP			
		8420596	Apr 10, 2031	DS DP			
		8466159	Sep 04, 2032	U-1637			
		8492386	Sep 04, 2032	U-1637			
		8501238	Sep 17, 2028	DS DP U-1636			
		8642538	Sep 10, 2029	DS DP U-1638			
		8680106	Sep 04, 2032	U-1637			
		8685984	Sep 04, 2032	U-1637			
		8686026	Jun 09, 2031	DP			
		8691938	Apr 13, 2032	DS DP			
		9006387	Jun 10, 2030	U-1687			
	>A>	9044480	Apr 10, 2031	U-1638			
DEFERASIROX - EXJADE							
N 021882 001						ODE	Jan 23, 2020
DEFERASIROX - EXJADE							
N 021882 002						ODE	Jan 23, 2020
DEFERASIROX - EXJADE							
N 021882 003						ODE	Jan 23, 2020
DEFERASIROX - JADENU							
N 206910 001		6465504	Apr 05, 2019	DS DP			
		6596750	Jun 24, 2017	DS U-735			
DEFERASIROX - JADENU							
N 206910 002		6465504	Apr 05, 2019	DS DP			
		6596750	Jun 24, 2017	DS U-735			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEFERASIROX - JADENU						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
DEOXYCHOLIC ACID - KYBELLA						
N 206333 001	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025	U-1690			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE						
A 200653 001					PC	May 16, 2015
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE						
A 200653 002					PC	May 16, 2015
DESONIDE - VERDESO						
N 021978 001	8962000	Aug 31, 2025	DP U-1412			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 003	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
DEXAMETHASONE - OZURDEX						
N 022315 001	8043628	Oct 20, 2020	U-1205			
	8088407	Oct 20, 2020	U-1205			
	9012437	Oct 20, 2020	U-1205			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 001	9011926	Feb 24, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 002	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 004	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE						
A 078908 002					PC	Aug 01, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE							
A 078908	003					>A> PC	Dec 19, 2015
DICLOFENAC - ZORVOLEX							
N 204592	001	8999387	Apr 23, 2030	U-55			
		9017721	Apr 23, 2030	DP			
DICLOFENAC - ZORVOLEX							
N 204592	002	8999387	Apr 23, 2030	U-55			
		9017721	Apr 23, 2030	DP			
DICLOFENAC POTASSIUM - CAMBIA							
N 022165	001	8927604	Jun 16, 2026	U-436			
DICLOFENAC SODIUM - DYLOJECT							
N 022396	001	6407079	Jun 18, 2019	DP			
		8946292	Mar 22, 2027	U-1659			
DICLOFENAC SODIUM - PENNSAID							
N 204623	001 >A>	9066913	Oct 17, 2027	DP U-1488			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	001	5061703	Apr 11, 2015	U-1641			
		5061703*PED	Oct 11, 2015				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	002	5061703	Apr 11, 2015	U-1641			
		5061703*PED	Oct 11, 2015				
		8039009	Mar 24, 2029	U-1641			
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025	U-1641			
		8362085	Nov 22, 2025	U-1641			
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025	U-1641			
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DOXYCYCLINE HYCLATE - DOXTERIC							
N 050795	006	6958161	Dec 15, 2022	DP U-918			
		8715724	Feb 03, 2028	DP			
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA							
N 021937	001	9018192	Jun 13, 2026	U-750			
		9018192	Jun 13, 2026	U-1170			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	001	>A> 6280959	Aug 01, 2027	DS DP U-930		>A> D-149	Jun 11, 2018
		>A> 6280959	Aug 01, 2027	DS DP U-1306		>A> I-711	Jun 11, 2018
		>A> 6280959	Aug 01, 2027	DS DP U-1575			
		>A> 6280959	Aug 01, 2027	DS DP U-1714			
		>A> 7160870	Nov 20, 2022	DS DP U-930			
		>A> 7160870	Nov 20, 2022	DS DP U-1306			
		>A> 7160870	Nov 20, 2022	DS DP U-1575			
		>A> 7160870	Nov 20, 2022	DS DP U-1714			
		>A> 7473686	May 24, 2021	DS DP U-930			
		>A> 7473686	May 24, 2021	DS DP U-1306			
		>A> 7473686	May 24, 2021	DS DP U-1575			
		>A> 7473686	May 24, 2021	DS DP U-1714			
		>A> 7547719	Jul 13, 2025	DS DP U-930			
		>A> 7547719	Jul 13, 2025	DS DP U-1306			
		>A> 7547719	Jul 13, 2025	DS DP U-1575			
		>A> 7547719	Jul 13, 2025	DS DP U-1714			
		>A> 7790704	May 24, 2021	U-930			
		>A> 7790704	May 24, 2021	U-1306			
		>A> 7790704	May 24, 2021	U-1575			
		>A> 7790704	May 24, 2021	U-1714			
		>A> 7795293	May 21, 2023	U-930			
		>A> 7795293	May 21, 2023	U-1306			
		>A> 7795293	May 21, 2023	U-1575			
		>A> 7795293	May 21, 2023	U-1714			
		>A> 8052993	Aug 01, 2027	DP U-930			
		>A> 8052993	Aug 01, 2027	DP U-1306			
		>A> 8052993	Aug 01, 2027	DP U-1575			
		>A> 8052993	Aug 01, 2027	DP U-1714			
		>A> 8052994	Aug 01, 2027	DP U-1714			
		>A> 8062665	Aug 01, 2027	DP U-1714			
		>A> 8071129	Aug 01, 2027	DP U-1714			
		>A> 8828430	Aug 01, 2027	DP U-1306			
		>A> 8828430	Aug 01, 2027	DP U-1619			
		>A> 8828430	Aug 01, 2027	DP U-1714			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	002	>A> 6280959	Aug 01, 2027	DS DP U-930		>A> D-149	Jun 11, 2018
		>A> 6280959	Aug 01, 2027	DS DP U-1306		>A> I-711	Jun 11, 2018
		>A> 6280959	Aug 01, 2027	DS DP U-1575			
		>A> 6280959	Aug 01, 2027	DS DP U-1714			
		>A> 7160870	Nov 20, 2022	DS DP U-930			
		>A> 7160870	Nov 20, 2022	DS DP U-1306			
		>A> 7160870	Nov 20, 2022	DS DP U-1575			
		>A> 7160870	Nov 20, 2022	DS DP U-1714			
		>A> 7473686	May 24, 2021	DS DP U-930			
		>A> 7473686	May 24, 2021	DS DP U-1306			
		>A> 7473686	May 24, 2021	DS DP U-1575			
		>A> 7473686	May 24, 2021	DS DP U-1714			
		>A> 7547719	Jul 13, 2025	DS DP U-930			
		>A> 7547719	Jul 13, 2025	DS DP U-1306			
		>A> 7547719	Jul 13, 2025	DS DP U-1575			
		>A> 7547719	Jul 13, 2025	DS DP U-1714			
		>A> 7790704	May 24, 2021	U-930			
		>A> 7790704	May 24, 2021	U-1306			
		>A> 7790704	May 24, 2021	U-1575			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	002	>A> 7790704	May 24, 2021	U-1714			
		>A> 7795293	May 21, 2023	U-930			
		>A> 7795293	May 21, 2023	U-1306			
		>A> 7795293	May 21, 2023	U-1575			
		>A> 7795293	May 21, 2023	U-1714			
		>A> 8052993	Aug 01, 2027	DP U-1714			
		>A> 8052994	Aug 01, 2027	DP U-930			
		>A> 8052994	Aug 01, 2027	DP U-1306			
		>A> 8052994	Aug 01, 2027	DP U-1575			
		>A> 8052994	Aug 01, 2027	DP U-1714			
		>A> 8062665	Aug 01, 2027	DP U-1714			
		>A> 8071129	Aug 01, 2027	DP U-1714			
		>A> 8828430	Aug 01, 2027	DP U-1306			
		>A> 8828430	Aug 01, 2027	DP U-1619			
		>A> 8828430	Aug 01, 2027	DP U-1714			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	003	>A> 6280959	Aug 01, 2027	DS DP U-930		>A> D-149	Jun 11, 2018
		>A> 6280959	Aug 01, 2027	DS DP U-1306		>A> I-711	Jun 11, 2018
		>A> 6280959	Aug 01, 2027	DS DP U-1575			
		>A> 6280959	Aug 01, 2027	DS DP U-1714			
		>A> 7160870	Nov 20, 2022	DS DP U-930			
		>A> 7160870	Nov 20, 2022	DS DP U-1306			
		>A> 7160870	Nov 20, 2022	DS DP U-1575			
		>A> 7160870	Nov 20, 2022	DS DP U-1714			
		>A> 7473686	May 24, 2021	DS DP U-930			
		>A> 7473686	May 24, 2021	DS DP U-1306			
		>A> 7473686	May 24, 2021	DS DP U-1575			
		>A> 7473686	May 24, 2021	DS DP U-1714			
		>A> 7547719	Jul 13, 2025	DS DP U-930			
		>A> 7547719	Jul 13, 2025	DS DP U-1306			
		>A> 7547719	Jul 13, 2025	DS DP U-1575			
		>A> 7547719	Jul 13, 2025	DS DP U-1714			
		>A> 7790704	May 24, 2021	U-930			
		>A> 7790704	May 24, 2021	U-1306			
		>A> 7790704	May 24, 2021	U-1575			
		>A> 7790704	May 24, 2021	U-1714			
		>A> 7795293	May 21, 2023	U-930			
		>A> 7795293	May 21, 2023	U-1306			
		>A> 7795293	May 21, 2023	U-1575			
		>A> 7795293	May 21, 2023	U-1714			
		>A> 8052993	Aug 01, 2027	DP U-1714			
		>A> 8052994	Aug 01, 2027	DP U-1714			
		>A> 8062665	Aug 01, 2027	DP U-714			
		>A> 8062665	Aug 01, 2027	DP U-930			
		>A> 8062665	Aug 01, 2027	DP U-1306			
		>A> 8062665	Aug 01, 2027	DP U-1575			
		>A> 8071129	Aug 01, 2027	DP U-1714			
		>A> 8828430	Aug 01, 2027	DP U-1306			
		>A> 8828430	Aug 01, 2027	DP U-1619			
		>A> 8828430	Aug 01, 2027	DP U-1714			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	004	>A> 6280959	Aug 01, 2027	DS DP U-930		>A> D-149	Jun 11, 2018
		>A> 6280959	Aug 01, 2027	DS DP U-1306		>A> I-711	Jun 11, 2018
		>A> 6280959	Aug 01, 2027	DS DP U-1575			
		>A> 6280959	Aug 01, 2027	DS DP U-1714			
		>A> 7160870	Nov 20, 2022	DS DP U-930			
		>A> 7160870	Nov 20, 2022	DS DP U-1306			
		>A> 7160870	Nov 20, 2022	DS DP U-1575			
		>A> 7160870	Nov 20, 2022	DS DP U-1714			
		>A> 7473686	May 24, 2021	DS DP U-930			
		>A> 7473686	May 24, 2021	DS DP U-1306			
		>A> 7473686	May 24, 2021	DS DP U-1575			
		>A> 7473686	May 24, 2021	DS DP U-1714			
		>A> 7547719	Jul 13, 2025	DS DP U-930			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 004	>A>	7547719	Jul 13, 2025	DS DP U-1306			
	>A>	7547719	Jul 13, 2025	DS DP U-1575			
	>A>	7547719	Jul 13, 2025	DS DP U-1714			
	>A>	7790704	May 24, 2021	U-930			
	>A>	7790704	May 24, 2021	U-1306			
	>A>	7790704	May 24, 2021	U-1575			
	>A>	7790704	May 24, 2021	U-1714			
	>A>	7795293	May 21, 2023	U-930			
	>A>	7795293	May 21, 2023	U-1306			
	>A>	7795293	May 21, 2023	U-1575			
	>A>	7795293	May 21, 2023	U-1714			
	>A>	8052993	Aug 01, 2027	DP U-1714			
	>A>	8052994	Aug 01, 2027	DP U-1714			
	>A>	8062665	Aug 01, 2027	DP U-1714			
	>A>	8071129	Aug 01, 2027	DP U-930			
	>A>	8071129	Aug 01, 2027	DP U-1306			
	>A>	8071129	Aug 01, 2027	DP U-1575			
	>A>	8071129	Aug 01, 2027	DP U-1714			
	>A>	8828430	Aug 01, 2027	DP U-1306			
	>A>	8828430	Aug 01, 2027	DP U-1619			
	>A>	8828430	Aug 01, 2027	DP U-1714			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 005						>A> D-149	Jun 11, 2018
						>A> I-711	Jun 11, 2018
ELUXADOLINE - VIBERZI							
N 206940 001	>A>	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	>A>	7786158	Mar 14, 2025	DS			
	>A>	8344011	Mar 14, 2025	U-1709			
	>A>	8609709	Mar 14, 2025	DS			
	>A>	8691860	Jul 07, 2028	DS U-1709			
ELUXADOLINE - VIBERZI							
N 206940 002	>A>	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	>A>	7786158	Mar 14, 2025	DS			
	>A>	8344011	Mar 14, 2025	U-1709			
	>A>	8609709	Mar 14, 2025	DS			
	>A>	8691860	Jul 07, 2028	DS U-1709			
ELVITEGRAVIR - VITEKTA							
N 203093 001		8981103	Oct 26, 2026	DS DP			
ELVITEGRAVIR - VITEKTA							
N 203093 002		8981103	Oct 26, 2026	DS DP			
EMPAGLIFLOZIN - JARDIANCE							
N 204629 001						>A> M-159	Jun 26, 2018
						>A> M-160	Jun 26, 2018
EMPAGLIFLOZIN - JARDIANCE							
N 204629 002						>A> M-159	Jun 26, 2018
						>A> M-160	Jun 26, 2018
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073 001		6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
		6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
		7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
		7407955	Aug 12, 2023	DS DP			
		7459428	Feb 02, 2019	U-1651			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		8119648	Aug 12, 2023	U-1651			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
EPINEPHRINE - AUVI-Q						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
EPINEPHRINE - AUVI-Q						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
ERIBULIN MESYLATE - HALAVEN						
N 201532 001	6214865	Jul 20, 2023	DS			
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERLOTINIB HYDROCHLORIDE - TARCEVA							
N 021743	003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
		5747498*PED	May 08, 2019			PED	Nov 14, 2016
		6900221	Nov 09, 2020	DS DP U-659			
		6900221	Nov 09, 2020	DS DP U-875			
		6900221	Nov 09, 2020	DS DP U-1046			
		6900221	Nov 09, 2020	DS DP U-1403			
		6900221*PED	May 09, 2021				
		7087613	Nov 09, 2020	U-659			
		7087613	Nov 09, 2020	U-1045			
		7087613	Nov 09, 2020	U-1403			
		7087613*PED	May 09, 2021				
		RE41065	Nov 08, 2018	DS DP			
		RE41065*PED	May 08, 2019				
ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR							
N 204655	001	5690960	Nov 25, 2014	DP U-1509			
		5690960*PED	May 25, 2015				
		5714504	Feb 03, 2015	DP U-1509			
		5714504*PED	Aug 03, 2015				
		5877192*PED	Nov 27, 2014				
		5900424	May 04, 2016	DS U-1509			
		5900424*PED	Nov 04, 2016				
		6369085	May 25, 2018	DS DP U-1509			
		6369085*PED	Nov 25, 2018				
		6428810	Nov 03, 2019	DP U-1509			
		6428810*PED	May 03, 2020				
		6875872*PED	Nov 27, 2014				
		7411070	May 25, 2018	DS			
		7411070*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	001	8945621	Oct 17, 2031	U-1661			
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	002	8945621	Oct 17, 2031	U-1661			
ESTRADIOL - MINIVELLE							
N 203752	005	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
EVEROLIMUS - AFINITOR							
N 022334	001	>A> 8410131	Nov 01, 2025	DS DP U-1368			
		>A> 8410131*PED	May 01, 2026				
		9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR							
N 022334	002	>A> 8410131	Nov 01, 2025	DS DP U-1368			
		>A> 8410131*PED	May 01, 2026				
		9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR							
N 022334	003	>A> 8410131	Nov 01, 2025	DS DP U-1368			
		>A> 8410131*PED	May 01, 2026				
		9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR							
N 022334	004	>A> 8410131	Nov 01, 2025	DS DP U-1368			
		>A> 8410131*PED	May 01, 2026				
		9006224	Jul 01, 2028	U-1681			
FENTANYL HYDROCHLORIDE - IONSYS							
N 021338	001	>A> 6169920	Jan 02, 2018	DP U-736			
		>A> 6181963	Nov 02, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL HYDROCHLORIDE - IONSYS									
N 021338	001	>A>	8301238	Sep 30, 2031		DP			
		>A>	8428708	May 21, 2032		U-736			
		>A>	8428709	Jun 11, 2032		DP U-736			
		>A>	8781571	Mar 31, 2032		DP U-736			
FERRIC CITRATE - AURYXIA									
N 205874	001		8901349	Feb 18, 2024		U-1577			
		>A>	9050316	Feb 18, 2024		U-1577			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC									
N 206317	001		6689275	Dec 31, 2016		U-1656			
			6779468	Dec 31, 2016		U-1656			
			7816404	Apr 17, 2029		DP U-1656			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY									
N 201373	001		8933097	Aug 16, 2032		DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES									
N 201373	002		8933097	Aug 16, 2032		DP			
FINAFLOXACIN - XTORO									
N 206307	001		6133260	Apr 12, 2017	DS	DP			
			6432948	Apr 12, 2017	DS	DP			
			8536167	Aug 08, 2031		U-1679			
FLUTEMETAMOL F-18 - VIZAMYL									
N 203137	001		8916131	Sep 16, 2028		DP			
FLUTEMETAMOL F-18 - VIZAMYL									
N 203137	002		8916131	Sep 16, 2028		DP			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA									
N 204275	001		6537983	Aug 03, 2021		DP U-1401		I-708	Apr 30, 2018
			6537983	Aug 03, 2021		DP U-1691			
			6759398	Aug 03, 2021		DP U-1401			
			6759398	Aug 03, 2021		DP U-1691			
			7101866	Aug 03, 2021	DS	DP U-1401			
			7101866	Aug 03, 2021	DS	DP U-1691			
			7439393	Sep 11, 2022	DS	DP U-1401			
			7439393	Sep 11, 2022	DS	DP U-1691			
			8511304	Jun 14, 2027		DP U-1424			
			8511304	Jun 14, 2027		DP U-1691			
			RE44874	Mar 23, 2023	DS	DP U-1548			
			RE44874	Mar 23, 2023	DS	DP U-1691			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA									
N 204275	002		5873360	Feb 23, 2016		DP		NP	Apr 30, 2018
			6537983	Aug 03, 2021		DP U-1691			
			6759398	Aug 03, 2021		DP U-1691			
			7101866	Aug 03, 2021	DS	DP U-1691			
			7439393	Sep 11, 2022	DS	DP U-1691			
			7629335	Aug 03, 2021		DP			
			7776895	Sep 11, 2022		DP			
			8113199	Oct 23, 2027		DP			
			8161968	Feb 05, 2028		DP			
			8511304	Jun 14, 2027		DP U-1691			
			8534281	Aug 10, 2029		DP			
			8746242	Oct 11, 2030		DP			
			RE44874	Mar 23, 2023	DS	DP U-1691			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - CUTIVATE						
N 021152 001					NPP	Jan 16, 2018
GADOXETATE DISODIUM - EOVIST						
N 022090 001					M-155	Mar 27, 2018
GADOXETATE DISODIUM - EOVIST						
N 022090 002					M-155	Mar 27, 2018
GLATIRAMER ACETATE - COPAXONE						
N 020622 003	8969302	Aug 19, 2030	U-441			
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE						
A 200881 001					PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE						
A 200881 002					PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE						
A 200881 003					PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE						
A 200881 004					PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 001					M-154	Mar 18, 2018
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 002					M-154	Mar 18, 2018
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 003					M-154	Mar 18, 2018
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 004					M-154	Mar 18, 2018
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 001	9023401	Oct 30, 2021	DP			
>A>	9056052	Oct 30, 2021	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 002	9023401	Oct 30, 2021	DP			
>A>	9056052	Oct 30, 2021	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 003	9023401	Oct 30, 2021	DP			
>A>	9056052	Oct 30, 2021	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 004	9023401	Oct 30, 2021	DP			
>A>	9056052	Oct 30, 2021	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 005 >A>	9056052	Oct 30, 2021	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 006 >A>	9056052	Oct 30, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA								
N 206627	007	>A>	9056052	Oct 30, 2021	DP			
IBRUTINIB - IMBRUVICA								
N 205552	001		8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
			8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
			8497277	Dec 28, 2026	U-1650			
			8957079	Dec 28, 2026	DS DP			
			8999999	Jun 03, 2031	U-1683			
			8999999	Jun 03, 2031	U-1684			
IBUPROFEN - CALDOLOR								
N 022348	002		8871810	Sep 30, 2029	U-1599			
			9012508	Sep 14, 2030	U-981			
ICATIBANT ACETATE - FIRAZYR								
N 022150	001	>A>	5648333	Jul 15, 2019	DS DP U-1187			
IDELALISIB - ZYDELIG								
N 205858	001	>A>	8138195	Apr 24, 2021	DS DP U-1549			
		>A>	8865730	Mar 05, 2033	DS DP U-1615			
			8980901	May 12, 2025	U-1678			
		>A>	RE44599	Jul 21, 2025	U-1558			
		>A>	RE44599	Jul 21, 2025	U-1615			
IDELALISIB - ZYDELIG								
N 205858	002	>A>	8138195	Apr 24, 2021	DS DP U-1549			
		>A>	8865730	Mar 05, 2033	DS DP U-1615			
			8980901	May 12, 2025	U-1678			
		>A>	RE44599	Jul 21, 2025	U-1558			
		>A>	RE44599	Jul 21, 2025	U-1615			
ILOPERIDONE - FANAPT								
N 022192	001		8652776	Aug 31, 2030	U-1685			
			8999638	Oct 28, 2030	U-1674			
ILOPERIDONE - FANAPT								
N 022192	002		8652776	Aug 31, 2030	U-1685			
			8999638	Oct 28, 2030	U-1674			
ILOPERIDONE - FANAPT								
N 022192	003		8652776	Aug 31, 2030	U-1685			
			8999638	Oct 28, 2030	U-1674			
ILOPERIDONE - FANAPT								
N 022192	004		8652776	Aug 31, 2030	U-1685			
			8999638	Oct 28, 2030	U-1674			
ILOPERIDONE - FANAPT								
N 022192	005		8652776	Aug 31, 2030	U-1685			
			8999638	Oct 28, 2030	U-1674			
ILOPERIDONE - FANAPT								
N 022192	006		8652776	Aug 31, 2030	U-1685			
			8999638	Oct 28, 2030	U-1674			
ILOPERIDONE - FANAPT								
N 022192	007		8652776	Aug 31, 2030	U-1685			
			8999638	Oct 28, 2030	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INDOMETHACIN - TIVORBEX							
N 204768	001	8992982	Apr 23, 2030	DP			
INDOMETHACIN - TIVORBEX							
N 204768	002	8992982	Apr 23, 2030	DP			
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH							
N 020986	005	8920383	Jul 17, 2026	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH							
N 021536	005	8920383	Jul 17, 2026	DP			
INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR							
N 021081	002	8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			
INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR							
N 206538	001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
		7918833*PED	Mar 23, 2028				
		8512297	Sep 15, 2024	DP			
		8556864	Mar 03, 2024	DP			
		8603044	Mar 02, 2024	DP			
		8679069	Apr 12, 2025	DP			
		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR							
N 021629	003	8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			
INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN							
N 205747	001	>A> 6034054	Jun 11, 2018	DP U-1707			
		>A> 6034054	Jun 11, 2018	DP U-1708			
		>A> 6551992	Jun 11, 2018	DP U-1707			
		>A> 6551992	Jun 11, 2018	DP U-1708			
		>A> 7291132	Aug 09, 2024	DP			
INSULIN RECOMBINANT HUMAN - AFREZZA							
N 022472	003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
		6652885	Jun 29, 2020	U-1535			
		7305986	Jan 16, 2023	DP			
		7464706	Mar 02, 2023	DP			
		7648960	Jun 29, 2020	U-1535			
		7943178	Jun 29, 2020	DP U-1535			
		7943572	Aug 10, 2026	U-1539			
		8119593	Aug 11, 2029	U-1537			
		8146588	Apr 24, 2023	DP			
		8156936	Jan 16, 2023	DP			
		8215300	Nov 24, 2022	DP			
		8258095	Aug 11, 2029	U-1537			
		8389470	Jun 29, 2020	DP U-1697			
		8394414	May 15, 2015	DP U-1533			
		8424518	Oct 17, 2031	DP			
		8485180	Mar 25, 2030	DP			
		8499757	Feb 19, 2032	DP			
		8551528	Jun 11, 2030	DP			
		8623817	Sep 18, 2029	U-1537			
		8636001	Jul 12, 2032	DP			
		8729019	Jun 06, 2028	DP			
		8734845	Jun 11, 2030	DP			
		8778403	Jun 11, 2030	DP U-1538			
		8889099	Jun 29, 2020	DP U-1621			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IPRATROPIUM BROMIDE - ATROVENT HFA						
N 021527 001	8474447	Jan 17, 2030	DP			
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		>A> ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					>A> GAIN	Mar 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		>A> ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					>A> GAIN	Mar 06, 2027
ISOTRETINOIN - ABSORICA						
N 021951 001	8952064	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 002	8952064	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 003	8952064	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 004	8952064	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
IVACAFTOR - KALYDECO						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
IVACAFTOR - KALYDECO						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO							
N 207925	002	7495103	May 20, 2027	DS DP			
		8324242	Apr 18, 2027	U-1311			
		8354427	Jul 06, 2026	U-1311			
		8410274	Dec 28, 2026	DP			
		8754224	Dec 28, 2026	DS DP			
		8883206	Feb 27, 2033	DP			
IVERMECTIN - SOOLANTRA							
N 206255	001	5952372	Sep 18, 2018	U-1631			
		6133310	Apr 26, 2019	U-1631			
		7550440	Apr 22, 2024	DP U-1631			
		8080530	Apr 22, 2024	DP U-1631			
		8093219	Apr 22, 2024	DP U-1631			
		8415311	Apr 22, 2024	DP U-1631			
		8470788	Apr 22, 2024	DP U-1631			
		8815816	Apr 22, 2024	DP U-1631			
KETOROLAC TROMETHAMINE - ACULAR LS							
N 021528	001	8946281	May 28, 2024	U-1662			
KETOROLAC TROMETHAMINE - ACUVAIL							
N 022427	001	8992952	Aug 05, 2024	DP			
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA							
N 205388	001 >A>	9066856	Oct 23, 2033	DP			
LAMIVUDINE - LAMIVUDINE							
A 203564	001					PC	Sep 01, 2015
LAMIVUDINE - EPIVIR							
N 020564	001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
		5905082*PED	Nov 18, 2016				
LAMIVUDINE - EPIVIR							
N 020564	003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
		5905082*PED	Nov 18, 2016				
LAMIVUDINE - EPIVIR							
N 020596	001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
		6004968	Mar 20, 2018	DP U-248			
		6004968*PED	Sep 20, 2018				
LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS							
N 206510	001	7169780	Oct 03, 2023	DS DP			
		7217713	Oct 21, 2022	U-1663			
		7435734	Oct 21, 2022	U-1663			
		7754731	Mar 11, 2029	DS DP U-1663			
		7820660	Apr 25, 2023	DS			
LAMOTRIGINE - LAMOTRIGINE							
A 200828	001					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE							
A 200828	002					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE							
A 200828	003					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE							
A 200828	004					PC	Sep 28, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMOTRIGINE - LAMICTAL						
N 020241 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 004					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 005					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 006					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 004					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 004					M-159	May 18, 2018
LANTHANUM CARBONATE - FOSRENOL						
N 204734 001	8980327	Dec 01, 2030	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 002	8980327	Dec 01, 2030	DP			
LAPATINIB DITOSYLATE - TYKERB						
N 022059 001 >A>	8821927	Sep 18, 2029	DS DP			
LENALIDOMIDE - REVLIMID						
N 021880 001 >A>	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
					ODE	Feb 17, 2022
LENALIDOMIDE - REVLIMID						
N 021880 002 >A>	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
					ODE	Feb 17, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID							
N 021880 003	>A>	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
						ODE	Feb 17, 2022
LENALIDOMIDE - REVLIMID							
N 021880 004	>A>	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
						ODE	Feb 17, 2022
LENALIDOMIDE - REVLIMID							
N 021880 005	>A>	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
						ODE	Feb 17, 2022
LENALIDOMIDE - REVLIMID							
N 021880 006		5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	>A>	9056120	Apr 11, 2023	U-1215		ODE	Feb 17, 2022
LENVATINIB MESYLATE - LENVIMA							
N 206947 001		7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
		7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
		9006256	Jul 27, 2027	U-1695			
LENVATINIB MESYLATE - LENVIMA							
N 206947 002		7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
		7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
		9006256	Jul 27, 2027	U-1695			
LEUPROLIDE ACETATE - LUPRON DEPOT							
N 020517 003		7429559	Jan 13, 2019	DP			
		8815801	Jun 28, 2022	DP			
		8921326	Feb 05, 2031	DP U-1666			
LEVALBUTEROL HYDROCHLORIDE - XOPENEX							
N 020837 001						M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX							
N 020837 002						M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX							
N 020837 003						M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX							
N 020837 004						M-151	Jan 22, 2018
LEVALBUTEROL TARTRATE - XOPENEX HFA							
N 021730 001						M-156	Mar 12, 2018
LEVETIRACETAM - ELEPSIA XR							
N 204417 001		8163306	Sep 03, 2027	DP			
		8425938	Feb 22, 2026	DP			
		8431156	Oct 31, 2027	DP			
		8470367	Jun 30, 2024	DP			
		8535717	Feb 22, 2026	DP			
LEVETIRACETAM - ELEPSIA XR							
N 204417 002		8163306	Sep 03, 2027	DP			
		8425938	Feb 22, 2026	DP			
		8431156	Oct 31, 2027	DP			
		8470367	Jun 30, 2024	DP			
		8535717	Feb 22, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM							
A 203563 001						PC	Oct 20, 2015
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM							
A 203563 002						PC	Oct 20, 2015
LEVONORGESTREL - LILETTA							
N 206229 001						NP	Feb 26, 2018
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM							
N 202231 001		9006289	Oct 03, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM							
N 202231 002		9006289	Oct 03, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM							
N 202231 003		9006289	Oct 03, 2032	DP			
LINACLOTIDE - LINZESS							
N 202811 001		8933030	Feb 17, 2031	DP			
LINACLOTIDE - LINZESS							
N 202811 002		8933030	Feb 17, 2031	DP			
LINAGLIPTIN - TRADJENTA							
N 201280 001		8673927	May 04, 2027	U-1503			
		8853156	Mar 05, 2031	U-1642			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281 001		8673927	May 04, 2027	U-1503			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281 002		8673927	May 04, 2027	U-1503			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N 201281 003		8673927	May 04, 2027	U-1503			
LINEZOLID - LINEZOLID							
A 078061 001						>A> PC	Dec 19, 2015
LINEZOLID - LINEZOLID							
A 200222 001						PC	Jul 04, 2015
LINEZOLID - ZYVOX							
N 021131 002	>A>	6559305	Jan 29, 2021	DS			
	>A>	6559305*PED	Jul 29, 2021				
LINEZOLID - ZYVOX							
N 021131 003	>A>	6559305	Jan 29, 2021	DS			
	>A>	6559305*PED	Jul 29, 2021				
LIRAGLUTIDE RECOMBINANT - VICTOZA							
N 022341 001		8846618	Jun 27, 2022	DP			
LIRAGLUTIDE RECOMBINANT - SAXENDA							
N 206321 001		6268343	Aug 22, 2022	DS DP U-1255			
		6458924	Aug 22, 2017	DS DP U-1255			
		6899699	Jan 01, 2022	DP			
		7235627	Aug 22, 2017	DS DP			
		7686786	Aug 03, 2026	DP			
		8114833	Aug 13, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIRAGLUTIDE RECOMBINANT - SAXENDA						
N 206321 001	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 001					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 002					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 003					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 004					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 005					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 006					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 007					I-703	Jan 30, 2018
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 006	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
LORATADINE - CLARITIN						
N 020641 002	6132758	Jun 01, 2018	DP			
LORCASERIN HYDROCHLORIDE - BELVIQ						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LORCASERIN HYDROCHLORIDE - BELVIQ							
N 022529 001		8980881	Dec 20, 2025	U-1255			
		8999970	Feb 07, 2033	U-1688			
		8999970	Feb 07, 2033	U-1689			
		8999970	Feb 07, 2033	U-1692			
LOXAPINE - ADASUVE							
N 022549 001		8955512	Oct 26, 2021	DP			
		8991387	May 21, 2024	DP			
LULICONAZOLE - LUZU							
N 204153 001		8980931	Apr 28, 2034	DP			
		9012484	Sep 06, 2033	DS DP U-540			
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 001	>A>	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 002	>A>	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 003	>A>	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 004	>A>	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 005	>A>	RE45573	Jun 23, 2025	DS			
MEGESTROL ACETATE - MEGACE ES							
N 021778 001	>A>	9040088	Apr 22, 2024	U-755			
MESALAMINE - APRISO							
N 022301 001		8940328	Apr 20, 2018	DP			
		8956647	Apr 20, 2018	DP			
METHOTREXATE - OTREXUP							
N 204824 001		8945063	Mar 19, 2030	DP U-1442			
METHOTREXATE - OTREXUP							
N 204824 002		8945063	Mar 19, 2030	DP U-1442			
METHOTREXATE - OTREXUP							
N 204824 003		8945063	Mar 19, 2030	DP U-1442			
METHOTREXATE - OTREXUP							
N 204824 004		8945063	Mar 19, 2030	DP U-1442			
METHOTREXATE - OTREXUP							
N 204824 005		8945063	Mar 19, 2030	DP U-1442			
METHYLPHENIDATE - DAYTRANA							
N 021514 001		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 002		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 003		9034370	Oct 07, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE - DAYTRANA						
N 021514 004	9034370	Oct 07, 2025	DP			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N 021121 001	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N 021121 002	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N 021121 004	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 005		8580310	Apr 12, 2022	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 006		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Apr 12, 2022	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 007		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Apr 12, 2022	DP			
METRONIDAZOLE - NUVESSA							
N 205223 001		7893097	Feb 19, 2028	DP			
		8658678	Jun 27, 2028	U-1682			
		8877792	Feb 02, 2028	DP			
		8946276	Jun 28, 2032	U-1664			
MIFEPRISTONE - KORLYM							
N 202107 001		8921348	Aug 27, 2028	U-1643			
MINOCYCLINE HYDROCHLORIDE - ARESTIN							
N 050781 001		7699609	Mar 29, 2022	DP			
MINOXIDIL - WOMEN'S ROGAINE							
N 021812 002		6946120	Apr 20, 2019	DP U-702			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 001	>A>	9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 002	>A>	9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 003	>A>	9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 004	>A>	9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 005	>A>	9072781	Mar 12, 2034	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 001		8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 002		8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 003		8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 004		8623418	Nov 07, 2029	U-1640			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321 005		8623418	Nov 07, 2029		U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N 022321 006		8623418	Nov 07, 2029		U-1640			
NALOXEGOL OXALATE - MOVANTIK								
N 204760 001		7056500	Jun 29, 2024		DP U-1185			
		9012469	Apr 02, 2032	DS	DP			
NALOXEGOL OXALATE - MOVANTIK								
N 204760 002		7056500	Jun 29, 2024		DP U-1185			
		9012469	Apr 02, 2032	DS	DP			
NALOXONE HYDROCHLORIDE - EVZIO								
N 205787 001		8926594	Mar 31, 2026		DP			
		8939943	Feb 28, 2031		DP			
		9022022	Feb 28, 2031		DP			
	>A>	9056170	Nov 23, 2024		DP			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ								
N 205777 001		8969369	May 10, 2022		DP U-1556			
	>A>	9056051	May 10, 2022		DP U-1556			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ								
N 205777 002		8969369	May 10, 2022		DP U-1556			
	>A>	9056051	May 10, 2022		DP U-1556			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ								
N 205777 003		8969369	May 10, 2022		DP U-1556			
	>A>	9056051	May 10, 2022		DP U-1556			
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET								
N 021926 001		6060499	Aug 14, 2017		DP U-867			
		6060499*PED	Feb 14, 2018					
		6586458	Aug 14, 2017		DP U-867			
		6586458*PED	Feb 14, 2018					
		7332183	Oct 02, 2025		DP U-867			
		7332183*PED	Apr 02, 2026					
		8022095	Aug 14, 2017		DP U-867			
		8022095*PED	Feb 14, 2018					
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET								
N 021926 002							>A> NP	May 14, 2018
							>A> PED	Nov 14, 2018
NEPAFENAC - ILEVRO								
N 203491 001		8921337	Mar 31, 2032		DP			
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO								
N 205718 001		8951969	Nov 18, 2030		DP			
NICOTINE - NICODERM CQ								
N 020165 004		8999379	Feb 13, 2020		U-1686			
NICOTINE - NICODERM CQ								
N 020165 005		8999379	Feb 13, 2020		U-1686			
NICOTINE - NICODERM CQ								
N 020165 006		8999379	Feb 13, 2020		U-1686			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES			PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NICOTINE POLACRILEX - NICORETTE									
N 022360	001	8940772	Apr 30, 2029	DP					
NICOTINE POLACRILEX - NICORETTE									
N 022360	002	8940772	Apr 30, 2029	DP					
NINTEDANIB ESYLATE - OFEV									
N 205832	001	7989474	Apr 06, 2024			U-1677			
NINTEDANIB ESYLATE - OFEV									
N 205832	002	7989474	Apr 06, 2024			U-1677			
OLAPARIB - LYNPARZA									
N 206162	001	7151102	Apr 29, 2022	DS	DP			ODE	Dec 19, 2021
		7449464	Oct 11, 2024	DS	DP				
		7981889	Oct 11, 2024	DS	DP				
		8143241	Aug 12, 2027			U-1634			
		8247416	Sep 24, 2028	DS					
		8859562	Aug 04, 2031			U-1634			
		8912187	Mar 12, 2024			U-1634			
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT									
N 206756	001	>A> 5964416	Oct 04, 2016		DP			NC	May 21, 2018
		>A> 6149054	Dec 19, 2016		DP			NCE	Jul 31, 2019
		>A> 6176442	Oct 04, 2016		DP				
		>A> 6453795	Dec 05, 2016		DP				
		>A> 6726124	Oct 04, 2016		DP				
		>A> 6846413	Aug 28, 2018		DP				
		>A> 6977042	Aug 28, 2018		DP				
		>A> 6988496	Feb 23, 2020		DP				
		>A> 7056916	Dec 07, 2023	DS	DP				
		>A> 7104470	Oct 04, 2016		DP				
		>A> 7220742	May 12, 2025	DS	DP	U-1703			
		>A> 7246615	May 31, 2016		DP				
		>A> 7284474	Aug 26, 2024		DP				
		>A> 7396341	Oct 10, 2026		DP				
		>A> 7491719	Nov 10, 2023	DS	DP				
		>A> 7727984	Nov 10, 2023	DS					
		>A> 7786111	Nov 10, 2023		DP				
		>A> 7802568	Feb 26, 2019		DP				
		>A> 7837235	Mar 13, 2028		DP				
		>A> 7896264	May 26, 2025		DP				
		>A> 7988001	Aug 04, 2021		DP				
		>A> 8034809	May 12, 2025			U-1702			
		>A> 8044046	Nov 10, 2023			U-1702			
		>A> 8733341	Dec 16, 2029		DP				
		>A> 9027967	Mar 31, 2027		DP				
		>A> RE39820	Jan 30, 2018	DS	DP	U-1702			
OLOPATADINE HYDROCHLORIDE - PAZEO									
N 206276	001	8791154	May 19, 2032		DP	U-1680		NP	Jan 30, 2018
								PED	Jul 30, 2018
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA									
N 205060	001	9012501	Feb 07, 2025		DP	U-1511			
		>A> 9050308	Jan 04, 2033			U-1511			
		>A> 9050309	Jan 04, 2033	DS					
OMEPRAZOLE - OMEPRAZOLE									
N 022032	001	9023391	Aug 16, 2025		DP				
OSPEMIFENE - OSPHENA									
N 203505	001	8642079	Jul 09, 2028		DP				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYBUTYNIN CHLORIDE - GELNIQUE							
N 022204 001		8920392	Mar 26, 2031	U-1644			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 001	>A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 002	>A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 003	>A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 004	>A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 005	>A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 006	>A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 007	>A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
PALBOCICLIB - IBRANCE							
N 207103 001		6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP			
		7456168	Jan 16, 2023	U-1658			
PALBOCICLIB - IBRANCE							
N 207103 002		6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP			
		7456168	Jan 16, 2023	U-1658			
PALBOCICLIB - IBRANCE							
N 207103 003		6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP			
		7456168	Jan 16, 2023	U-1658			
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946 001		6077843	May 12, 2017	DP U-543		NP	May 18, 2018
		6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946 002		6077843	May 12, 2017	DP U-543		NP	May 18, 2018
		6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946 003		6077843	May 12, 2017	DP U-543		NP	May 18, 2018
		6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946 004		6077843	May 12, 2017	DP U-543		NP	May 18, 2018
		6077843*PED	Nov 12, 2017				
PANOBINOSTAT LACTATE - FARYDAK							
N 205353 001		6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669			
		7989494	Jan 17, 2028	DS DP			
		8883842	Jun 13, 2028	U-1669			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PAROXETINE MESYLATE - BRISDELLE						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
PERAMPANEL - FYCOMPA						
N 202834 001					>A> I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 002					>A> I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 003					>A> I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 004					>A> I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 005					>A> I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 006					>A> I-710	Jun 19, 2018
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 004	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PIRFENIDONE - ESBRIET						
N 022535 001	7696236	Dec 18, 2027	U-1601			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
POMALIDOMIDE - POMALYST							
N 204026 001		5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST							
N 204026 002		5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST							
N 204026 003		5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST							
N 204026 004		5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469 001		9029533	Dec 22, 2026	U-836			
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469 002		9029533	Dec 22, 2026	U-836			
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469 003		9029533	Dec 22, 2026	U-836			
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
POSACONAZOLE - NOXAFIL							
N 205596 001		9023790	Jul 04, 2031	DP U-1698			
PREDNISONE - RAYOS							
N 202020 001	>A>	9040085	Apr 23, 2024	U-1362			
PREDNISONE - RAYOS							
N 202020 002	>A>	9040085	Apr 23, 2024	U-1362			
PREDNISONE - RAYOS							
N 202020 003	>A>	9040085	Apr 23, 2024	U-1362			
REGADENOSON - LEXISCAN							
N 022161 001	>A>	9045519	Jun 22, 2019	DP			
REGORAFENIB - STIVARGA							
N 203085 001	>A>	8637553	Feb 16, 2031	DS DP			
	>A>	8680124	Jun 02, 2030	U-1506			
RIFAXIMIN - XIFAXAN							
N 022554 001	>A>	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
	>A>	6861053	Aug 11, 2019	U-1708			
	>A>	7452857	Aug 11, 2019	U-1707			
	>A>	7452857	Aug 11, 2019	U-1708			
	>A>	7605240	Aug 11, 2019	U-1707			
	>A>	7605240	Aug 11, 2019	U-1708			
	>A>	7718608	Aug 11, 2019	U-1707			
	>A>	7718608	Aug 11, 2019	U-1708			
	>A>	7915275	Feb 23, 2025	U-1707			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIFAXIMIN - XIFAXAN							
N 022554	001	>A> 7915275	Feb 23, 2025	U-1708			
		>A> 7935799	Aug 11, 2019	U-1707			
		>A> 7935799	Aug 11, 2019	U-1708			
		>A> 8193196	Sep 02, 2027	DS DP U-1707			
		>A> 8193196	Sep 02, 2027	DS DP U-1708			
		>A> 8309569	Jul 18, 2029	U-1707			
		>A> 8309569	Jul 18, 2029	U-1708			
		>A> 8741904	Feb 27, 2026	DS U-1526			
		>A> 8741904	Feb 27, 2026	DS U-1707			
		>A> 8741904	Feb 27, 2026	DS U-1708			
		8946252	Jul 24, 2029	U-1481			
		8969398	Oct 02, 2029	U-1481			
RISEDRONATE SODIUM - RISEDRONATE SODIUM							
A 077132	001					PC	Nov 28, 2015
RISEDRONATE SODIUM - RISEDRONATE SODIUM							
A 077132	002					PC	Nov 28, 2015
RISEDRONATE SODIUM - RISEDRONATE SODIUM							
A 077132	003					PC	Nov 28, 2015
ROFLUMILAST - DALIRESP							
N 022522	001	5712298	Jan 27, 2016	DS DP U-1115			
SIMEPREVIR SODIUM - OLYSIO							
N 205123	001	>A> 9040562	Jul 28, 2026	DS DP U-1467			
SODIUM OXYBATE - XYREM							
N 021196	001	8952062	Dec 22, 2019	U-1101			
		8952062	Dec 22, 2019	U-1102			
		>A> 9050302	Mar 15, 2033	U-1532			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148	008	8920383	Jul 17, 2026	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148	009	8920383	Jul 17, 2026	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148	010	8920383	Jul 17, 2026	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148	011	>A> 5849700	Dec 15, 2015	U-1041			
		>A> 5849704	Dec 15, 2015	DS DP U-1041			
		>A> 6899699	Jan 02, 2022	DP			
		>A> 7686786	Aug 03, 2026	DP			
		>A> 8672898	Jan 02, 2022	DP			
		>A> 8684969	Oct 20, 2025	DP			
		>A> 8841252	Dec 26, 2017	DP			
		>A> 8920383	Jul 17, 2026	DP			
SORAFENIB TOSYLATE - NEXAVAR							
N 021923	001	8841330	Jan 12, 2020	U-1696			
SPINOSAD - NATROBA							
N 022408	001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
SUMATRIPTAN SUCCINATE - ZECUITY							
N 202278	001	8983594	Nov 19, 2030	DP U-1328			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TASIMELTEON - HETLIOZ							
N 205677 001	>A>	9060995	Jan 25, 2033	U-1710			
TEDUGLUTIDE RECOMBINANT - GATTEX KIT							
N 203441 001		5789379	Apr 14, 2016	DS DP U-1320			
TESTOSTERONE - AXIRON							
N 022504 001		8435944	Sep 27, 2027	U-1390			
		8993520	Jun 02, 2026	U-1390			
TIGECYCLINE - TYGACIL							
N 021821 001		8975242	Oct 24, 2028	DP			
TOPIRAMATE - TROKENDI XR							
N 201635 001		8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - TROKENDI XR							
N 201635 002		8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - TROKENDI XR							
N 201635 003		8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - TROKENDI XR							
N 201635 004		8992989	Nov 16, 2027	DP U-1675			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114 001	>A>	8703781	Oct 15, 2030	DS DP U-1712			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114 002	>A>	8703781	Oct 15, 2030	DS DP U-1712			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114 003	>A>	8703781	Oct 15, 2030	DS DP U-1712			
TRANEXAMIC ACID - LYSTEDA							
N 022430 001		8957113	Mar 04, 2025	DP U-1182			
	>A>	9060939	Mar 04, 2025	DP			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496 001		7417070	Jul 30, 2026	DS			
	>A>	9050311	May 24, 2024	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496 002		7417070	Jul 30, 2026	DS			
	>A>	9050311	May 24, 2024	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496 003		7417070	Jul 30, 2026	DS			
	>A>	9050311	May 24, 2024	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496 004		7417070	Jul 30, 2026	DS			
	>A>	9050311	May 24, 2024	DS DP			
TRETINOIN - RETIN-A-MICRO							
N 020475 003		5955109	Sep 21, 2016	DP U-134			
ULIPRISTAL ACETATE - ELLA							
N 022474 001		8962603	Jun 12, 2030	U-1657			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 021304 001					D-148	Apr 23, 2018
					NPP	Apr 23, 2018
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 022257 001					D-148	Apr 23, 2018
					NPP	Apr 23, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 001					D-146	Mar 16, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 002					D-146	Mar 16, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 003					D-146	Mar 16, 2018
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 001	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 003	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 004	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm